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Introduction 
At present, there is an increasing interest in the use of food supplements including 
supplements made from natural sources such as for example clay or plant ingredients. 
Such use may result in intake levels that exceed the normal dietary intake of bioactive 
ingredients and/or contaminants present in the food supplements. Although food sup-
plements are widely marketed, the safety of these preparations, especially when con-
taining other ingredients than nutrient sources such as vitamins or minerals, is not 
generally assessed before they enter the market. Regulatory bodies have become more 
aware of this and are increasing their efforts to ensure the safety of food supplements. 
The ‘Nederlandse Voedsel en Waren Autoriteit’ (NVWA) (Netherlands Food and Con-
sumer Product Safety Authority) performs the official controls on the safety of food 
supplements that are on the market in the Netherlands. Therefore, selected food sup-
plements are analyzed by the NVWA or by other laboratories for contaminants.  
 The aim of the present PhD study was to investigate the presence and actual levels 
of selected contaminants in selected food supplements on the Dutch market and to 
estimate the associated health risks. The selection of food supplements for the studies 
in the present thesis was based on reports in literature such as the presence of metals 
in clay products for oral use (Abrahams 2002; Bakraji and Karajou 2003; Abrahams et al. 
2006; Al-Rmalli et al. 2010; RASSF Number Notification 2002/336), the presence of 
polycyclic aromatic hydrocarbons (PAH) such as benzo[a]pyrene (BAP) in edible oils and 
food supplements (van der Wielen et al. 2006; Martena et al. 2011), the presence of 
dioxins in the feed chain resulting from the use of kaolinic clay for the sorting process of 
potatoes (Hoogenboom et al. 2010), and the presence of active pharmaceutical ingre-
dients (APIs) in herbal food supplements such as the presence of APIs with aphrodisiac 
properties and APIs with weight reducing properties in herbal supplements (Blok-Tip et 
al. 2004; Zou et al. 2006; Wang et al. 2008; Chen et al. 2009). Therefore, the categories 
of foods and food supplements selected for the studies in the present thesis were: 
1) clay products for oral use, 
2) herbal food supplements claiming to enhance sexual potency,  
3) herbal food supplements used for weight loss.  
Furthermore, the food supplements selected for the present thesis are generally con-
sidered safe by the consumers using them, especially because they are of natural origin, 
but can contain contaminants at levels that can be cause for concern. The three catego-
ries of food supplements selected for the studies in the present thesis are regularly 
included in surveys by the NVWA because of their presumed use by vulnerable groups 
such as child bearing and lactating women, and people who are suffering from any 
disease linked to erectile dysfunction, or being overweight or suffering from obesity. 
The research presented includes quantification of selected contaminants of concern in 
CHAPTER 1 
 12 
the respective food supplements but also an analysis of associated risks. To put the 
studies in perspective the subsequent sections in this introduction chapter describe the 
selected food supplements investigated as well as the contaminants analyzed and their 
legal framework, thereby providing the background for the work performed.  
Ad 1) Clay products for oral use 
The practice of eating clay or soil is termed geophagy. It is reported that clay and prod-
ucts of clay are used in traditional society by pregnant and lactating women and chil-
dren mainly on the African continent, in Asia, and in North and South America (Halsted 
1968; Vermeer 1971; Abrahams and Parsons 1996; Mahaney et al. 2000). These clay 
products, termed as traditional clay products, have African names such as calabash 
chalk, white clay, calabar stone, la craie, argile, nzu, mabele, emumba and ulo, Bengali 
names such as sikor, mithi, patri, khuri, kattha, poorcha or slatti, or a Suriname name 
which is pimba (Vermeer 1971; Hunter 1993; Mahaney et al. 2000; Reilly and Henry 
2000; Smith et al. 2000; FSA 2002; Bakraji and Karajou 2003; Abrahams et al. 2006; De 
Korte 2006; Yanai et al. 2009; Al-Rmalli et al. 2010). Figures 1a and 1b show examples 
of clay products.  
 Use of clay products is influenced by social and cultural factors, such as culturally 
ingrained food preferences, supplementing the diets for spiritual reasons or to promote 
fertility, while some pregnant women use these products against morning sickness or 
to prevent miscarriage (Danford 1982; Abrahams and Parsons 1996; Aufreiter et al. 
1997; Geissler et al. 1999; Henry and Matthews Kwong 2003; De Korte 2006; Kawai et 
al. 2009). Immigrants from the continents and regions mentioned above, also brought 
these habits to Western society such as to the United Kingdom (FSA 2002; Bakraji and 
Karajou 2003; Abrahams et al. 2006; Al-Rmalli et al. 2010; Katulek et al. 2010), the 
United States (Halsted 1968; Danford 1982; Katulek et al. 2010), Austria (Katulek et al. 
2010), Belgium (Katulek et al. 2010) and the Netherlands (Schuttelaar & Partners 2003). 
In the Netherlands these clay products are generally sold in small ethnic shops and at 
markets (Schuttelaar & Partners 2003). Contamination of clay products for oral use is a 
recognized problem. Contaminants include toxic constituents such as the metals lead, 
mercury, and cadmium, the metalloid arsenic, persistent organic pollutants, microbes 
or parasites (Abrahams 2002; FSA 2002; Dean et al. 2004; Al-Rmalli 2010; Katulek et al. 
2010).  
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a) 
 
b) 
Figure 1. Pictures of some clay preparations including a) sticks and b) pimba balls. 
CHAPTER 1 
 14 
The occurrence of metals and the metalloid arsenic in clay products intended for oral 
use and the associated health risks. 
Metals and metalloids occur naturally in various levels in the environment such as in 
water, soil and atmosphere, but can also be present in the environment as a result of 
human activities such as farming and industry. People are exposed to metals and metal-
loids by ingestion of food, water and soil. Accumulation of metals and metalloids in the 
body can lead to detrimental effects over time. For example, adverse health effects of 
exposure to lead and mercury could be brain damage. Young children are the most 
vulnerable group for these adverse health effects (EFSA 2004; 2010). Skin defects, de-
velopment of skin cancer and induction of lung and urinary bladder cancer are reported 
as toxicological effects of exposure to inorganic arsenic (EFSA 2009) and kidney damage 
could be a toxicological effect of exposure to cadmium (EFSA 2012). Various authors 
reported levels of metals and metalloids such as lead, arsenic, cadmium and mercury in 
traditional clay products (Ibeanu et al. 1997; Dean et al. 2004; Al-Rmalli et al. 2010; 
Katulek et al. 2010). In 2002 there was an alert by EU-Member States to the presence 
on the Belgian and German market of calabash chalk with high lead contents (RASSF 
Number Notification 2002/336). In chapter 2 of the present thesis the occurrence and 
connected risk assessment of the selected metals and metalloid in clay products on the 
Dutch market are explored. 
Contamination of African traditional pregnancy clay products with dioxins 
(polychlorinated dibenzo-p-dioxins and polychlorinated dibenzofurans).  
The name ‘dioxins’ is often used for the family of structurally and chemically related 
polychlorinated dibenzo-p-dioxins (PCDDs) and polychlorinated dibenzofurans (PCDFs) 
(Figure 2). 
 
Figure 2. Chemical structures of polychlorinated dibenzo-p-dioxins (PCDDs) and polychlorinated dibenzofu-
rans (PCDFs). 
 
Certain dioxin-like polychlorinated biphenyls (PCBs) with similar toxic properties are 
also included under the term ‘dioxins’ (WHO 2010a). The 17 dioxins which are of con-
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cern are non-polar and persistent compounds that accumulate in the environment 
(sediment and soil) as well as in the fatty tissues of animals and humans (RIVM 2009; 
WHO 2010a). The aromatic rings of the structures of dioxins can be chlorinated to vary-
ing degrees. PCDDs and PCDFs can have up to 8 chlorine atoms substituting for hydro-
gen atoms (WHO 2010b). The WHO reported in 2010 that 419 dioxin-related com-
pounds have been identified. Only about 30 of these 419 are considered to have signifi-
cant toxicity, with 2,3,7,8- tetrachlorodibenzo-p-dioxin (TCDD) (figure 3) being the most 
toxic congener (WHO 2010a). 
 
Figure 3. Chemical structure of 2,3,7,8-tetrachlorodibenzo-p-dioxin. 
 
Human exposure either through food or the environment usually involves a complex 
mixture of dioxins and dioxin-like compounds, with each having its own degree of tox-
icity. In order to assess the potential toxicological risk of the whole mixture, the con-
cept of toxic equivalence has been applied to this group of contaminants. TCDD, the 
most toxic member of the family, is used as reference compound, and all other dioxins 
are assigned a toxic potency relative to TCDD, based on experimental studies (WHO 
2010a). The relevant dioxins have similar toxicity profiles and a common mechanism of 
action via interaction with the cellular Aryl hydrocarbon (Ah) receptor. Exposure of 
humans to high levels of dioxins may result in skin lesions, such as chloracne and patchy 
darkening of the skin, and altered liver function. Furthermore, exposure to dioxins is 
linked to impairment of the immune system, the developing nervous system, the endo-
crine system and reproductive functions (Van den Berg et al. 1998; White and Birn-
baum 2009). Numerous animal studies with TCDD showed effects on the developing 
fetus, including a decreased sperm production of male rats exposed in utero (Faqi et al. 
1998, Van den Berg et al. 2012), and these effects may require only a short-term expo-
sure during a critical window of development. Dioxins are usually generated in a num-
ber of thermal and industrial processes as unwanted and often unavoidable by-
products. In clay, the observed PCDDs are thought to have been formed under natural 
conditions in prehistoric ages, possibly by forest fires, volcanos or under high pressure 
and temperature in specific layers in the earth (Holmstrand et al. 2006; Gu et al. 2008; 
Horii et al. 2008). 
 The presence of PCDDs in clay was previously reported for clays applied in the food 
chain (Rappe et al. 1998; Hayward et al. 1999; Ferrario et al. 2000; Jobst and Aldag 
2000). Our survey on dioxins in clay products was started in 2004, after an NVWA alert 
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of a French fries company in the Netherlands which changed its production process and 
used kaolinic clay for the sorting of potatoes. A by-product, small potato peels, contam-
inated with the clay, was fed to dairy cows at sone farms. Subsequently, high levels of 
PCDDs were detected in the fat of the milk obtained from these cows. It appeared that 
the absorption and carry-over of PCDDs from the clay to cow’s milk was very efficient 
(Hoogenboom et al. 2010). Knowing that also human milk can be an important route 
for excretion of PCDDs (Malisch et al. 2010), the question was raised if dioxins would be 
present in traditional clay products that are used during pregnancy. We therefore ana-
lyzed Suriname and African traditional clay products, which were collected on the 
Dutch market, for the presence of dioxins. We also included some extra traditional clay 
products that were collected in several African countries. The occurrence and assess-
ment of the potential risk due to dioxin exposure resulting from the use of contaminat-
ed clays during pregnancy are explored in chapter 3 of the present thesis. 
Ad 2) Sildenafil and analogous phosphodiesterase type 5 (PDE-5) inhibitors in herbal 
food supplements for the enhancement of sexual potency  
Herbal food supplements, claiming to enhance sexual potency, may contain deliberate-
ly added active pharmacological ingredients (APIs) that can be used for the treatment 
of erectile dysfunction (ED), such as the APIs sildenafil and analogous phosphodiester-
ase type 5 (PDE-5) inhibitors. These APIs are used in synthetic drugs marketed for treat-
ing ED, such as for example in the drugs Viagra® containing sildenafil (Figure 4a) as API, 
Cialis®, containing the API tadalafil (Figure 4b) and Levitra®, containing the API varden-
afil (Figure 4c).  
 Sildenafil and analogous phosphodiesterase type 5 (PDE-5) inhibitors have their 
mode of action on the nitric oxide–cyclic guanosine monophosphate (cGMP)-specific 
PDE-5 enzyme (Singh et al. 2009; Venhuis and de Kaste 2012). The PDE-5 enzyme is 
present in the lining of the blood vessels supplying the corpus cavernosum penis, which 
is the erectile tissue of the penis. As a result of this, use of PDE-5 inhibitors increase the 
blood flow to the penis during sexual stimulation (Corbin et al. 2002; Pissarnitski 2006). 
Therefore, in medical practice PDE-5 inhibitors are used to treat erectile dysfunction. 
ED is defined as the persistent inability to attain and maintain an erection sufficient to 
permit satisfactory sexual performance (NIH 1993). 
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Figure 4. Chemical structures of a) sildenafil b) tadalafil and c) vardenafil. 
 
The PDE-5 enzyme is also present in the arterial wall of the smooth muscles within the 
lungs. PDE-5 inhibitors give a selective vasodilatation of the pulmonary blood vessels 
and are therefore used in medical practices to decrease pulmonary hypertension (PH). 
Revatio® (Pfizer) and Adcirca® (Lilly) are examples for drugs marketed for PH, and in-
clude the PDE-5 inhibitors sildenafil and tadalafil, respectively. Use of PDE-5 inhibitors is 
contra-indicated in patients who are treated with other types of antihypertensives such 
as nitrates (eg. nitroglycerine, doxazosin and terazosin) (Boden et al. 2012; EMA 2013). 
PDE-5 inhibitors are also contra-indicated in patients suffering from hypotension, but 
who are not treated for this (Kloner 2007). After the NVWA was alerted to the presence 
on the Dutch market of herbal food supplements intended for ED and containing 
sildenafil, the NVWA started a continuous survey in 2002. Subsequently, illegal APIs 
such as analogous PDE-5 inhibitors were identified in herbal food supplements market-
ed for ED. Most of these APIs are not registered drug substances and have not been 
tested for their safety. Often these APIs are by-products of the discovery process for 
the original drug carried out by the pharmaceutical industry. To illustrate the scale of 
this illegal practice in food supplements on the market one should consider that litera-
 
a) 
 
b) 
 
c) 
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ture shows that until 2011 at least 46 different analogues of sildenafil, vardenafil and 
tadalafil were detected in food supplements (Venhuis and de Kaste 2012). The food 
supplements to which this relates are reported to be present on the market in coun-
tries such as India, Taiwan, Singapore, the United States of America and the Nether-
lands and are often obtained via Internet shops (Lin et al. 2006; Zou et al. 2006; Singh 
et al. 2009; Venhuis and de Kaste 2012; FDA 2013). The occurrence and connected risk 
assessment of sildenafil and analogues of PDE-5 inhibitors in herbal food supplements 
is explored in chapter 4 of the present thesis.  
Ad 3) Sibutramine, desmethylsibutramine, didesmethylsibutramine, rimonabant and 
phenolphthalein in herbal food supplements used for weight loss  
Nowadays, overweight and obesity are considered a growing public health issue with 
more than 1.4 billion adults being overweight. Overweight is a status that can be de-
fined by a body mass index (BMI) between 25–30 kg m-2. The WHO estimates that at 
least 500 million people are obese (BMI greater or equal to 30 kg m-2) (WHO 2013). In 
the past a limited number of approved pharmaceuticals to treat obesity and overweight 
were available on the market.  
 The general public uses many other methods for weight loss including herbs, vita-
mins, nutritional supplements, and meal replacement preparations (Hassini-Ranjbar et 
al. 2009) and this includes the wide variety of herbal food supplements intended for 
weight loss present on the market. In the Netherlands, the presence of sibutramine and 
phenolphthalein in a vitamin supplement and in capsules was first reported by the 
National Customs Laboratory in 2004 (RIVM 2009). Based on frequent reports of adul-
terations and side effects resulting from the use of herbal food supplements for the 
treatment of overweight, obesity and constipation, shown to contain APIs such as sibu-
tramine, fenfluramine, rimonabant, orlistat, and phenolphthalein (Yuen et al. 2007; Zou 
et al. 2007; Wang et al. 2008; Chen et al. 2009; RIVM 2009; Tang et al. 2010; Vaysse et 
al. 2010; Stypulkowska et al. 2011; De Carvalho et al. 2012; Dunn et al. 2012; Phattan-
awasin et al. 2012; Ancuceanu et al. 2013), and reports by health authorities such as 
from the Netherlands (IGZ 2010), Australia (Australian government 2007), Canada 
(Health Canada 2006), and the UK (MHRA 2010), the NVWA started also a survey on 
herbal products intended for weight loss and identified the presence of APIs such as 
sibutramine, desmethylsibutramine (DMS), didesmethylsibutramine (DDMS), rimona-
bant and the laxative phenolphthalein.  
 Sibutramine, the chemical structure of which is shown in figure 5a, is a combined 
serotonin (5-HT) and noradrenaline (NA) re-uptake inhibitor. This API was prescribed 
until 2010 in regular medical practice to manage obesity. The increased levels of neuro-
transmitters, serotonin and noradrenalin in the brain helped patients to feel full after a 
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meal, and this helps to reduce their food intake. Sibutramine was suspended from mar-
keting in the EU in 2010 because of risk of serious, non-fatal cardiovascular events, such 
as stroke or heart attack and also because of the rebound of weight gain after termina-
tion of therapy (EMA 2014).  
 In chapter 5 of the present thesis we investigated the presence of DMS and DDMS, 
of which sibutramine is a prodrug, in a series of selected herbal supplements. The 
chemical structures of DMS and DDMS are shown in figures 5b and 5c. We also quanti-
fied the API rimonabant (Figure 5d), which is a selective cannabinoid-1 receptor (CB1) 
blocker (Van Gaal et al. 2005; Padwal and Majumdar 2007). Furthermore, the laxative 
phenolphthalein, which is a benzofuran derivate and of which the chemical structure is 
shown in figure 5e, was quantified in these herbal supplements. In 1996, the US Na-
tional Toxicology Program (NTP) published data on the genotoxity of phenolphthalein 
and its carcinogenicity in laboratory animal studies (NTP 1996). The EMA concluded 
that the National Competent Authorities should take these NTP data into account in 
their considerations of any restriction of phenolphthalein containing medicinal prod-
ucts on the national markets (EMA 1997). 
 The presence of these APIs in herbal supplements characterized the third group of 
food supplements investigated in the present thesis. The occurrence and connected risk 
assessment of the presence of sibutramine, DMS, DDMS, rimonabant, and phenol-
phthalein to herbal food supplements for weight loss is explored in chapter 5 of the 
present thesis. 
 It should be noted that the views expressed in this thesis are those of the author 
and co-authors and do not reflect the official policy or position of the NVWA, and/or 
any scientific institute and/or any Ministry of the Netherlands. 
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Figure 5. Chemical structures of a) sibutramine b) desmethylsibutramine c) didesmethylsibutramine d) 
rimonabant, and e) phenolphthalein. 
Legal framework  
In the next sections a short overview is presented of the legal framework that covers 
the products of concern. 
Ad 1) Clay products for oral use 
The European Food Law and the Dutch Commodities Act, of which the latter is based to 
a large extent on European Food Law, have specific legislation regarding food supple-
ments such as vitamins, minerals, and herbal preparations. Dietary supplements may 
be presented in a pharmaceutical form (e.g. tablets, capsules), though dietary supple-
ments may not claim to be medicines. Furthermore, dietary supplements require no 
pre-marketing evaluation for safety or efficacy (VWS 2003). Of the clay products includ-
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ed in the studies presented, only health clay products are covered by this definition of 
food supplements because these products are marketed in dose form. Traditional clay 
products are mostly not sold in dose form but rather without labelling as powder, sticks 
or balls (see figures 1a and 1b). Therefore, traditional clay products can formally not be 
considered to be food supplements. For the different metals and the metalloid arsenic, 
enforcement on both categories of clay products was initially based on the legal re-
quirement laid down in article 14.1 of Regulation (EC) No. 178/2002 indicating that 
food shall not be placed on the market if it is unsafe (EC 2002). In the course of our 
study, the European Commission established maximum levels for lead, mercury, and 
cadmium in food supplements in Regulation (EC) No. 1881/2006 (EC 2008). These EC 
maximum levels could be applied to the health clay products, given that only these clay 
products can be considered to be food supplements. 
Ad 2 and 3) Herbal food supplements  
The Dutch Commodities Act Decree ‘Herbal preparations’ (in Dutch ‘Warenwetbesluit 
Kruidenpreparaten) covers herbal preparations that are brought on the market as foods 
and non food products (VWS 2001). The decree defines herbal preparations as ‘herbal 
substances, subjected to treatment or not, including herbal extracts, which are intend-
ed to be used by humans’. Herbal substances and herbal preparations from which it is 
plausible that these herbal substances or preparations are designated to be processed 
or further processed to medicines are not covered by this decree because medicines 
are outside the scope of this decree. In the General Food Law medicinal products are 
excluded from the definition of food (EC 2002). Herbal supplements are not subjected 
to strict regulation for medicines (Venhuis et al. 2008), and recent examples such as the 
presence of lipid-lowering and weight reducing agents, and APIs with sedative, anti-
diabetic, hormonal and aphrodisiac properties in herbal supplements (Chen et al. 2009; 
Toriaans et al. 2010) show that herbal supplements, which are covered by the defini-
tion of food, are apparently an ideal matrix for adding APIs. A product can fall within 
the definition of a medicinal product when it is capable of appreciably restoring, cor-
recting or modifying physiological functions by exerting a pharmacological, immunolog-
ical or metabolic action (European Court of Justice 2009). A product can also fall within 
this definition when it is presented as having properties for treating or preventing dis-
ease in human beings by for instance using a medical claim in an advertisement for a 
product. Enforcement of herbal food supplements containing APIs could take place by 
applying the Dutch Commodities Act or the Dutch Medicines Act. Enforcement by the 
Dutch Commodities Act is based on the legal requirement that a food shall not be 
placed on the market if it is unsafe, as laid down in article 14.1 of Regulation (EC) No. 
178/2002. Therefore, when applied to herbal supplements with APIs a risk manage-
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ment authority needs to prove that the herbal supplement is unsafe, based on the 
intake levels of the API when the product is used as intended. One could also explore 
an enforcement strategy for herbal supplements using the Dutch Medicines Act be-
cause herbal supplements containing APIs could fall within the definition of a medicinal 
product based on its pharmaceutical activity. Medicinal products are subject to approv-
al before marketing, and herbal products that fall within the definition of medicinal 
product have often not been approved. In order to investigate whether a product is a 
medicinal product based on its pharmaceutical activity it is essential to prove that the 
observed levels can result in pharmacological effects. For both enforcement scenarios, 
i.e. the one based on the Dutch Commodities Act and the one based on the Dutch Med-
icines Act, the safety or pharmacological effects of the herbal supplement containing 
APIs when used as intended should be assessed. 
Objective and outline of this thesis  
The aim of the present PhD project was to investigate the presence and actual levels of 
various contaminants and pharmacologically active substances in selected food sup-
plements on the Dutch market and to estimate the associated health risks. This was 
done for clay products for oral use, herbal food supplements for the enhancement of 
sexual potency and herbal food supplements used for weight loss.  
 
 Chapter 1 of this thesis, the present chapter, provides a general introduction to 
safety concerns about clay products for oral use, herbal preparations for the enhance-
ment of sexual potency and herbal weight loss food supplements that were brought on 
the market as food commodities in the Netherlands. It also provides a short introduc-
tion on legislation and regulation relating to these products. 
 Chapter 2 discusses the results of investigations into the occurrence of selected 
metals and the metalloid arsenic in clay products intended for oral use and the associ-
ated risks. 
 Chapter 3 focuses on the contamination of traditional clay products, which are 
generally used during pregnancy, with polychlorinated dibenzo-p-dioxins and polychlo-
rinated dibenzo-furans and the associated risks.  
 Chapter 4 presents data on sildenafil and analogous PDE-5 inhibitors in herbal 
preparations used for the enhancement of sexual potency, and the evaluation of asso-
ciated risks.  
 Chapter 5 investigates the contamination with sibutramine, desmethylsibutramine, 
didesmethylsibutramine, rimonabant and phenolphthalein in herbal preparations used 
for weight loss, and evaluates associated risks. 
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 Chapter 6 presents a summary of the results obtained in this thesis and provides a 
discussion on how these results can be translated to the safety of food supplements 
currently on the Dutch market.  
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Abstract  
Pregnant women in Africa, Asia and Suriname, and some immigrants in western 
societies traditionally consume clay products known by a variety of names such as 
mabele, calabash chalk, sikor and pimba. Furthermore, clay is used for health purposes 
in western societies. Because certain clays can contain high levels of metals and 
metalloids, the aim of this study was to determine lead, arsenic, mercury and cadmium 
in clay products for oral use available on the Dutch market. Traditional clays originating 
from Africa (n=10) and Suriname (n=26) and health clays (n=27) were sampled from 
2004 up to and including 2012.  
 Total metal and metalloid contents were measured by ICP-MS and showed 
maximum levels of lead, arsenic, mercury, and cadmium of 99.7, 45.1, 2.2 and 0.75 mg 
kg-1 respectively. In the absence of maximum limits for these type of clays, the potential 
exposure was estimated from the determined concentration, the estimated daily use 
level of the clays and the estimated bioaccessibility of the different metals and arsenic. 
The intake estimates were compared to existing health based guidance values. For lead, 
the use of 34 of the 36 traditional clays and two of the 27 health clays would result in 
intake levels exceeding the toxicological limit by up to 20-fold. Use of 15 of the 35 
traditional clays and 11 of the 27 health clays would result in intake levels exceeding 
the toxicological limit for inorganic arsenic by up to 19-fold. Although limited 
bioaccessibility from the clay may limit the exposure and exceedance of the health 
based guidance values, it was concluded that lead and arsenic intakes from some clay 
products could be of concern also because of their use by pregnant women and the 
potential developmental toxicity. As a result the use of these products, especially by 
pregnant women, should be discouraged. 
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Introduction 
Geophagy, the practice of eating clay or soil, is observed among people of many 
continents. This practice has mainly been reported for children and for pregnant and 
lactating women in parts of the African continent, in Asia, and in South and Central 
America (Halsted 1968; Vermeer 1971; Abrahams and Parsons 1996; Mahaney et al. 
2000). The eating of clay or soil is determined by social and cultural factors. However, 
the medical profession considers geophagy as an aberrant behaviour, and potentially 
hazardous because of the presence of toxic constituents in the material such as metals 
and metalloids, persistent organic pollutants, microbes and parasites (Abrahams 2002; 
Katulek et al. 2010). Clay can be defined as the fine fraction of a soil and contains 
particles of less than 2 µm size (Soil Survey Division Staff 1993). In Africa the habit of 
consuming clay is practiced by pregnant women against morning sickness, for 
supplementing the diet, and for spiritual reasons, but also to promote fertility in non-
pregnant women (Danford 1982; Abrahams and Parsons 1996; Aufreiter et al. 1997; 
Geissler et al. 1999; Henry and Matthews Kwong 2003; Kawai et al. 2009). Examples of 
the large variety of names used for these clay products at local markets in African 
countries like Ghana, Uganda, Tanzania, and Zambia are calabash chalk, white clay, 
calabar stone, la craie, argile, nzu, mabele, emumba and ulo (Vermeer 1971; Hunter 
1993; Reilly and Henry 2000; Smith et al. 2000; FSA 2002; Yanai et al. 2009). Women in 
Java and in the Bengal area of South Asia are also reported to consume clay products 
during pregnancy. The products from the Bengal area are available in the form of 
powder or a solid tablet form with names like sikor, mithi, patri, khuri, kattha, poorcha 
or slatti (Mahaney et al. 2000; Bakraji and Karajou 2003; Abrahams et al. 2006; Al-
Rmalli et al. 2010). In Suriname, pimba, balls of white or reddish clay, are eaten by 
some pregnant women of the Creole society. Pimba is used orally to prevent 
miscarriage, treat acid reflux or promote delivery and it is also applied to the skin for 
spiritual reasons (De Korte 2006).  
 Immigrants from Africa, Java, Bengal area, and Suriname have brought the 
traditional practice of clay consumption to western countries. In the United Kingdom 
for instance, different sorts of clay are consumed by the Nigerian and the wider West-
African Community and in Asian communities (FSA 2002; Abrahams et al. 2006; Al-
Rmalli et al. 2010). Immigrants from Mexico have brought this practice into the United 
States as well (Halsted 1968; Danford 1982). In the Netherlands, pregnant women from 
Suriname are reported to consume pimba (Schuttelaar & Partners 2003). Clay products 
originating from Africa, Asia and Suriname are generally sold in small ethnic shops and 
at markets in the Netherlands. Often labelling of these products is poor, or in many 
cases absent, and the intended use is not specified.  
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In addition to its traditional use, clay is also marketed in capsules, tablets or powdered 
dose form as health food. These health clay products are generally well packaged and 
labelled and are widely available in health- and Internet shops in the Netherlands. 
Health clays are claimed to protect the gastrointestinal tract and aid detoxification and 
are also recommended for use during pregnancy.  
 In literature increased intakes of lead and arsenic due to geophagy were reported 
(Abrahams 2002; Bakraji and Karajou 2003; Abrahams et al. 2006; Al-Rmalli et al. 2010). 
Especially lead readily crosses the placenta, and poses a risk to the unborn child, 
because it may interfere with the neurological development of the fetus (Baars et al. 
2001). In 2002, EU-member states were alerted through the EU-Rapid Alert System for 
Food and Feed to the presence on the Belgian and German market of calabash chalk 
with high lead contents ranging from 8.2 up to 16.1 mg kg-1 (RASSF Number Notification 
2002/336). Subsequently, the Netherlands Food and Consumer Product Safety 
Authority (NVWA) identified similar traditional clay products intended for oral use on 
the Dutch market. At a later stage, clay products marketed as health foods were 
analyzed for lead, other metals and the metalloid arsenic. This paper presents the 
results of a survey on lead, arsenic, mercury and cadmium, and in addition some other 
components like aluminum, magnesium, copper, chromium, iron and zinc in clay 
products for oral use collected on the Dutch market from 2004 up to and including 
2012. Exposure levels to these metals and the metalloid arsenic were estimated using 
the analytical data and the estimated or recommended daily dose levels of the 
individual clay products. Since absorption of metals from soil including clay may be 
rather poor in comparison to the salts used in toxicological studies, the risk assessment 
was refined by applying estimates of the bioaccessibility of the different metals and the 
metalloid arsenic for soil. 
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a) 
 
b) 
Figure 1. Pictures of some clay preparations including a) sticks and b) pimba balls. 
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Material and methods 
Sampling 
For this study NVWA inspectors sampled 63 clay products from 2004 up to and 
including 2012. Sampling locations were selected from the NVWA inspection database 
or identified by an Internet search. All traditional clay products (n=36) were collected 
from importers and vendors of ethnic foods throughout the Netherlands, and were 
exclusively of African and Surinam origin. The clay products which we included in our 
study are likely to be mixtures of different soil types with different particle sizes and 
consisted of pellets, balls, sticks, and powder. Only products for oral use were included.  
 Since traditional products were not labelled, vendors were asked to confirm that 
the products were intended to be used orally. Figures 1a and 1b show two types of 
traditional clay products. These products were only available without label. The vendor 
identified the product shown in Figure 1b as pimba for use against morning sickness in 
the first trimester of pregnancy. Health clays were sampled in health shops. All samples 
of health clays (n=27) were pre-packaged and in the form of powder, capsules, tablets 
or a liquid solution. Except for three health clay products, the label included 
instructions for use. As stated on the label several health clay products were intended 
to be used by pregnant women. 
ICP-MS determination of metals and the metalloid arsenic 
A routine method for the determination of metals and metalloids in clays for oral use 
based on Inductively Coupled Plasma Mass Spectrometry (ICP-MS) was developed and 
validated for enforcement purposes for lead, arsenic, mercury and cadmium. In 
addition, aluminum, magnesium, copper, chromium, iron, and zinc were also analyzed. 
However, the analytical method employed for this was not validated. Samples were 
completely homogenized by grinding them to powder with a grinder (Retsch, Haan 
GmbH, Germany). To 200 mg of the powdered sample 3 ml nitric acid (HNO3, 65%) and 
3 ml hydrochloric acid (HCl, 30%) were added. Digestion of the samples was then 
performed using a microwave oven (Ethos Plus Microwave Labstation, Milestone, Italy) 
in which the samples were treated for 25 minutes at 2000C. The solution produced by 
the digestion process was then quantitatively transferred with de-ionized water from 
the digestion vessel to a 100 ml volumetric flask. Because of the presence of particles, 
the solution was filtered while transferring it to the volumetric flask. Throughout the 
analysis Milli-Q grade de-ionized water was used. The sample solutions were measured 
with ICP-MS (Thermo Electron PQ Excell, Thermo Scientific, United Kingdom) using the 
‘Collision Cell Technology mode’ (CCT-mode) with a helium/hydrogen flow (95/5%). 
METALS IN CLAY PRODUCTS 
 35
Using this gas mixture in the CCT-mode most interferences were reduced (Van der 
Wielen et al. 2005). In order to test if each vessel was clean prior to use, test runs were 
performed on each vessel with only 3 ml HNO3 (65%) and 3 ml HCl (30%) before each 
series of samples. This was repeated after each series in order to confirm that no 
detectable metalloid or metals were left in the vessels. For the in house validation of 
the method, first the limits of detection and quantification (LOD and LOQ, respectively) 
were determined and it was checked if these fulfilled the requirements of Commission 
Regulation (EC) No. 333/2007. The LOQ was defined as half the concentration of the 
lowest calibration standard. The LOD was defined as half the LOQ. The range of the 
calibration curve was used to calculate the range of application. When necessary, 
samples were diluted and reanalyzed to fit within the range of the calibration curve. 
The accuracy of the method was determined by analysis of a soil Certified Reference 
Material (CRM) (LGC Standards; CRM24-050 – Metals on Soil), which contained certified 
levels of the metalloid and metals analyzed. The results of this CRM analysis are 
required to be within the 95% confidence interval of the corresponding certified values. 
Furthermore, the relative standard deviation (RSD) was measured by replicate analysis 
(n=6) of the CRM under repeatability conditions. The CRM was also used as quality 
control sample in each series of measurements. The expanded measurement 
uncertainty (in mg kg-1) was determined as the reproducibility from measurements 
(n>10) of this CRM, analyzed by different persons on different days. Table S-1 lists the 
following method performance characteristics LOD, LOQ, range of application, recovery 
and the RSD for repeatability. The recovery was only determined for lead, arsenic, 
mercury and cadmium. According to the ‘AOAC Guidelines for Single Laboratory 
Validation of Chemical Methods for Dietary Supplements and Botanicals’, the recovery 
has to be between 75 and 120% at the measured concentrations (AOAC 2002). The 
values for the recovery of the method for cadmium, mercury, arsenic and lead that are 
listed in Table S-1, fitted well within these limits. For the other metals that can be 
analyzed with this method the recovery has not been determined. The RSD values for 
lead, arsenic, mercury, cadmium, aluminum, magnesium, copper, chromium, iron and 
zinc, with arsenic displaying the highest value of 13.0%, were found to be below the 
required 15% at the measured concentrations (AOAC 2002). To overcome the build up 
of mercury residues in the system, AuCl was added to the sample and rinse solutions. 
AuCl was selected for this purpose because of the capability of mercury to complex 
with gold (Falciani et al. 2000). 
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Table S-1. Method performance characteristics of the ICP-MS analysis for different metals and metalloid, 
determined by in house validation.  
Metal/metalloid LOD  
(mg kg-1) 
LOQ  
(mg kg-1) 
Range of application 
(mg kg-1) 
Range of application 
(mg week-1) 
Recovery 
(%) 
RSDa 
(%) 
Aluminum 0.63 1.25   0.14 – 3.7 Not validated 7.0
Arsenic 0.063 0.125   0.01 – 0.37 89.7 13.0
Cadmium 0.063 0.125 0.03 – 1.25 0.009 – 0.37 95.9 5.8
Chromium 0.063 0.125   0.015 – 0.37 Not validated 9.5
Copper 0.63 1.25   0.1 – 3.7 Not validated 6.6
Iron 0.63 1.25   0.1 – 3.7 Not validated 7.0
Lead 0.05 0.10 0.10 – 1.25 0.03 – 0.37 93.9 3.3
Magnesium 0.63 1.25   0.1 – 3.7 Not validated 6.6
Mercury 0.013 0.025 0.006 – 0.25 0.002 – 0.074 97.3 5.8
Zinc 0.63 1.25   0.16 – 3.7 Not validated 6.7
Note:  
a Relative Standard Deviation for repeatability 
Estimation of the weekly intake of metals and the metalloid arsenic, selection of 
health based guidance values, and estimation of bioaccessible fractions 
For traditional clay products, we used 42 g as the estimated daily dose level, which was 
defined using reports on geophagy in different countries as an estimate for the daily 
dose level of traditional clay products (Reeuwijk et al. 2013). This estimate is based on a 
study by Geissler et al. (1999) on dose levels used in Kenya in which a median daily dose 
level of 41.5 g day-1 was determined. To calculate the estimated daily intake of the 
selected metalloid and metals with a health clay product we applied the highest 
recommended dose level per day stated on the label of the product, which ranged from 
1.5 to 35.1 g day-1 (Table S-2). For three health clay products no daily dose levels were 
recommended on the label and therefore for these products estimated daily dose 
levels of 7 g day-1 were used, which is the mean of the recommended dose levels 
identified on labels of the other health clay samples. In the Netherlands, consumers of 
African origin, who use traditional clays, estimated the daily consumption of calabash 
chalk by pregnant women in Africa to be 20 clay sticks. However, daily use levels in the 
Netherlands were estimated to be ten times less (Schuttelaar & Partners 2003). 
Although daily use levels in the Netherlands might be lower than in Africa or other 
countries of origin, we maintained the default daily dose level of 42 g in order to 
protect those pregnant women in the Netherlands who adhere to use levels which have 
been reported for Africa or other countries of origin. RIVM/SIR (2003) and the Food 
Standards Agency (FSA) (2002) both estimated a daily dose level of calabash chalk of 60 
g. No data on the dose levels of pimba from Suriname were identified in literature. 
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Table S-2. Contents of metals and arsenic in clay products and estimated or recommended daily dose level 
for individual clay products. 
Origin of 
clay 
producta 
Name clay product Content (mg kg-1) Daily dose 
(g day-1) Aluminum Arsenic Cadmium Chromium Copper Iron Lead Magnesium Mercury Zinc 
Africa Mabele 150000 10.6 0.452 128  14000 46.8 931   42 
 Mabele sale 150000 2.75 0.430 67.3  6800 36.8 2460   42 
 Mabele sale 78000 2.04 0.201 47.6 13 11000 37.4 3480 0.548 41 42 
 Mabele non-sale < LOQ 4.08 0.272 95.2 22 210000 19.2 18600 0.156 130 42 
 Mabele Cameroon 120000 8.74 0.218 120 13 24000 47.6 1070 0.160 51 42 
 Mabele 95000 2.13 0.201 71.4 15 14000 45.9 4210 0.561 54 42 
 Mabele, Nigeria 88000 17.3 < LOQ 110 41 37000 27.5 7480 0.299 37 42 
 Mabele whole, Zaïre < LOQ 10.9 0.418 81.6 61 32000 38.1 13900 0.0646 220 42 
 Mabele broken, Zaïre < LOQ 8.50 0.173 110 18 12000 23.4 1830 2.20 48 42 
 Mabele 87000 11.5 < LOQ 103 38 26000 19.3 6470 0.0630 35 42 
Suriname Pimba 180000 0.875 0.382 193  5100 23.9 211   42 
 Pimba 210000 0.633 0.205 165  6200 56.5 183   42 
 Pimba 190000 0.658 0.164 158  6000 59.3 156   42 
 Pimba 180000 0.414 0.176 42.6  5000 28.1 65.9   42 
 Pimba 150000 0.538 0.238 56.1  5600 59.4 67.6   42 
 Pimba 190000 0.520 0.210 46.3  5400 32.6 81.6   42 
 Pimba 200000 0.436 0.175 55.0  6200 99.7 75.7   42 
 Pimba balls 200000 0.511 0.267 58.1  5400 30.0 90.5   42 
 Pimba balls 190000 0.531 0.403 98.0  4300 28.6 132   42 
 Pimba balls 180000 0.890 0.383 188  5000 35.2 200   42 
 Pimba balls 180000 0.317   131  6000 21.7 395   42 
 Pimba balls 180000 0.580 0.405 98.8  3900 23.1 144   42 
 Pimba Doti        16.0    42 
 Pimba  280000 27.2 0.201 4.97 41 7500 33.3 1660 1.82 29 42 
 Pimba  140000 0.490 < LOQ 48.8 5.0 10000 30.2 83.2 0.0790 17 42 
 Pimba  190000 1.02 0.142 43.2 5.9 6800 24.9 59 0.0530 17 42 
 Pimba  170000 1.89 < LOQ 50.5 18 9100 35.2 4450 0.481 58 42 
 Pimba  < LOQ 1.02 0.190 91.8 11 5100 50.0 106 0.221 34 42 
 Pimba balls 120000 1.05 0.184 57.8 8.2 6500 30.3 106 0.194 15 42 
 Pimba  130000 0.583 < LOQ 36.6 6.2 3900 25.6 47.4 0.0380 31 42 
 Pimba  160000 0.523 < LOQ 50.0 5.3 6500 26.2 63.0 0.0560 18 42 
 Pimba  170000 0.352 0.133 57.7 6.3 5500 25.8 76.7 0.0470 13 42 
 Pimba 4400 3.85 < LOQ 6.6 4.3 2700 < LOQ 3500 < LOQ 5.9 42 
 Pimba 160000 0.556 < LOQ 60.4 2.6 5700 30.0 154 0.0490 26 42 
 Pimba  160000 12.5 < LOQ 121 33 42000 26.5 7220 0.0480 44 42 
 Pimba  42000 5.38 0.296 9.22 5.1 11000 1.77 9020 0.248 10 42 
Europe  Health Clay Ib 1200 0.480 < LOQ 2.21 < LOQ  0.510  < LOQ 2.7 7 
 Health Clay IIb 1400 0.500 < LOQ 2.39 < LOQ  0.540  < LOQ 2.7 7 
 Health Clay IIIb 78000 9.70 < LOQ 73.5  36000 15.0 13900   7 
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Origin of 
clay 
producta 
Name clay product Content (mg kg-1) Daily dose 
(g day-1) Aluminum Arsenic Cadmium Chromium Copper Iron Lead Magnesium Mercury Zinc 
 Health Clay IVb 6900 3.30 < LOQ 57.7 49 33000 22.3 6560 < LOQ 130 2.6 
 Health Clay Vb 19000 20.6 0.206 50.8 22 23000 14.8 11200 0.151 74 10.4 
 Health Clay VIb 18000 19.0 0.201 45.8 21 25000 14.1 10600 0.123 70 12.8 
 Health Clay VIIb 24000 7.36 < LOQ 38.1 13 19000 9.78 6840 < LOQ 42 3.3 
 Health Clay VIIIb < LOQ 13.1 0.750 59.5 26 29000 20.6 13300 0.476 92 12.0 
 Health Clay IXb < LOQ 10.4 0.357 66.7 20 39000 21.9 7680 0.107 79 12.0 
 Health Clay Xb < LOQ 5.24 < LOQ 76.2 67 28000 8.57 7190 0.762 140 3.0 
 Health Clay XIb 70000 10.5 < LOQ 55.3 20 38000 15.1 16000 < LOQ 84 2.2 
 Health Clay XIIb 32000 7.37 0.141 41.6 23 20000 11.7 10700 0.0490 72 12.6 
 Health Clay XIIIb 39000 9.52 0.139 31.7 24 19000 11.8 10900 0.0450 74 13.6 
 Health Clay XIVb 57000 11.2 < LOQ 62.6 21 32000 15.4 23900 < LOQ 90 1.5 
 Health Clay XVb 40000 5.71 0.214 76.1 39 33000 4.90 6740 < LOQ 100 6 
 Health Clay XVIb 75000 29.0 0.639 205 40 51000 20.9 16000 0.109 110 4.4 
 Health Clay XVIIb 71000 11.7 < LOQ 57.9 16 38000 16.6 25300 < LOQ 90 4.4 
 Health Clay XVIIIb 200000 < LOQ < LOQ 55.3 6.8 4600 31.4 57.0 < LOQ 18 3.2 
 Health Clay XIXb 32000 7.02 0.145 25.6 20 20000 11.9 9950 0.0300 67 16.0 
 Health Clay XXb 35000 8.78 0.136 53.2 21 27000 11.7 11700 0.0410 71 13.2 
 Health Clay XXIb 22000 1.30 < LOQ 0.777 2.3 2100 3.07 2780 < LOQ 11 3.0 
 Health Clay XXIIb 75000 4.04 < LOQ 7.62 16 28000 19.9 63500 < LOQ 83 1.6 
 Health Clay XXIIIb 80000 45.1 0.352 81.5 36 46000 36.4 21900 0.0370 110 2.2 
 Health Clay XXIVb 46000 5.62 0.180 60.8 48 48000 4.74 9820 0.0280 130 3.2 
 Health Clay XXVb 30000 6.45 0.139 44.2 10 19000 11.0 11400 < LOQ 46 35.1 
 Health Clay XXVIb 36000 5.81 < LOQ 70.2 32 37000 4.38 7680 < LOQ 85 2.8 
 Health Clay XXVIIb 40000 5.78 < LOQ 73.5 32 39000 3.81 7180 < LOQ 81 2.8 
Notes:   
LOQ = Limit of Quantification  
a origin based on information gathered by NVWA inspectors  
b brand names are blinded 
 
For each metalloid or metal analyzed we selected an established health based guidance 
value by reviewing risk assessments by national and international bodies (Table S-3). 
Pertinent differences in toxicity between various chemical species of a metal or 
metalloid can exist (WHO 2006). When possible this was taken into account when 
selecting appropriate health based guidance values. Given that clay products are often 
consumed by pregnant women risk assessment was primarily aimed at adverse effects 
on the fetus. However, when health based guidance values for developmental effects 
were lacking, the risk assessment was based on other health based guidance values for 
other toxic effects relevant to the mother. These values could either be tolerable intake 
levels for adverse effects with a threshold or benchmark dose (BMD) values for adverse 
effects without a threshold. During our study a BMDL01 value was set for lead (EFSA 
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2010). The BMDL01 value represents the 95th percentile lower confidence limit of the 
BMD resulting in 1% extra risk (EFSA 2010). Although this BMDL value contains no extra 
safety values, it can be used to judge the safety of estimated exposure levels based on 
the margin of safety. The European Food Safety Authority (EFSA) and the Joint 
FAO/WHO Expert Committee on Food Additives (JECFA) recommends using a margin of 
exposure (MOE) approach as priority setting for risk managers (EFSA 2005; JECFA 2005). 
The MOE is the ratio between the BMDL for the adverse effect and the estimated 
intake of the metal or metalloid and can be used. We applied the MOE approach for 
lead and arsenic. 
 
Table S-3. Toxicological health based guidance values for different metals and metalloids.  
Metal/ 
metalloid 
Health based 
guidance 
value  
Type of Health 
based guidance 
value 
Health based 
guidance value set 
by  
Health based guidance value set for Health based 
guidance value
(mg week-1) a  
Aluminum 1 mg kg bw-1 
week-1 
PTWIb;TWIc JECFA (2007) ; EFSA
(2008) 
all aluminum containing additives in 
food 
60 
 2 mg kg bw-1 
week-1 
PTWIb JECFA (2011a) All aluminum compounds in food. 
including food additives 
120 
Arsenic 1.0 µg kg bw-
1 day-1  
TDId RIVM (Baars et al. 
2001)  
Inorganic arsenic 0.42 
 0.3- 8 μg kg 
bw-1 day-1 
BMDL01e EFSA (2009a)  BMDL01 values for use in the risk 
characterization for inorganic arsenic 
for relevant health endpoints, i.e. 1 % 
increased risk for cancer in the lungs, 
skin and bladder and skin lesions. 
0.13 - 3.36  
 3.0 (range 
2.0 - 7.0) μg 
kg bw-1 day-1 
BMDL0.5f JECFA (2011b)  Inorganic arsenic BMDL0.5 value for 
0.5% increased risk on lung cancer 
1.26 (range 
0.84 – 2.94) 
Cadmium 2.5 µg kg bw-
1 week-1 
TWIc EFSA (2009b) Cadmium in food 0.15 
Chromium 5 mg kg bw-1 
day-1 
TDId RIVM (Baars et al. 
2001) 
Insoluble chromium (III) compounds 
and metallic chromium 
2100 
 5 µg kg bw-1 
day-1 
TDId RIVM (Baars et al. 
2001) 
Soluble chromium (III) compounds 2.1 
 250 µg day-1 
 
ULg; Maximum 
Intake Level 
WHO (1996); 
EFSA (2010a) 
Trivalent chromium as a nutrient 
added for nutritional purposes to 
foodstuffs for particular nutritional 
uses and foods intended for the 
general population (including food 
supplements)  
1.75 
Copper 140 µg kg 
bw-1 day-1 
 
TDId RIVM (Baars et al. 
2001) 
Dietary intake of copper  58.8 
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Metal/ 
metalloid 
Health based 
guidance 
value  
Type of Health 
based guidance 
value 
Health based 
guidance value set 
by  
Health based guidance value set for Health based 
guidance value
(mg week-1) a  
 5 mg day-1 ULg of the safe 
range of mean 
population intakes
EC SCF (2003) Dietary intake of copper 35 
Iron 0.8 mg kg 
bw-1 day-1 
PMTDIh JECFA (1983) Iron from all sources, except iron 
oxides used as coloring agents, 
supplemental iron taken during 
pregnancy and lactation and 
supplemental iron for specific clinical 
requirements  
336 
Lead 25 µg kg bw-1 
week-1  
PTWIb IPCS (2000) Lead from all food sources 1.5 
 0.54 μg kg 
bw-1 day-1 
BMDL01e EFSA (2010b)  Maternal BMDL01 intake level for lead 
for neurodevelopmental effects on 
the developing fetus 
0.23  
Magnesium 250 mg day-1 Tolerable Upper 
Intake Level 
EC SCF (2001) Readily dissociable magnesium salts 
in nutritional supplements, water, or 
added to food and beverages 
1750 
Mercury 2 µg kg bw-1 
day-1  
TDId;  
TDId 
ICPS (2003); 
RIVM (Baars et al. 
2001) 
Inorganic mercury 0.84 
 4 µg kg bw-1 
week-1 
PTWIb; TWId JECFA (2011b); 
EFSA (2012) 
Inorganic mercury 1.68 
Zinc 500 µg kg 
bw-1 day-1 
TDI RIVM (Baars et al. 
2001) 
Dietary intake of zinc 210 
 0.3-1.0 mg kg 
bw-1 day-1 
PMTDIh JECFA (1982) Dietary intake of zinc 126-420 
Notes:   
Values in bold were the values used in the present paper for the safety assessments. 
a expressed on a weekly basis and calculated for a 60 kg adult (except for magnesium and WHO/EFSA health 
based guidance value for chromium); 
b Provisional Tolerable Weekly Intake  
c Tolerable Weekly Intake  
d Tolerable Daily Intake  
e Benchmark Dose Lower Confidence Limit of 1% extra risk 
f Benchmark Dose Lower Confidence Limit of 0.5% extra risk 
g Upper Limit  
h Provisional Maximum Tolerable Daily Intake 
 
For our risk assessment of lead from clay products, we initially selected for 
enforcement purposes the PTWI for lead from all food sources of 25 μg kg bw-1 week-1, 
set by the International Programme on Chemical Safety (IPCS) of the World Health 
Organization (WHO) (IPCS 2000). In the course of our study, EFSA concluded in a 
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Scientific Opinion on Lead in Food that this PTWI, established by IPCS, was no longer 
appropriate. EFSA based this conclusion on the absence of evidence for a threshold for 
a number of critical endpoints including developmental neurotoxicity. EFSA also 
concluded that due to maternal exposure to lead at current dietary exposure levels a 
risk to the developing fetus could not be excluded. EFSA derived a maternal BMDL01 for 
neurodevelopmental effects (a decrease of 1 IQ point) on the developing fetus of 0.54 
μg kg bw-1 day-1, which is equivalent to 0.23 mg week-1 for a 60 kg adult (EFSA 2010). 
 For our risk assessment of inorganic arsenic we applied the TDI of 1.0 µg kg bw-1 
day-1, which was established by RIVM focusing on skin cancer as the critical effect 
(Baars et al. 2001). This TDI, which we applied for enforcement purposes, is equivalent 
to 0.42 mg week-1 for a 60 kg adult. During our study, EFSA published a Scientific 
Opinion on Arsenic in Food, in which BMDL01 values for cancer in the lungs, skin and 
bladder and skin lesions ranging from 0.3 to 8 µg kg bw-1 day-1 were derived (EFSA 
2009a). Furthermore, JECFA (2011a) also published a safety evaluation of arsenic in 
food, in which JECFA derived a BMDL0.5 of 3.0 µg kg bw-1 day-1 for inorganic arsenic, 
resulting in a 0.5% increased incidence of lung cancer (JECFA 2011a). We applied the 
lowest BMDL value derived in these recent risk assessments, which is the BMDL01 
intake value of 0.3 µg kg bw-1 day-1 derived by EFSA for lung cancer which is equivalent 
to 0.13 mg week-1 for a 60 kg adult, to our data (EFSA 2009a). For arsenic no specific risk 
assessment has been performed for the developmental effects mentioned (stillbirth 
etc.).  
 For our risk assessment of mercury in clay products, we assumed that mercury in 
clay is present as inorganic mercury and we selected therefore a TWI for inorganic 
mercury of 4 µg kg bw-1 day-1 which is based on renal toxicity and was recently 
established by EFSA (EFSA 2012). This TWI is equivalent to 1.68 mg week-1 for a 60 kg 
adult (Table S-3). Data on the reproductive toxicity of inorganic mercury compounds in 
humans are lacking, but animal studies suggest that exposure to inorganic mercury 
compounds could result in toxic effects during development (EFSA 2012).  
 For our risk assessment of aluminum we selected the JECFA-PTWI of 2 mg kg bw-1 
week-1 which applies to all aluminum compounds in food, including food additives and 
is equivalent to 120 mg week-1 for a 60 kg adult (JECFA 2011b).  
 In agreement with European Regulation (EC) No. 333/2007 we established for 
enforcement purposes for each metal and metalloid the estimated weekly intake level 
at which the health based guidance value expressed on a weekly basis for a 60 kg adult 
was exceeded beyond reasonable doubt (EC 2007). We derived these decision limits by 
adding to the selected health based guidance values for these elements, the analytically 
obtained expanded measurement uncertainty (Table 1). In the course of our study, the 
European Commission established maximum levels for lead, mercury, and cadmium in 
food supplements in Regulation (EC) No. 1881/2006, but no limit has yet been 
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proposed for arsenic. These limits apply since 1 July 2009 (EC 2008) and we also applied 
the EC maximum levels to our data. Because of the dose form, the health clays included 
in the current study, but not the traditional clay products, are covered by the definition 
of food supplements as specified in the European Directive 2002/46/EC (EC 2002a). 
Therefore, the EC maximum levels for these metals in principle only apply to the health 
clays investigated in this study. In accordance with the requirements established in 
Regulation (EC) No. 333/2007, we established for lead, mercury, and cadmium at what 
level the respective maximum product level in Regulation (EC) No. 1881/2006 is 
exceeded beyond reasonable doubt (EC 2008). In order to define such decision limits, 
the analytically obtained expanded measurement uncertainty values for lead, mercury 
and cadmium were added to these EC maximum product levels (Table 2). 
 
Table 1. Decision limits to the health based guidance values at which health based guidance values are 
exceeded beyond reasonable doubt, consisting of the health based guidance value plus the expanded 
measurement uncertainty.  
Metal/metalloid Health based guidance 
values (mg week-1)a 
Expanded measurement 
uncertainty (mg week-1)a.b 
Decision limit (to health based 
guidance values) (mg week-1)a 
Aluminum 120 24c 144 
Arsenic TDI 0.42 0.10 0.52 
Arsenic BMLD01 0.13   
Cadmium 0.15 0.017 0.17 
Chromium 2100 630c 2730  
Copper 58.8 6.30c 65.1 
Iron 336 112c 450  
Lead PTWI 1.5 0.27 1.77 
Lead BMDL01 0.23   
Magnesium 1750 177c 1930  
Mercury 1.68 0.26 1.94 
Zinc 210 21.5c 232  
Notes: 
a expressed on a weekly basis and calculated for a 60 kg adult (where applicable), derived from Table S-3. 
b determined by in house validation 
c recovery not included in measurement uncertainty 
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Table 2. Decision limits at which EU maximum product levels for lead, mercury and cadmium in food 
supplements as set in Commission Regulation (EC) No. 1881/2006a are exceeded beyond reasonable doubt. 
consisting of the EU maximum levels plus the expanded measurement uncertainty of the method applied by 
NVWA. 
Metal EC maximum product levels 
in food supplements 
(mg kg-1) 
Expanded measurement 
uncertainty b 
(mg kg-1) 
Decision limits for maximum product 
levels in food supplements 
(mg kg-1) 
Cadmium 1.0 0.114 1.114 
Lead 3.0 0.54 3.54 
Mercury 0.1 0.016 0.116 
Notes: 
a as amended by Regulation (EC) No. 629/2008 
b determined by in house validation 
 
Furthermore, we assumed that the metal and metalloid content of the clay products 
would not be fully available for intestinal absorption and therefore we refined our risk 
assessment by applying a range of bioaccessible fractions per metal and metalloid in 
clay to our data. For this we collected data of in vitro bioaccessibility studies of metals 
and the metalloid arsenic in soil fractions (Table S-4). In order to estimate the range of 
the bioaccessible fractions we selected per metal or metalloid the lowest and highest 
reported bioaccessibility values which are shown in Table 3. For the refinement of our 
risk assessment we based our estimated intake levels on three bioaccessibility 
scenarios. For the first scenario we corrected for the lower bound of the bioaccessible 
fraction, which presents the least conservative estimated intake estimation. For the 
second scenario we corrected for the upper bound of bioaccessible fraction, which 
presents a less conservative estimated intake. In the third scenario no correction for 
bioaccessibility was made, which means that the measured metal and metalloid 
content would be fully bioaccessible, thereby presenting the worst case estimated 
intake level scenario.  
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Supplementary Table S-4. Bioaccessible fractions of selected metalloid and metals in soil identified in 
literature. 
Metal or 
metalloid 
Reported 
range of the 
bioaccessible 
fraction (%)a 
Bioaccessible 
fraction (%) 
Type of soil Origin 
soil/clay 
Method Author(s) 
Aluminum 0.26-1.7     
  0.26-1.7 
(median)  
Soil (ground 
soil) (n=9), 
termite nest 
soil (n=8), 
traditional 
herbal soil 
remedies 
(n=5) 
Uganda PBETb Smith et al 
(2000) 
  0.53 (mean) Soil termite 
nest (n=2) 
Zimbabwe Gastrointestinal 
mineral 
dissolutionc 
Aufreiter et 
al. (1997) 
  1.3 (mean) Soil (n=1) USA (North 
Carolina) 
Gastrointestinal 
mineral 
dissolutionc 
Aufreiter et 
al. (1997) 
  1.7 (mean) Soil suburb 
city (n=3) 
China (Hunan 
province) 
Gastrointestinal 
mineral 
dissolutionc 
Aufreiter et 
al. (1997) 
Arsenic 1-44      
  1-22 (range), 5 
(median), 6.9 
(average) 
highly 
mineralised 
locations 
containing 
geogenic As 
sources 
(gossans) 
(n=11) 
Australian 
Capital 
Territory and 
South 
Australia 
SBETd Juhaz et al. 
(2007) 
  4.8 and 6.3 
(mean of 250 
μm and 2 mm 
size fractions) 
Surface soils 
(n=20) 
N-S transect 
United States 
and Canada 
Simulated 
gastric fluid 
described by 
Drexler and 
Brattin (2007)e 
Morman et 
al. (2009) 
  5-14 (range), 9 
(mean), 9 
(median) 
Geogenic 
domains 
dominated by 
iron stones 
(n=49) 
Northampton 
urban area, 
United 
Kingdom 
UBMf Appleton et 
al. (2012) 
  9 (median - not 
affected by 
mining activities)
mineralized 
soils (n=20)  
Devon, UK PBETb Palumbo-
Roe and 
Klinck (2007) 
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Metal or 
metalloid 
Reported 
range of the 
bioaccessible 
fraction (%)a 
Bioaccessible 
fraction (%) 
Type of soil Origin 
soil/clay 
Method Author(s) 
  9.7-28.7 (mean, 
range for three 
different 
ingestion 
scenarios) 
Urban 
playground 
soils (n=25) 
Urban 
Uppsala, 
Sweden  
In vitro 
digestion 
described by 
Oomen et al. 
(2002)g 
Ljung et al. 
(2007)  
  25±19.5 (mean 
relative 
bioaccessible 
fraction across 
all soils 
Different soils 
collected from 
different 
regions (n=50)
Australia SBETd Smith et al. 
(2009) 
  29 Forest soil 
with high clay 
content from 
abandoned 
gold mine 
North 
Brookfield 
District (n-=1) 
Nova Scotia, 
Canada 
PBETb Meunier et 
al. (2010) 
Cadmium 12.9-68      
  12.9-27.2 (mean, 
range for three 
different 
ingestion 
scenarios) 
Urban 
playground 
soils (n=25) 
Urban 
Uppsala, 
Sweden  
In vitro 
digestion 
described by 
Oomen et al. 
(2002)g 
Ljung et al. 
(2007)  
  16-59 (range), 
31 (mean), 32 
(median) for 
gastro-intestinal 
phase 
58-61 (range), 
68 (mean) , 68 
(median) for 
gastric phase 
Topsoil 
samples from 
2 lead and zinc 
smelters 
(n=27) 
Northern 
France 
UBMf Roussel et al. 
(2010) 
  58.8 and 64.9 
(mean of 2 mm 
and 250 μm size 
fractions) 
Surface soils 
(n=20) 
N-S transect 
United States 
and Canada 
Simulated 
gastric fluid 
described by 
Drexler and 
Brattin (2007)e 
Morman et 
al. (2009) 
Chromium 1-16      
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Metal or 
metalloid 
Reported 
range of the 
bioaccessible 
fraction (%)a 
Bioaccessible 
fraction (%) 
Type of soil Origin 
soil/clay 
Method Author(s) 
  1-16 (range) 0-10 cm in 
depth samples 
from Tirono 
(n=5) and 
Sevilla (n=5) 
Northern 
Italy and 
southern 
Spain 
SBETd Madrid et al. 
(2008) 
  1.4 and 1.6 
(mean of 2 mm 
and 250 μm size 
fractions) 
Surface soils 
(n=20) 
N-S transect 
United States 
and Canada 
Simulated 
gastric fluid 
described by 
Drexler and 
Brattin (2007)d 
Morman et 
al. (2009) 
  1.9-4.5 (mean, 
range for three 
different 
ingestion 
scenarios) 
Urban 
playground 
soils (n=25) 
Urban 
Uppsala, 
Sweden  
In vitro 
digestion 
described by 
Oomen et al. 
(2002)g 
Ljung et al. 
(2007)  
Copper 11.1-60      
  11.1 (median) Soil (n=13) Uganda 0.1 M HCl 
extractionh 
Abrahams 
(1997) 
  19.7-54.5 
(mean) 
Soil  Bengali area 
south Asia 
PBETb Abrahams et 
al (2006) 
  38-60 (range) 0-10 cm in 
depth soil 
samples from 
Tirono (n=5) 
and Sevilla 
(n=5) 
Northern 
Italy and 
southern 
Spain 
SBETd Madrid et al. 
(2008) 
Iron 0.1-4.1      
  0.1- 2.9 (median 
bioaccessibility) 
Soil (ground 
soil (n=9), 
termite nest 
soil (n=8), 
traditional 
herbal soil 
remedies 
(n=5) 
Uganda PBETb Smith et al 
(2000) 
  0.2-4.1 Soil  Bengali area 
south Asia 
PBETb Abrahams et 
al (2006) 
  1.7 (mean)  Soil (n=1) USA (North 
Carolina) 
Gastrointestinal 
mineral 
dissolutionb 
Aufreiter et 
al. (1997) 
  1.7 (median) Soil (n=13) Uganda 0.1 M HCl 
extractionh 
Abrahams 
(1997) 
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Metal or 
metalloid 
Reported 
range of the 
bioaccessible 
fraction (%)a 
Bioaccessible 
fraction (%) 
Type of soil Origin 
soil/clay 
Method Author(s) 
  2.4 (mean) Soil suburb 
city (n=3) 
China (Hunan 
province) 
Gastrointestinal 
mineral 
dissolutionc 
Aufreiter et 
al. (1997) 
Lead 2.8-76      
  2.8-15.4 (mean, 
range different 
ingestion 
scenarios) 
Urban 
playground 
soils (n=25) 
Urban 
Uppsala, 
Sweden  
In vitro 
digestion 
described by 
Oomen et al. 
(2002)g 
Ljung et al. 
(2007)  
  3.0 and 3.4 
(point estimates)
Soil (n=2) Bengali area 
south Asia 
PBETb Abrahams et 
al. (2006) 
  4.0 and 18.3 
(mean of 2 mm 
and 250 μm size 
fractions, 
respectively) 
Surface soils 
(n=20) 
N-S transect 
United States 
and Canada 
Simulated 
gastric fluid 
described by 
Drexler and 
Brattin (2007)e 
Morman et 
al. (2009) 
  14-63 (range), 
32 (mean), 32 
(median) for 
gastro-intestinal 
phase 
33-76 (range), 
62 (mean), 65 
(median) for 
gastric phase 
Topsoil 
samples from 
2 lead and zinc 
smelters 
(n=27) 
Northern 
France 
UBMf Roussel et al. 
(2010) 
  16.3 (median) Soil (n=13) Uganda 0.1 M HCl 
extractionh 
Abrahams 
(1997) 
  17.8-59.1 
(range) and 42 
(median) 
soils (n=19) New South 
Wales and 
South 
Australia, 
Australia 
SBETd Lamb et al. 
(2009) 
  30-60 (range) 0-10 cm in 
depth soil 
samples from 
Torino (n=5) 
and Sevilla 
(n=5) 
Northern 
Italy and 
southern 
Spain 
SBETd Madrid et al. 
(2008) 
Magnesium 5.5-51.7     
  5.5-51.7 (mean) Soil  Bengali area 
south Asia 
PBETb Abrahams et 
al (2006) 
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Metal or 
metalloid 
Reported 
range of the 
bioaccessible 
fraction (%)a 
Bioaccessible 
fraction (%) 
Type of soil Origin 
soil/clay 
Method Author(s) 
  7-33 (median 
bioaccessibility) 
Soil (ground 
soil (n=9), 
termite nest 
soil (n=8), 
traditional 
herbal soil 
remedies 
(n=5) 
Uganda PBETb Smith et al 
(2000) 
  9.2 (mean) Soil suburb 
city (n=3) 
China (Hunan 
province) 
Gastrointestinal 
mineral 
dissolutionc 
Aufreiter et 
al. (1997) 
  9.5 (mean) Soil termite 
nest (n=2) 
Zimbabwe Gastrointestinal 
mineral 
dissolutionc 
Aufreiter et 
al. (1997) 
  10.8 (mean) Soil (n=1) USA (North 
Carolina) 
Gastrointestinal 
mineral 
dissolutionc 
Aufreiter et 
al. (1997) 
  28.2 (median) Soil (n=13) Uganda 0.1 M HCl 
extractionh 
Abrahams 
(1997) 
Mercury 0.3-46      
  0.3-14 (range), 
3.2 (average) 
(n=19)\46 (point 
estimate (n=1) 
average for 
n=20: 5.3 
East Fork 
Poplar Creek, 
Oak Ridge site 
(HgS-
contaminated) 
(n=20) 
Tennessee, 
United States
In vitro 
simulation of 
the stomach 
and small 
intestines 
Barnett and 
Turner 
(2001) 
  <0.93-<3.14 
(gastric phase) 
<1.02-<3.15) 
(intestinal 
phase) 
Clays near a 
chlor-alkali 
plant in 
eastern 
Canada (n=2),
and silty loam 
collected near 
a gold mine in 
Quebec (n=1) 
Canada CDM method 
described by 
Barnett and 
Turner (2001)i  
Zagury et al. 
(2009) 
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Metal or 
metalloid 
Reported 
range of the 
bioaccessible 
fraction (%)a 
Bioaccessible 
fraction (%) 
Type of soil Origin 
soil/clay 
Method Author(s) 
  <10 Unpublished in 
vitro study on 
soil from site 
in Los Gatos 
(n=unknown) 
California, 
United States
5-hr ‘stomach 
phase’ 
incubation at a 
pH of 2.5 
followed by a 4-
hr ‘small 
intestinal phase’ 
at a pH of 6.5 
Schoof and 
Nielsen 
(1997) 
Zinc 8-85     
  8-47 (range), 23 
(mean), 23 
(median) for 
gastro-intestinal 
phase 
17-85 (range), 
47 (mean), 48 
(median) for 
gastric phase 
Topsoil 
samples from 
2 lead and zinc 
smelters 
(n=27) 
Northern 
France 
UBMf Roussel et al. 
(2010) 
  9.8-33.3 (mean) Soil  Bengali area 
south Asia 
PBETb Abrahams et 
al (2006) 
  12.6 (median) Soil (n=13) Uganda 0.1 M HCl 
extractionh 
Abrahams 
(1997) 
  21-83 (median) Soil (ground 
soil (n=9), 
termite nest 
soil (n=8), 
traditional 
herbal soil 
remedies 
(n=5) 
Uganda PBETb Smith et al 
(2000) 
  34-83 (range) 0-10 cm in 
depth samples 
from Torino 
(n=5) and 
Sevilla (n=5) 
Northern 
Italy and 
southern 
Spain 
SBETd Madrid et al. 
(2008) 
Notes:  
a For the estimation of the range of the bioaccessible fraction we selected from the studies, which are shown 
in this table, the lowest and highest reported bioaccessible value per metal or metalloid. 
b PBET; in vitro physiologically based extraction test (simulates gastric and small intestinal mode of action) 
c Gastrointestinal mineral dissolution; Low pH chemical extraction 
d SBET; simplified bioaccessibility extraction test; represents the gastric phase 
e Simulated gastric fluid described by Drexler and Brattin (2007); simulates gastric fluid 
f UBM; Unified BARGE Method, which is an in vitro physiological gastro-intestinal (GI) simulation described by 
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Wragg et al. (2011) and Denys et al. (2012); includes gastric and gastro-intestinal phases 
g In vitro digestion described by Oomen et al. (2002); model includes mouth, stomach and small intestines 
h 0.1 M HCl extraction; simulates stomach  
i CDM method described by Barnett and Turner (2001); includes gastric phase and intestinal phase extractions 
Results  
Contents of metals and the metalloid arsenic in clay products 
In total 63 samples were analyzed for selected metals and the metalloid arsenic. These 
63 samples could be subdivided in the following categories: African clays (n=10), 
Suriname clays (n=26), and health clays (n=27). Not every sample was analyzed for all 
selected elements. Table S-2 shows that the highest level of lead (99.7 mg kg-1) was 
found in a Suriname clay product named ‘pimba’. The mean lead content in health clay 
products was significantly lower (P<0.05) than the mean lead content found in 
traditional clay products of African and Suriname origin. The highest level of arsenic 
(45.1 mg kg-1) was found in a health clay product, and that of mercury (2.20 mg kg-1) in 
an African clay product named ‘Mabele broken Zaïre’. The highest cadmium levels were 
found in a health clay product (0.75 mg kg-1), that of aluminum (280,000 mg kg-1) in a 
clay product originating from Suriname and those for magnesium (63,500 mg kg-1), 
copper (67 mg kg-1), and chromium (205 mg kg-1) in health clay products. The highest 
levels for iron (210,000 mg kg-1) and zinc (220 mg kg-1) were found in African clay 
products.  
Estimated weekly intake levels in relation to health based guidance values 
From the contents of the metalloid and metals determined in the individual clay 
products and their estimated or recommended ingestion levels of traditional and health 
clays, the estimated weekly intake levels were calculated as described in the Material 
and Methods section for three scenarios: by applying the estimated lower and upper 
bounds of the reported bioaccessibility ranges, which are shown in Table 3, and by 
assuming that the contents of all metals and arsenic would be fully bioaccessible.  
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Table 3. Reported lower and upper bound of bioaccessible fraction per metal or metalloid 
Metal/metalloid Lower bound (%)a Upper bound (%)a
Aluminum 0.26 1.7 
Arsenic 1.0 44 
Cadmium 12.9 68 
Chromium 1.0 16 
Copper 11.1 60 
Iron 0.1 4.1 
Lead 2.8 76 
Magnesium 5.5 51.7 
Mercury 0.3 46 
Zinc 8.0 85 
Note:  
a For the estimation of the range of the bioaccessible fraction we selected from the studies which are shown 
in Table S-4 the lowest and highest reported bioaccessible value per metal or metalloid. 
 
Table S-5 shows for each metal or metalloid in the combined group of clay products and 
each of the subgroups of clay products the mean, highest and lowest estimated intake 
levels, resulting from the use of these products at estimated or recommended dose 
levels, assuming that the metals and the metalloid would be 100% bioaccessible. Table 
4 shows for each analyzed metal or metalloid and for the three scenarios the number of 
clay products for which the use would lead to an exceedance of the health based 
guidance values. In Table 4 it is shown that, when applying the lower bound of the 
reported bioaccessibility range, except for the PTWI for aluminum and BMDL01 for lead, 
no individual estimated intake levels of lead and arsenic exceed the health based 
guidance values. From Table 5 it is shown that the ranges of MOE values for lead in 
traditional clay products are above 1 except for the full bioaccessibility scenario and 
upper bound scenario. The ranges of MOE values for arsenic are above 1 except for the 
African clay products for the full bioaccessibility scenario and the upper bound scenario 
(Table 5). No clay products when used at the estimated doses were found to result in 
intake levels exceeding health based guidance values of mercury and cadmium for all 
three bioaccessiblility scenarios. For mercury, considering that this metal would be 
100% bioaccessible, the highest estimated weekly intake level was found in a clay 
product of African origin (0.65 mg week-1). The use of this clay product, at the daily 
dose level of 42 g, would result in a weekly intake amounting to 39% of the selected 
health based guidance value of 1.68 mg week-1 for mercury (Table S-3). For cadmium, 
considering this metal would be fully bioaccessible, the highest estimated weekly 
intake, when used at the estimated daily dose level of 42 g of the clay products 
analyzed for this metal, was 87% of the selected health based guidance value of 0.15 
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mg week-1 (Table S-3), and was found in a mabele originating from Africa (0.13 mg 
week-1). At the estimated daily dose level of 42 g, use of a clay product from Suriname 
would result in an estimated weekly aluminum intake of 83,000 mg week-1. This level 
exceeds the selected health based guidance value up to 600 times. When considering 
the full bioaccessibility scenario, or the lower and upper bounds of the bioaccessibility 
range for aluminum, the use of respectively 53, 6 and 32 clay products at the estimated 
or recommended dose levels, would lead to intake levels that would exceed the health 
based guidance value for this metal (Table 4). Assuming that the iron in the clay 
products is fully accessible, the use of the clay products would result in relatively high 
intake levels of this metal and could lead to a considerable exceedance of health based 
guidance levels. However, when taking into account the reported bioaccessibility range 
of 4.1 to 0.1%, only two clay products or no clay products at all, would lead to an 
exceedance of the health based guidance value (Table 4). Assuming magnesium would 
be fully bioaccessible, the use of eight out of the 60 products analyzed for magnesium 
would lead to exposure above the Tolerable Upper Intake Level, equivalent to 1750 mg 
week-1. However, this number would be reduced to only three or none at all when 
considering that the bioaccessibility of the magnesium contents would range between 
51.7% and 5.5% (Table 4). Use of the analyzed products would not result in estimated 
weekly intakes of copper, chromium and zinc above the corresponding health based 
guidance values even when assuming full bioaccessibility for these metals.  
 The EU has set maximum levels for lead, cadmium and mercury but these are only 
applicable to the health clays. Table 6 shows the number of health clay products 
exceeding the EU maximum levels for food supplements for these metals in comparison 
to the number of clays of which the use would lead to an exceedance of the health 
based guidance levels taking into account the three scenarios of bioaccessible fractions. 
 
Table S-5. Metal and metalloid estimated weekly intake levels (mg week-1) in clay productsa 
Metal/metalloid 
All clays 
Number of clay products 
analyzed for metal (n) 
Mean  
(mg week-1) 
Lowest value  
(mg week-1) 
Highest value  
(mg week-1) 
Aluminum 55 26000 < LOQ (n=7) 83000 
Arsenic 61 0.914 < LOQ (n=1) 7.99 
Cadmium 38 0.0584 < LOQ (n=23) 0.133 
Chromium 62 14.9 0.016 56.7 
Copper 45 3.2 < LOQ (n=2) 18 
Iron  60 3600 43 62000 
Lead 62 5.97 < LOQ (n=1) 29.3 
Magnesium 60 854 1.28 7310 
Mercury 32 0.0714 < LOQ (n=15) 0.646 
Zinc 47 8.2 0.13 65 
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Metal/metalloid 
All clays 
Number of clay products 
analyzed for metal (n) 
Mean  
(mg week-1) 
Lowest value  
(mg week-1) 
Highest value  
(mg week-1) 
African clays     
Aluminum 7 32000 < LOQ (n=3) 45000 
Arsenic 10 2.31 0.600 5.10 
Cadmium 8 0.0869 < LOQ (n=2) 0.133 
Chromium 10 27.5 14 37.6 
Copper 8 8.1 3.7 18 
Iron  10 11000 2000 62000 
Lead 10 10.1 5.64 14.0 
Magnesium 10 1780 274 5460 
Mercury 8 0.149 0.0190 0.646 
Zinc 8 23 10 65 
Suriname clays     
Aluminum 24 48000 < LOQ (n=1) 83000 
Arsenic 25 0.745 0.0932 7.99 
Cadmium 17 0.0718 < LOQ (n=7) 0.119 
Chromium 25 22.7 1.46 56.7 
Copper 13 3.3 0.76 12 
Iron  25 2200 790 12000 
Lead 25 10.0 < LOQ (n=1) 29.3 
Magnesium 25 333 13.9 2650 
Mercury 12 0.0817 < LOQ (n=1) 0.535 
Zinc 13 6.5 1.7 13 
Health clays     
Aluminum 24 2700 < LOQ (n=3) 12000 
Arsenic 26 0.541 < LOQ (n=1) 1.70 
Cadmium 13 0.0233 < LOQ (n=14) 0.630 
Chromium 27 3.12 0.0160 12.5 
Copper 24 1.51 < LOQ (n=3) 5.5 
Iron  25 1800 43 7100 
Lead 27 0.697 0.0250 2.70 
Magnesium 25 1010 1.28 7310 
Mercury 12 0.00941 < LOQ (n=14) 0.0400 
Zinc 26 4.6 0.13 17 
Note: a not corrected for the bioaccessible fractions of the metals and metalloid  
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Table 4. Number of clay products the use of which would lead to estimated intakes exceeding selected 
health based guidance valuesa, assuming either 100% bioaccessible or taking into account the reported upper 
and lower bound values of the bioaccessible fraction.  
Metal/ metalloid No. of products tested per 
metal/metalloid 
100% bioaccessible Lower bound  Upper bound  
Aluminum 55 (7/24/24)b 53 (7/24/22)c 6 (0/6/0)c 32 (7/23/2)c 
Arsenic TDI 61 (10/25/26)b 26 (10/5/11) c 0 13 (7/3/3)c 
Arsenic BMDL01 49 (10/22/17)c 0 32 (10/8/14)c 
Cadmium  38 (8/17/13)b 0 0 0 
Chromium 62 (10/25/27)b 0 0 0 
Copper 45 (8/13/24)b 0 
 
0 0 
Iron  60 (10/25/25)b 56 (10/25/21)c 0 2 (1/1/0)c 
Lead PTWI 62 (10/25/27)b 36 (10/24/2) c 0 35 (10/24/1)c 
Lead BMDL01 51 (10/25/16)c 21 (6/15/0)c 50 (10/25/15)c 
Magnesium 60 (10/25/25)b 8 (3/2/3)c 0 3 (2/0/1)c 
Mercury  32 (8/12/12) b 0 0 0 
Zinc 47 (8/13/26) b 0 0 0 
Notes:   
a Expressed on a weekly basis and calculated for a 60 kg adult (Table S-3) 
b Between brackets respective numbers of African, Suriname and health clay products tested per metal or 
metalloid 
c Between brackets respective numbers of African, Suriname and health clay products exceeding the health 
based guidance values  
 
Table 5. Ranges in Margins of Exposure (MOE) for leada and arsenicb in three categories of clay products for 
three scenarios: lead in clay products is either 100% bioaccessible, or the bioaccessability is at the reported 
upper bound level, or at the reported lower bound level.  
Product 100% bioaccessible Upper bound  Lower bound  
Lead  Arsenic Lead Arsenic Lead Arsenic 
African clays (n= 10) 0.02-0.04 0.03-0.22 0.02-0.05 0.06-0.49 0.59-1.46 2.6-21.7 
Suriname clays (n=25) 0.01-0.44 0.02-1.4 0.01-0.58 0.04-3.2 0.28-15.8 1.6-139.5 
Health clays (n=27) 0.09-9.20 0.08-5.5 0.11-12.1 0.17-12.6 3.04-328.6 7.7-553.2 
Notes:  
a expressed as the ratio between the maternal BMDL01 intake level for lead for neurodevelopmental effects 
on the developing fetus of 0.54 μg kg bw-1 day-1 (Table S-3) (EFSA 2010b) and the intake levels for lead in clay 
products, expressed per kg bw-1 day-1. 
b expressed as the ratio between the BMDL01 values for use in the risk characterization for inorganic arsenic 
for cancer in the lungs of 0.3 μg kg bw-1 day-1 (Table S-3) (EFSA 2009a) and the intake levels for arsenic in clay 
products, expressed per kg bw-1 day-1. 
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Table 6. Number of health clay products (n=27) exceeding the decision limits based on the EU maximum 
levels for food supplements and health based guidance values assuming 100% bioaccessible or corrected for 
the reported upper and lower bounds of the bioaccessible fractions.  
Metal EU maximum 
levelsa 
health based guidance 
value,  
100% bioaccessibleb 
health based guidance 
valueb upper bound of the 
bioaccessible fraction 
health based guidance 
valueb lower bound of the 
bioaccessible fraction 
Cadmium -  - - - 
Lead PTWI 24 2 1 - 
Lead BMDL01 24 16 15 - 
Mercury 4 - - - 
Notes:   
a taking into account the expanded measurement uncertainty  
b expressed on a weekly basis and calculated for a 60 kg adult 
Discussion 
In this study different metals and the metalloid arsenic were quantified in traditional 
and health clay products available on the Dutch market. Of special interest were, 
relative to typical food stuff concentrations, high lead, arsenic and aluminum contents 
found in these clay products.  
 Dean et al. (2004) reported levels for chromium and lead in calabash chalk, 
quantified using Energy Dispersive X-ray Fluorescence (EDXRF), which were comparable 
to the levels found in African clay products in our study. In the study of Dean et al. 
(2004), arsenic, mercury and cadmium were not detected. However, Ibeanu et al. 
(1997) found lead, by using EDXRF, in three samples of Nigerian and Kenyan clays at 
levels that were two to three times higher than the mean level found in the African clay 
products in the current study. In the UK, the FSA (2002) reported for calabash chalk, 
lead levels of 8.2 up to 16.1 mg kg-1, which were below the range of lead levels of 
African clay products included in our study (19.2– 47.6 mg kg-1). Katulek et al. (2010) 
published data similar to data from our study on lead and mercury contents of 88 
African clay products analyzed with Atomic Absorption Spectrophotometry. The mean 
cadmium value of the samples determined by Katulek et al. was four times lower than 
in our study for the African clay products. Using the same type of analysis (ICP-MS) as 
we did, Al-Rmalli et al. (2010) published data for lead, arsenic, cadmium, iron and zinc 
in sikor, obtained in ethnic Bangladeshi shops in the United Kingdom, which were 
similar to data from our study. 
 Our analytical method was not equipped to determine the speciation of arsenic 
and metals in the clay samples, and the results were thus expressed as the total 
amount of the metalloid or metals. Moreover, except for arsenic (see below), data in 
literature on the speciation of metals in different types of clays and soils were generally 
CHAPTER 2 
 56 
scarce and difficult to relate to the samples in the present study because the geological 
identity of the clay products in our study was not established. Speciation is important 
regarding differences in toxicity. An additional factor to take into account when 
performing a risk assessment is the bioaccessibility of metals and metalloids present in 
clay products. To this end we identified in the literature bioaccessibility studies for 
metals and arsenic from soil including clay (Table S-4). In these studies different 
bioaccessiblility models and geological soil types were used. It should be noted that the 
0.1 M HCl extraction method (Abrahams 1997), the simulated gastric fluid method 
described by Drexler and Brattin (2007) and Morman et al. (2009) and the simplified 
bioaccessibility extraction test (SBET) (Madrid et al. 2008; Lamb et al. 2009; Smith et al. 
2009) only include simulation of the stomach at a low pH and do not include a change 
in pH when passing to the small intestine. Chemical elements such as lead are 
solubilised in the acidic human stomach but will subsequently precipitate or adsorb 
onto solid particles at the higher intestinal pH (Abrahams 2012). Therefore, the 
bioaccessible fractions calculated from such models which only simulate the stomach 
are probably overestimated. Another factor which we did not include was the influence 
of the presence of food on the bioaccessibility (Abrahams 2012). Preferably, 
bioaccessibility data were taken from naturally enriched (geogenic) soils. Table S-4 
includes also studies with geophagic soils originating from Africa and Asia (Abrahams 
1997; Aufreiter et al. 1997; Smith et al. 2000; Abrahams et al. 2006). For mercury and 
cadmium, studies of bioaccessible fractions in uncontaminated soils were scarce. 
Therefore, for these metals estimations from the selected studies on bioaccessiblility 
do probably not reflect the real situation for bioaccesssibility of these metals in clay 
products.  
 When applying the BMDL01 values to the estimated bioaccessibility scenarios for 
lead the use of many clay products at estimated or recommended dose levels would be 
without any margin of exposure and in most cases would lead to an exceedance of 
these BMDL01 values. It should be noted that even at the lower bound of the estimated 
bioaccessibility for lead 21 out of 62 clay products would lead to an exceedance of the 
BMDL01 value for lead (Table 4). To conclude, the offspring of women who use African 
and Surinam clay products, particularly during pregnancy, may be at risk for retardation 
in the mental development resulting from lead exposure considering all bioaccessiblility 
scenarios for lead. Furthermore, it was interesting to note that estimated mean lead 
intake levels at estimated dose levels for African and Suriname clay products were at 
least 14 times higher than estimated mean lead intake levels for health clay products 
when considering the full bioaccessibility scenario (Table S-5).  
 Arsenic is reported to be mainly present in soils as inorganic arsenic, in the form of 
arsenate (As(V)) and arsenite (As(III)) (Lin and Puls 2000; Turpeinen et al. 2003; Wang 
and Mulligan 2008). In sikor, the main species was inorganic arsenic (As(V)), which was 
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found in levels of up to 100% of the total extractable arsenic (Al-Rmalli et al. 2010). 
These arsenic species have a considerably higher toxicity than organic arsenic species 
found in e.g. seafood (EFSA 2009a). The use of respectively 49 and 32 out of 61 clay 
products would lead to an exceedance of the BMDL01 for the scenarios that all the 
arsenic from clay products would be fully bioaccessible and for the estimated upper 
bound of the bioaccessible fraction (Table 4). It can therefore be concluded that 
women who use these clay products during pregnancy at the estimated dose levels 
could be exposed to levels of inorganic arsenic that could be of concern. 
 For mercury the use of clay products at the estimated dose levels amounts to 
exposure levels of 39%, 18% and 0.1% of the selected TWI for mercury for the full 
bioaccessibility scenario, the estimated upper bound and lower bound of the 
bioaccessible fraction respectively. To conclude, because of the estimated intake levels 
and the possible limited bioaccessibility of mercury, the associated health risks could be 
limited.  
 Aluminum is a common element in the earth’s crust and is present in numerous 
mineral and organic complexes. Especially in clay, aluminum is present in layered 
aluminum silicates (Barabasz et al. 2002; Priest 2004; Mol and Spijker 2007; RIVM-
RIKILT 2009). It is reported that aluminum is able to reach the placenta and fetus and 
toxicological effects of this metal include adverse effects on neurodevelopment, growth 
retardation, skeletal anomalies, embryo toxicity and reduced body weight gain (JECFA 
2007; EFSA 2008). High intake levels of aluminum, resulting from use at the estimated 
dose levels, were found especially for clay products of Suriname origin. However, even 
when taking into account the possibly limited bioaccessibility of aluminum in soils, 
which was reported to be in the range of 0.26-1.7%, the use of respectively 6 and 32 
clay products of which 6 and 23 clay products were from Suriname would still lead to 
an exceedance of the health based guidance value for aluminum. This implies a 
significant health risk. 
 For magnesium, the Tolerable Upper Intake Level would be exceeded for 8 clay 
products with a maximum of 4 times the Tolerable Upper Intake Level when assuming 
magnesium in clay would be fully bioaccessible. Due to the lack of data on the 
toxicological effects of long term use of magnesium and a broad bioaccessibility range 
(5.5 - 51.7%), it is difficult to draw conclusions regarding the safety of the magnesium 
levels in clay products.  
 Harvey et al. (2000) concluded that the consumption of iron from soil does not 
significantly influence the iron status of the users in developing countries. The literature 
shows relatively low bioaccessible fractions for iron in the range 0.1 – 4.1%. For this 
reason we concluded that adverse effects due to intake of iron are limited.  
 The estimated intake levels of chromium, copper, and zinc, resulting from use of 
the clay products at the estimated dose levels, do not exceed the health based 
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guidance values (Table 4) for the respective metals and therefore no short- or long-
term adverse effects are expected. Estimated intake levels of cadmium did not exceed 
the selected health based guidance value for cadmium either, but a sample was found 
for which the use at the estimated dose level would result in an intake level of 
cadmium equivalent to 87% of the selected TWI for cadmium. Considering the relatively 
high background exposure of cadmium (EFSA 2009b) the additional intake level of 
cadmium by clay products is undesirable.  
 Table 6 shows the implications of applying the maximum levels for lead, mercury, 
and cadmium in food supplements which are laid down in Regulation (EC) No. 
1881/2006. In comparison with the application of the legal requirement laid down in 
article 14.1 of Regulation (EC) No. 178/2002 to health clay products (EC 2002b), 
relatively more clay products are non-compliant with the maximum levels for lead and 
mercury in food supplements.  
 Overall, the results of the present study reveal that lead and arsenic concentrations 
in clay products on the Dutch market, when used at the estimated dose levels, may 
result in estimated intake levels above established health based guidance values. This is 
true for the reported upper bounds of the bioaccessible fractions of lead and arsenic. 
Therefore, adverse effects on health of lead and arsenic intake due to the consumption 
of clay products cannot be excluded. Furthermore, it would be helpful to further 
quantify the bioaccessibility, in particular for lead, arsenic, mercury, aluminum and 
cadmium from clay products, e.g. by simulation of their release under the 
physicochemical conditions in the human gastrointestinal tract. Finally, it would be of 
interest, given the high levels of clay intake (approximately 40 g per day), to consider 
possible nutrient interactions, although this remains a topic for future research. It is 
concluded that consumption of some of the examined types of clay are a cause of 
concern and use of these clay products should be discouraged. 
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Abstract  
Geophagy, the practice of consuming clay or soil, is encountered among pregnant 
women in Africa, Eastern Asia and Latin America, but also in Western societies. 
However, certain types of clay are known to contain high concentrations of 
polychlorinated dibenzo-p-dioxins and dibenzofurans (PCDD/Fs). The aim of this study 
was to determine the PCDD/F contents of orally consumed clays purchased from Dutch 
and African markets. Congener patterns were compared with those of pooled human 
milk samples collected in eight African countries, to investigate a possible relationship 
with clay consumption. From the Dutch market thirteen clay products were examined, 
seven of African and six of Suriname origin. From seven African countries, twenty clay 
products were collected. All 33 clay products were screened with a cell-based bioassay 
and those showing a high response were analyzed by GC/HRMS. High PCDD/F 
concentrations were measured in three clay products from the Dutch market, ranging 
from 66 to 103 pg TEQ g-1, whereas clay products from African countries were from 24 
to 75 pg TEQ g-1. Patterns and relatively high concentrations of PCDD/Fs in human milk 
samples from the Democratic Republic of the Congo and Côte d’Ivoire suggest a 
relationship with the consumption of contaminated clay. Frequent use of PCDD/F 
contaminated clay products during pregnancy may result in increased exposure of the 
mother and subsequently the developing fetus and new-born child. The use of these 
contaminated clays during pregnancy should be carefully considered or even 
discouraged. 
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Introduction 
Soil or clay contaminated with polychlorinated dibenzo-p-dioxins (PCDDs), 
polychlorinated dibenzofurans (PCDFs) and/or dioxin-like PCBs (dl-PCBs) is a known 
source for these contaminants in the food chain. In 1998 the use of ball clay for feed 
production in the United States of America (USA) caused the contamination of chickens 
and catfish with PCDD/Fs (Rappe et al. 1998; Hayward et al. 1999; Ferrario et al. 2000). 
A similar application of kaolinic clay in Europe, used for the homogeneous mixing of 
vitamins and minerals in feed, also was shown to be an important source of PCDD/Fs 
(Jobst and Aldag 2000). In 2004, a French fries company in the Netherlands started to 
use kaolinic clay for the sorting of potatoes. A by-product, small potato peels, 
contaminated with the clay, were fed to dairy cows, causing PCDD/F levels as high as 20 
pg TEQ (Toxic Equivalents) g-1 fat in the milk. The absorption and carry-over of PCDD/Fs 
from the clay to cow milk appeared to be very efficient (Hoogenboom et al. 2010). The 
clay used in this process contained PCDD/F concentrations between 1 and 2 ng TEQ g-1 
product. 
 Less well-known in Western societies is the intentional consumption of soil and clay 
materials by humans. This practice called geophagy, has already been described by 
Aristotle (Wilson 2003), Dioscorides and Avicenna in 40 BC and 1000 AD respectively 
(Dominy et al. 2007) and subsequently by anthropologists, colonial physicians and 
explorers like von Humboldt and Livingstone in South America and Africa respectively 
(Woywodt 2002). In traditional medicine, pregnant women consume clay as a cure 
against morning sickness but possibly also as a source of minerals like iron (Abrahams 
and Parsons 1996). Whether this practice has actually beneficial effects has never been 
described. In Africa, clays for oral use are collected in rural mines, dry river beds, 
termite nests and walls of housing but they can also be purchased at local markets, 
traditional remedy shops or even upmarket retail shops. In Suriname, Pimba, which are 
balls of white or reddish clay, are eaten by some pregnant women of the Creole society. 
It is used to prevent miscarriage, to prevent acid reflux or to promote delivery but also 
for spiritual reasons for which it is appliedto the skin (De Korte 2006). Migrants from 
Africa, Asia and Suriname have introduced the practice of geophagy to Western 
societies like the United Kingdom (UK), the Netherlands, Belgium and Austria (Mahaney 
et al. 2000; Abrahams et al. 2006; De Korte 2006; Katulek et al. 2010). These clay 
products can be purchased in ethnic shops. Data from literature suggests that intake 
levels are typically between 30 to 80 g day-1 (Table S-1). 
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Table S-1. Examples of estimated dose levels of traditional clay products identified in literature.  
Product  Daily dose 
(range) 
(g day-1) 
Study details Authors 
Bentonite clay (Aleppo belouneh) 26  
(-) 
Market survey in Syria Bakraji and Karajou 
(2003) 
Eye clay  30 (mean) 
(1-300) 
Interviews Ewe women 
(n=1248), Ghana 
Vermeer (1971) 
Soil material  30  
(-) 
Interviews women Akha 
tribe in North Thailand  
Abrahams and 
Parsons (1997) 
Different clays (riverine, termite and 
ant clays) 
- 
(28-85) 
Field observations five 
countries southern Africa 
Hunter (1993) 
Different clays (sedimental red roamy 
sand (walls houses), grey clay, soft 
stones (riverbeds), termite clays) 
41.5 (median) 
(3-219) 
Interviews pregnant women 
(n=52) and traditional 
healers (n=4), Kilifi, Kenya 
Geissler et al. (1999) 
Sikor - 
(49–65) 
Interviews pregnant women, 
Bengali community in the UK
Abrahams et al. 
(2006) 
 
However, geophagy is considered as an aberrant behavior, and potentially hazardous 
because of the contamination with toxic constituents such as metals, metalloids, 
parasites, pathogens, or persistent organic pollutants such as PCDD/Fs (Abrahams 
2002). Elevated levels of metals and metalloids such as lead and arsenic were reported 
in traditional clay products sampled in the UK by the British Food Standards Agency 
(FSA 2002) and by Kutalek et al. (2010) in traditional clay products from African 
countries but also from Austria and Belgium. In 2004, the Netherlands Food and 
Consumer Product Safety Authority (NVWA) started a survey and obtained similar 
results (RIVM-RIKILT 2009). Knowing the problems caused by PCDD/Fs in clay materials 
used in feed and food production, these pregnancy clays were also analyzed for the 
presence of PCDD/Fs. The present paper shows that some of the clay products were 
indeed highly contaminated. Clay products were also collected in Africa and in some 
cases also showed high levels of PCDD/Fs.  
 It is of particular interest to evaluate the possible consequences of consumption of 
clays with elevated levels of PCDD/Fs. To obtain a first indication, congener patterns of 
PCDD/Fs in clay products were compared with those in mother milk samples, collected 
in different African countries within the World Health Organization (WHO) program on 
human milk (Malisch et al. 2010; UNEP 2013). In addition, a risk assessment was 
performed on the health risk associated with the intake of clay products with the higher 
PCDD/F levels observed in this study. 
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Material and methods 
For this study, NVWA inspectors sampled 13 clay products originating from African 
countries and Suriname at local ethnic shops in the Netherlands. Additionally, 20 
different clay products were collected in trading centers in various African countries, 
namely Uganda (12), Kenya (2), Tanzania (1), Nigeria (1), Mali (1), Côte d’Ivoire (1) and 
Zimbabwe (2) by African students from Wageningen University. Within the fifth round 
of the mothers’ milk survey, which was organized by the WHO jointly with the United 
Nations Environment Programme (UNEP), pooled breast milk samples consisting of 50 
individual milk samples, were analyzed for PCDD/Fs and dl-PCBs. Milk samples from 
Africa were collected in Côte d’Ivoire, Democratic Republic of the Congo, Nigeria, 
Senegal, Ghana, Uganda, Kenya and Mali (WHO 2007; UNEP 2013). 
Screening of clays with a cell-based bioassay  
A cell-based bioassay (DR CALUX®, Biodetection Systems, the Netherlands) was used by 
both NVWA and RIKILT to screen the clay products sampled in respectively the 
Netherlands and African countries for the presence of dioxin-like activity. In this assay, 
substances binding to the Ah-receptor are detected, which is an essential step in 
determining the possible presence of PCDD/Fs and dl-PCBs. For this assay 5 g 
homogenized clay was mixed with 15 ml water/methanol 15/85 (v/v) and subsequently 
extracted twice with 20 ml hexane/diethyl ether 97/3 (v/v). The combined extracts 
were reduced to a small volume and purified on a column containing 10 g acid silica 
(33%), eluted with 40 ml hexane/diethyl ether 97/3 (v/v). The eluate was evaporated 
using 30 or 40 µl DMSO as a keeper. This was subsequently mixed with 2 ml incubation 
medium and 0.25 ml of this mixture was added to cells grown in 48-well plates in 0.25 
ml medium for two days. After 24 h the medium was removed, the cells washed with 
phosphate buffer saline (PBS) and lysed. The luciferase activity was determined with a 
Luminoskan Ascent (Thermo Scientific, Breda, the Netherlands). The luciferase activity 
for various concentrations of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (1 pM to 1 
nM) was plotted in a calibration curve. At RIKILT, each test series also included a 
number of reference feed samples with known PCDD/F and dl-PCB content. This 
resulted in an estimated level expressed in BEQs (bioequivalents). For screening of clays 
in the present study, the method was used with a decision limit of 1 pg BEQ g-1 product, 
meaning that samples exceeding this estimated level were analyzed by GC/HRMS. 
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GC/HRMS 
The analysis by GC/HRMS was performed by RIKILT for confirmation of the presence of 
PCDD/Fs and dl-PCBs in the suspected clay products and performed as described 
previously (Tuinstra et al. 1994; Hoogenboom et al. 2010). Samples were spiked with 
13C labeled standards and extracted using pressurized extraction (ASE, Dionex, 
Amsterdam, the Netherlands). This was followed by clean-up on an automated system 
(PowerPrep™ system, FMS, Watertown, USA), which was composed of disposable pre-
packed columns (Jumbo silica, mixed bed silica, alumina and carbon (FMS)). This 
resulted in two fractions, one with mono-ortho and indicator PCBs and the other with 
PCDD/Fs and non-ortho PCBs. The fractions were concentrated (Turbo-Vap, Buchi, 
Germany) and analyzed by gas chromatography combined with high resolution mass 
spectrometry (GC/HRMS) using an Agilent (Wilmington, USA) gas chromatograph 
6890N (GC column DB5 MS 60m, 0.25mm i.d., 0.25µm; J&W, Folson, USA) and an 
AutoSpec Ultima high resolution mass spectrometer (Waters, Milford, USA) operated in 
electron impact ionization mode using selected-ion monitoring and controlled by a 
Masslynx data system. GC/HRMS data were processed using DIOXNOP software to 
determine the concentrations. Subsequently the TEQs were calculated based on WHO 
TEFs of 1998 (Van den Berg et al. 1998). Levels of non-detectable congeners were set at 
the Limit of Quantification (upperbound principle). Blanks were included in each test 
series starting at the ASE extractions and quality control was according to EPA method 
1613, revision B. Recoveries were within the range 60-120% except for PCBs 77 and 81, 
and in some cases OCDD and OCDF. However, in these samples these congeners did not 
contribute significantly to the TEQ-level, making this deviation acceptable.  
2.3 Protocol of the WHO/UNEP coordinated studies 
Samples were collected by the participating countries following their national 
protocols, which dealt primarily with number and type of samples, selection of donors, 
collection, storage and pooling of samples, and shipping of samples to the reference 
laboratory. Milk from well-defined groups of 50 mothers was collected and pooled. For 
selection of donating mothers the following criteria were applied: a) they should be 
primiparae, b) healthy, c) exclusively breastfeeding one child (i.e. no twins), and d) 
residing in the area for about five years. For further details see the WHO Website (WHO 
2007). Samples of the fifth round were collected in 2008-2009. 
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Analysis of human milk samples 
Analysis of POPs in human milk were performed by the State Institute for Chemical and 
Veterinary Analysis of Food (CVUA) in Freiburg, Germany (WHO 2000). The analytical 
procedure for solvent extraction, clean-up and determination by GC-HRMS of the 
PCDDs/PCDFs, dioxin-like PCBs (DL-PCBs) and non-dioxin-like PCBs was performed as 
described previously (Malisch et al. 2000; Malisch and van Leeuwen 2002; Malisch and 
Dilara 2007). The limit of quantification (LOQ) for PCDDs, PCDFs and DL-PCBs expressed 
as WHO toxic equivalencies (TEQs) was 0.1 pg g-1 lipid. As for the clay, TEFs 1998 were 
applied and levels of non-detectable congeners were set at the Limit of Quantification 
(upperbound principle). A rigid quality control programme is carried out on a 
continuous basis as described (Malisch and van Leeuwen 2003; UNEP 2013).  
Results 
In 2007 and 2009, the NVWA collected 13 clay products, seven termed Mabele 
(originating from Africa) and 6 termed Pimba (originating from Suriname). These 
products were screened for PCDD/Fs and dl-PCBs using the DR CALUX® bioassay. Four 
clay products, showing a response indicative of a level above 1 pg TEQ g-1, were 
classified as suspected and analyzed by GC/HRMS. Clays termed Mabele salé, Mabele 
Cameroon 2 and Mabele broken Zaire showed the highest WHO-PCDD/F TEQ levels, 
being respectively 103.0, 66.3 and 65.5 pg TEQ g-1 product (Table S-2).  
 
Table S-2. PCDD/F levels (ng kg-1) in clay products purchased in the Netherlands, Zimbabwe, Nigeria and Côte 
d’Ivoire (result of a single analysis). 
PCDD/Fa  
levels  
(ng kg-1) 
Mabele 
saléb 
Mabele 
 
Cameroon 1b 
Mabele 
 
Cameroon 2b 
Mabele 
broken 
Zaire b 
Nzu 
 
Nigeriac 
Termite 
nest 
Zimbabwec 
Kaolin 
Côte 
d’Ivoirec 
2,3,7,8-TCDF <0.05 <0.05 <0.05 <0.05 0.36 <0.05 <0.05 
1,2,3,7,8-PeCDF <0.05 <0.05 <0.05 0.06 0.17 <0.05 <0.05 
2,3,4,7,8-PeCDF 0.09 <0.05 <0.05 <0.05 0.12 <0.05 <0.05 
1,2,3,4,7,8-HxCDF 0.06 <0.05 <0.05 <0.05 0.07 <0.05 <0.05 
1,2,3,6,7,8-HxCDF 0.21 <0.05 0.13 0.17 0.06 <0.05 <0.05 
2,3,4,6,7,8-HxCDF <0.05 <0.05 <0.05 <0.05 <0.05 <0.05 <0.05 
1,2,3,7,8,9-HxCDF <0.05 <0.05 <0.05 0.06 <0.05 0.16 <0.05 
1,2,3,4,6,7,8-HpCDF 0.21 <0.05 <0.05 <0.05 0.07 0.05 <0.05 
1,2,3,4,7,8,9-HpCDF <0.05 <0.05 <0.05 <0.05 <0.05 <0.05 <0.05 
OCDF <0.10 <0.10 <0.10 <0.10 <0.10 0.15 <0.10 
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PCDD/Fa  
levels  
(ng kg-1) 
Mabele 
saléb 
Mabele 
 
Cameroon 1b 
Mabele 
 
Cameroon 2b 
Mabele 
broken 
Zaire b 
Nzu 
 
Nigeriac 
Termite 
nest 
Zimbabwec 
Kaolin 
Côte 
d’Ivoirec 
2,3,7,8-TCDD 6.1 0.11 6.9 2.9 0.4 <0.05 4.8 
1,2,3,7,8-PeCDD 3.4 0.98 2.3 28.6 8.1 0.16 37.5 
1,2,3,4,7,8-HxCDD 3.3 6.5 2.2 70.6 35.5 0.29 83.0 
1,2,3,6,7,8-HxCDD 31 3.8 19 45 20.2 0.36 42.1 
1,2,3,7,8,9-HxCDD 674 12 410 180 49.0 0.66 153.0 
1,2,3,4,6,7,8-HpCDD 2051 108 1279 434 480 58 499 
OCDD 17438 300 10967 510 1673 7241 419 
TEQ (WHO 1998) 103.0 4.5 66.3 65.5 24.1 1.7 75.2 
a Abbreviations: tetra (T), penta (Pe), hexa (Hx), hepta (Hp) or octa (O) chlorinated dibenzofuran (CDF) or 
dibenzo-p-dioxin (CDD) 
b Clay product purchased in the Netherlands 
c Clay product collected in Africa 
 
Twenty clay products were collected from African countries in 2009 and were all tested 
at RIKILT with the DR CALUX® bioassay. Figure 1 shows the response of these samples in 
one test series. Four samples showed a response indicative of a level higher than 1 pg 
TEQ g-1 and were classified as suspected. Three of these samples (S/N13, S/N17 and 
S/N20) showed a clearly elevated response and one (S/N9) a slightly elevated response. 
These products originated from Nigeria (Nzu, S/N13), Zimbabwe (termite nest, S/N17), 
Côte d’Ivoire (Kaolin, S/N20) and Uganda (S/N9). Based on the comparison of the 
response in the bioassay with those of reference feed samples, the levels of the 
samples S/N13, S/N17 and S/N20 were estimated to be 13, 11 and 24 pg BEQ g-1 
product respectively. However, these values are only a rough estimate, also due to the 
very high response of the samples in the upper part of the calibration curve where the 
response reaches a plateau. 
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Figure 1. Response of the 20 African clay products in the CALUX assay. Results are expressed as percentage 
of the maximum response observed with TCDD. Samples with elevated response came from Uganda (S/N9), 
Nigeria (Nzu, S/N13), Zimbabwe (termite nest, S/N17) and Côte d’Ivoire (Kaolin, S/N20). 
 
Subsequent analysis of the three samples with a high response by GC/HRMS showed 
PCDD/F levels of respectively 24.1, 1.7 and 75.2 pg TEQ g-1 product (Table S-2). Sample 
S/N9 from Uganda, with a slightly elevated response, and two negative samples 
(Mabele Nigeria sampled in the Netherlands and S/N16 (Mali)) were also analyzed by 
GC/HRMS and showed dioxin TEQ levels of 0.3, 0.6 and 0.2 pg TEQ g-1 (data not shown). 
Levels of dl-PCBs were low in all suspected clay samples analyzed by GC/HRMS (4 from 
the Netherlands and 4 from African countries), being respectively 0.2 and 0.3 pg TEQ g-1 
in Mabele sale and Mabele Cameroon 1, and less than 0.1 for Mabele Cameroon 2 and 
Mabele DR Congo for the Dutch samples, and for four of the remaining African samples. 
Levels of the so-called indicator or non-dioxin-like PCBs (PCBs 28, 52, 101, 138, 153 and 
180) were below 1 ng g-1 for these eight samples, with the exception of the sample 
named Mabele Cameroon 1 with also the highest level of dl-PCBs, showing a level for 
non-dioxin-like PCBs of 9.5 ng g-1. 
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PCDD/F patterns in selected clay products 
Figure 2 shows the congener patterns of PCDD/Fs for the four clay products with the 
highest levels, expressed as the contribution to the PCDD/F-TEQ level. The TEFs of 1998 
were used for this evaluation since these are still applied for official control in Europe 
until 2012. In general this does not differ very much from applying the TEFs 2005 due to 
the fact that the TEFs for the PCDDs were not changed with the exception of that for 
OCDD which was raised three-fold (Van den Berg et al. 1998; 2006). In all these four 
samples, the PCDFs did not really contribute to the TEQ level. As shown in Table S-2, all 
clay products showed relatively high levels of HpCDD and octachlorodibenzodioxin 
(OCDD). However, HpCDD and especially OCDD have a relatively low toxic potency, as 
reflected by their TEFs 1998 of 0.01 and 0.0001, and as such contribute relatively little 
to the TEQ level. An exception was the sample from Zimbabwe (S/N17), where OCDD 
and HpCDD made up 75% of the TEQ, but this sample had a relatively low TEQ-level. 
Only in this sample the TEQ level would significantly increase (1.8x) by applying the 
TEFs 2005. Also remarkable are the relatively high levels of 1,2,3,7,8,9-
hexachlorodibenzo-p-dioxins (HxCDD), which in some of the Mabele samples showed 
the highest contribution to the TEQ-level (>60%). In four other samples the contribution 
of this congener was between 20-25%. In these samples PeCDD and the two other 
HxCDDs also contributed highly to the TEQ-level. 
 
 
Figure 2. PCDD/F patterns in a number of clay samples collected in The Netherlands (Mabele clays) and Côte 
d’Ivoire. Patterns are presented in terms of contribution to the TEQ (TEQ in parenthesis in the legend in pg 
TEQ g-1 product). 
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Comparison of congener patterns in clay and human milk 
The WHO has a program to evaluate the levels of PCDD/Fs and dl-PCBs in pooled 
human milk from various countries in the world (WHO 2007). The last round (2008-
2009) included human milk samples from a number of African countries (Malisch et al. 
2010). Highest levels of PCDD/Fs were observed in milk samples from Côte d’Ivoire and 
the Democratic Republic of the Congo, being 11.1 and 12.5 pg TEQ g-1 fat respectively. 
The milk sample from Senegal showed a level of 7.2 pg TEQ g-1 fat, but those from the 
other countries were much lower, being in the range from 1.5 to 3.9 pg TEQ g-1 fat 
(UNEP 2013). Figure 3 shows the patterns observed in the human milk, expressed as 
the relative contribution of different PCDD/Fs to the TEQ. It is clear that the PCDDs 
contribute most, varying from 57% for Nigeria to 85 and 90% for Côte d’Ivoire and the 
Democratic Republic of the Congo. In most samples, also PCDFs and especially 
2,3,4,7,8-PeCDF contribute to some extent to the TEQ, but especially in the higher 
contaminated samples, this contribution is less than 15%. Regarding the relatively high 
levels and the high contribution of PCDDs, the latter two samples were evaluated in 
more detail and the patterns compared to those observed in the different clays. 
 
 
Figure 3. Congener patterns observed in different African human milk samples, expressed as contribution to 
the PCDD/Fs TEQ (TEQ levels in parenthesis in the legend in pg TEQ g-1 fat). 
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Figure 4A shows the pattern for human milk from the Democratic Republic of the 
Congo with three different clays that were characterized by an unusually high 
contribution of 1,2,3,7,8,9-HxCDD. The patterns match to a high degree. A similar 
comparison was made for the milk sample from Côte d’Ivoire (Figure 4B). The pattern 
was highly comparable with the kaolinic clay causing the 2004 incident in the 
Netherlands and the clay sample collected from Côte d’Ivoire and labeled Kaolin. Also 
the pattern in the Mabele clay collected in the Netherlands and labeled Democratic 
Republic of the Congo showed a close resemblance to these clays.  
 
Figure 4. Comparison of the congener pattern in human milk from A, the Democratic Republic of the Congo 
with the patterns observed in three different Mabele clay samples and B, the congener pattern in human milk 
from Côte d'Ivoire with the patterns observed in two Kaolinite and one Mabele clay samples. 
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Discussion 
High PCDD/F levels in pregnancy clays 
Previous studies showed that clays used during pregnancy may contain high levels of 
heavy metals (Ibeanu et al. 1997; Dean et al. 2004; FSA 2007; Reeuwijk et al. 2013). The 
present study shows that some of these clays, termed as different types of Mabele and 
Kaolin, contain also high levels of PCDD/Fs (Table S-2). This was not unexpected 
considering previous observations of high levels of PCDD/Fs in Mississippi ball clay and 
kaolinic clay (Hayward et al. 1999; Ferrario et al. 2000; Jobst and Aldag 2000; 
Hoogenboom et al. 2010). Very typical for these contaminated clays is that they contain 
only PCDDs, although with different patterns. The kaolinic clay responsible for high 
levels of dioxins in bovine milk in the Netherlands in 2004, showed relative 
contributions of PeCDD, 1,2,3,7,8,9-HxCDD and TCDD to the TEQ-level of 53, 12 and 
16% (Hoogenboom et al. 2010), that are also typical for other samples of this clay from 
the mine in the German Eifel. Four of the current clay products also showed a relatively 
high contribution of PeCDD and 1,2,3,7,8,9-HxCDD, but a relatively low contribution of 
TCDD. These included the samples from Côte d’Ivoire and Nigeria marketed as Kaolin. 
Two other samples, sold as Mabele in the Netherlands, showed a very high contribution 
of 1,2,3,7,8,9-HxCDD, followed by heptachlorodibenzo-p-dioxin (HpCDD). Another 
sample, obtained in Zimbabwe, is clearly marked by the high contribution of the hepta- 
and octa-CDD. However, due to the low TEF- values of these congeners, the TEQ-level 
in this sample was relatively low.  
 The highest level observed in the present study was 103 pg TEQ g-1 in a clay sample 
labeled Mabele salé, but based on previous studies, levels as high as 1 to 2 ng g-1 may 
also be encountered in ball clay and kaolinite (Ferrario et al. 2000; Hoogenboom et al. 
2010). The PCDDs in these clays are thought to be formed under natural conditions in 
prehistoric ages, possibly by forest fires, volcanos or under high pressure and 
temperature in specific layers in the earth (Holmstrand et al. 2006; Gu et al. 2008; Horii 
et al. 2008). The source of the PCDDs detected in the contaminated pregnancy clays 
may be similar but further studies are required to reveal the origin of these clays and 
the contamination source. 
Clays as a potential source of PCDD/Fs in human milk samples 
PCDD/Fs accumulate in liver and especially fat tissues. However, it is well-known that 
milk is an important route for excretion of PCDD/Fs, both in lactating animals and in 
humans (Hoogenboom et al. 2010; Malisch et al. 2010). Human milk levels normally 
reflect the existing body burden, when expressed on a lipid base (body burden can be 
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defined as the concentration of PCDD/Fs in the body (JECFA 2002). Existing body 
burdens and hence mother milk levels reflect the low level exposure through the food. 
It was remarkable that the levels in the pooled milk of some African countries were 
much higher than those in other countries, suggesting a difference in the levels in the 
food. However, the close resemblance in the congener patterns in human milk samples 
with the highest PCDD/F levels, i.e., the samples from the Democratic Republic of the 
Congo and Côte d’Ivoire, with the patterns observed in certain clays (Figure 4) suggest a 
different possibility for the higher levels. Both samples showed the typical high 
contribution of PCDDs to the TEQ level. Furthermore, the pattern in the milk sample 
from Côte d’Ivoire was highly comparable with that of the kaolinic clay involved in the 
2004 incident in the Netherlands, the pregnancy clay collected from Côte d’Ivoire 
(labeled as Kaolin) and the Mabele clay from the Democratic Republic of the Congo 
(Figure 4B). The human milk from the Democratic Republic of the Congo showed the 
very specific pattern with the high contribution of 1,2,3,7,8,9-HxCDD observed also in 
the Mabele clays labeled as salé and Cameroon, but collected in the Netherlands. 
Unfortunately, no clay was collected directly from the DR of the Congo. Overall, it 
cannot be excluded that the relatively high levels in these milk samples and the close 
resemblance in the patterns are caused by consumption of contaminated clays. 
Potential risk of the use of contaminated clays during pregnancy 
Exposure to TCDD has been shown to result in adverse effects on reproduction, 
development and endocrine functions (Van den Berg et al. 1998). Numerous animal 
studies with TCDD showed effects on the developing fetus, including a decreased sperm 
production of male rats exposed in utero (Faqi et al. 1998, Vandenberg et al. 2012). The 
exact mechanism behind these effects is still unclear but may be related to 
disturbances of the hormone status. Induction of certain biotransformation enzymes 
may cause the increased degradation of thyroid hormones. Also decreased 
testosterone levels have been observed in male rats. The studies on the decreased 
sperm production are the critical studies used by the Scientific Committee on Food 
(SCF) to derive the exposure limit (Tolerable Weekly Intake - TWI) of 14 pg TEQ kg bw-1 
week-1 (SCF 2001). In a similar manner, the Joint FAO/WHO Expert Committee on Food 
Additives (JECFA) derived a Provisional Tolerable Monthly Intake (PTMI) of 70 pg TEF kg 
bw-1 month-1 (JECFA 2002), for which additional reproductive toxicity studies were 
taken into account. These exposure limits were set for the chronic low-dose intake of 
PCDD/Fs and dl-PCBs through the daily intake of food contaminated with relatively low 
levels of these contaminants. They should prevent that women at child-bearing age 
have a body burden that exceeds critical levels as derived from the animal studies. This 
critical level is 4 ng TEQ kg bw-1. 
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Regarding the above mentioned developmental effects, the question arises whether 
contaminated clay products used during pregnancy may have potential consequences 
for the developing child. Katulek et al. (2010) reported that in certain African regions 
between 46% and 73% of the pregnant and breastfeeding women regularly consume 
soil. Various other authors examined the consumption of clay during pregnancy and 
estimated the daily intake to be 30 to 80 g (Table S-1). At the highest observed level of 
103 pg TEQ g-1 product, this would amount to an exposure of 3 to 8 ng TEQ per day, or 
22 to 58 ng TEQ per week. A similar exposure would be obtained when using the 2005 
TEFs instead of those from 1998 (see Results). Based on a body weight of 65 kg, this 
would be equivalent to 333 to 887 pg TEQ kg bw-1 week-1, being 24 to 63 times higher 
than the TWI of 14 pg TEQ kg bw-1 week-1. However, as the TWI was set for a chronic 
exposure, the question arises to what extent the intake of contaminated clay could 
affect the body levels of the mother and as such the exposure of the fetus. Based on an 
average background level for women in the Netherlands of 9 ng TEQ kg-1 fat, a body 
weight of 65 kg, 28% body fat and 75% of the PCDD/Fs and dl-PCBs in the fat (De Mul et 
al. 2008), the average total body burden anno 2008 was estimated at 220 ng TEQ. This 
amounts to 3.4 ng TEQ kg bw-1 (or 9 ng TEQ per kg fat), being just below the above 
mentioned critical limit. The intake of a single portion of the highest contaminated clay, 
containing 3-8 ng TEQ, would contribute only to a relatively small extent to the body 
burden of 220 ng TEQ. However, a prolonged daily intake during the first trimester 
(270-720 ng TEQ) or even the whole pregnancy (810-2160 ng TEQ) could lead to a 
serious elevation of the body burden (potentially up to 4-10x in the average Dutch 
woman). In African women, with apparently a much lower exposure through the food 
(based on the human milk levels), the relative impact on the body burden would be 
even much higher. The levels in the pooled milk samples from DR of the Congo and 
Côte d’Ivoire are comparable to the current levels observed in the Dutch women. 
However, it seems likely that some of the 50 milk samples in the pool contained much 
higher levels, especially when caused by the intake of contaminated clay. An increased 
body burden means an elevated exposure of the fetus but would also result in clearly 
elevated levels in the breast milk, thus prolonging the exposure of the child after birth. 
Of course this is based on a worst case scenario, although levels in certain clays might 
even be much higher than the ones observed in this study. 
 However, even when considering a relatively short exposure, it is important to 
realize that under normal conditions the fraction of the PCDD/Fs in the body that is 
actually circulating and causing the exposure of the fetus, is rather low. Levels of 
PCDD/Fs in the blood lipids are normally in equilibrium with those in the adipose tissue. 
Since blood contains only a small amount of fat (in total around 25 g), the total amount 
of PCDD/Fs in the blood at an average level of 9 pg TEQ g-1 fat observed in Dutch 
women would amount to 0.23 ng TEQ. The question is whether an intake of 3-8 ng TEQ 
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through a portion of highly contaminated clay could cause a serious increase of the 
blood levels and as such the increased exposure of the fetus. When deriving the TWI for 
chronic low-dose exposure, the original data were actually corrected by SCF by a factor 
of 2.3 since it was shown that the single high dose of TCDD applied in the animal 
studies resulted in relatively higher levels in the fetus than a similar dosage provided 
over a longer period (SCF 2001). It is also important to note that effects of TCDD on the 
fetus were in most animal studies observed after a single treatment of the mother 
during a specific period of the pregnancy (around gestational day 15). This indicates a 
short time period as the critical exposure window for the induction of reproductive 
toxicity. As such, comparing the contribution of the absolute amount of dioxins from 
the intake of a highly contaminated product solely with the existing and the critical 
body burden (4 ng TEQ kg bw-1) may not take into account the temporary increase in 
the blood levels and as a result the increased exposure of the fetus during this critical 
window of development. Further studies are required to better understand this issue, 
including improvement and validation of existing physiologically based pharmacokinetic 
(PBPK) models with respect to the exposure of the fetus (RIVM-RIKILT 2009). Overall it 
seems clear that the intake of highly contaminated clays, especially during pregnancy, 
presents a clear risk for the unborn child. It should also be pointed out that in addition 
to PCDD/Fs, some of these clays were shown to contain high levels of metals and 
metalloids such as lead and arsenic (Reeuwijk et al. 2013). The combined effects of 
these compounds and PCDD/Fs are another matter of concern. 
Application of a bioassay for screening of clay products 
The present study shows that a bioassay such as the DR CALUX®-assay is a very useful 
tool to screen clay products for potentially high levels of PCDD/Fs. The test was capable 
of selecting the higher contaminated samples as confirmed by GC/HRMS. A possible 
exception seems sample S/N17 which showed a similar response as sample S/N13 
(Figure 1), but a 15-fold lower GC/HRMS determined level (Table S-2). This can be 
explained by the high content of OCDD and HpCDD in this sample, which show 
relatively high relative potencies in the DR CALUX®-assay as compared to the assigned 
TEF value. The fact that three samples classified as slightly or non-suspected (Mabele 
Nigeria, S/N9 and S/N16) were confirmed by GC/HRMS to indeed have low TEQ levels, 
further demonstrates the suitability of the bioassay for screening purposes. The use of 
a relatively cheap bioassay for screening purposes could be relevant especially in 
developing countries. Confirmation of suspected samples by GC/HRMS is however 
prudent.  
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Conclusions  
Consumption of several of the examined clays results in intakes above the TWI and 
could be a cause of concern for the developing fetus. The use of these contaminated 
clays, especially during pregnancy and lactation, should be discouraged. Although the 
benefits of breast feeding clearly outweigh the risks of these contaminants, a further 
reduction of contaminant levels in human milk is clearly a target for the current policies 
on reducing the levels of dioxins and related compounds in the food chain. Therefore, 
strict control on contaminated clay products should be carried out to prevent 
introduction, spreading and use of such products.  
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Abstract  
Herbal food supplements, claiming to enhance sexual potency, may contain deliberate-
ly added active pharmacological ingredients (APIs) that can be used for the treatment 
of erectile dysfunction (ED). The aim of this study was to determine whether herbal 
food supplements on the Dutch market indeed contain APIs that inhibit phos-
phodiesterase type 5 (PDE-5), such as sildenafil and analogous PDE-5 inhibitors. Herbal 
food supplements intended to enhance sexual potency (n=71), and two soft drinks, 
were sampled from 2003 up to and including 2012. In 23 herbal supplements nine dif-
ferent PDE-5 inhibitors were identified, in a few cases (n=3) more than one. The pres-
ence of these APIs was however not stated on the label. The concentrations of PDE-5 
inhibitors per dose unit were analyzed. Furthermore, the potential pharmacological 
active properties of the detected PDE-5 inhibitors were estimated using data from sci-
entific and patent literature regarding i) in vitro PDE-5 activity, ii) reported effective 
doses of registered drugs with PDE-5 inhibitor activity, and iii) similarity to other struc-
tural analogues. It was concluded that 18 of the 23 herbal food supplements, when 
used as recommended, would have significant pharmacological effects due to added 
APIs. Adequate use of existing regulation and control measures seems necessary in 
order to protect consumers against adverse effects of these products. 
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Introduction 
Herbal food supplements that claim to enhance sexual potency are marketed world-
wide and are readily available from Internet shops (FDA 2013, Lin et al. 2006; Singh et 
al. 2009; Venhuis and de Kaste 2012). These products generally claim to be ‘all natural’ 
but there are regular reports of adulterations with drugs for the treatment of erectile 
dysfunction (ED) (Blok-Tip et al. 2004; Lin et al 2006; Oh et al. 2006; Zou et al. 2006; 
Venhuis et al. 2008a; 2008b; 2011; 2012; Reepmeyer and Woodruff 2007; Reepmeyer et 
al. 2007; Hasegawa et al. 2008; Singh et al. 2009; Savaliya et al. 2010; Wollein et al. 
2011; Kee et al. 2012; Lee et al. 2013). ED is defined as the persistent inability to attain 
and maintain an erection sufficient to permit satisfactory sexual performance (NIH 
1993).  
 In recent decennia synthetic drugs for the treatment of ED were developed, which 
started with the introduction of Viagra® in 1998 containing sildenafil (Figure 1) as the 
active pharmacological ingredient (API). This was followed in 2002 by Cialis®, containing 
the API tadalafil (Figure 1) and in 2003 by Levitra®, containing the API vardenafil (Figure 
1). Sildenafil, tadalafil, and vardenafil, the APIs of these three registered drugs available 
on the Dutch market, belong to the class of nitric oxide–cyclic guanosine monophos-
phate (cGMP)-specific phosphodiesterase type 5 (PDE-5) inhibitors (Singh et al. 2009; 
Venhuis and de Kaste 2012). In mammalian tissues, 11 PDE families have been identi-
fied with different tissue localizations (Corbin et al. 2002; Gresser and Gleiter 2002). 
PDEs vary in their substrate specificity, and PDE-5, PDE-6 and PDE-9 are known to be 
specific for hydrolysing cGMP (Corbin et al. 2002). PDE-5 is widely distributed in vascu-
lar and visceral smooth muscle cells, platelets, kidney, lung, and the lining of the blood 
vessels supplying the corpus cavernosum penis, the erectile tissue of the penis (Corbin 
et al. 2002; Pissarnitski 2006; Flores Toque et al. 2008). PDE-6 is located in the retina 
and has a role in visual transduction (Corbin et al. 2002). Sildenafil, vardenafil and tada-
lafil are moderately selective competitive inhibitors for PDE-5. Use of these APIs results 
in an increased smooth muscle relaxation, increased blood flow and an improved erec-
tion (Dale et al. 2000; Corbin et al. 2002; Pissarnitski 2006).  
 PDE-5 inhibitors have also vasodilatating effects on the pulmonary vessels and are 
therefore applied in registered drugs such as Revatio®, containing the API sildenafil, and 
Adcirca®, containing the API tadalafil, for the treatment of pulmonary hypertension. 
Because of the vasodilatating effects on the pulmonary vessels, PDE-5 inhibitors are 
contra-indicated in patients who are treated with other types of antihypertensives such 
as nitrates (eg. nitroglycerine, doxazosin and terazosin) (Boden et al. 2012; EMA 2013a). 
PDE-5 inhibitors are also contra-indicated in patients suffering from hypotension, but 
who are not treated for this (Kloner 2007). Reported side effects for the three market-
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ed PDE-5 inhibitors include headache, facial flushing, nasal congestion, and dyspepsia 
(Gresser and Gleiter 2002).  
sildenafil    R1=O, R2=CH3, R3=H 
homohydroxysildenafil R1=O, R2=HOCH2CH2, R3=H 
thiosildenafil   R1=S, R2=CH3, R3=H 
aildenafil   R1=O, R2=H, R3= CH3 
thioaildenafil  R1=S, R2=H, R3= CH3 
acetildenafil  R4=Et 
noracetildenafil  R4=H 
vardenafil   R5=EtN 
piperidino-vardenafil  R5=CH2 
tadalafil    R6=CH3 
aminotadalafil  R6=NH2 
Figure 1. Chemical structures of sildenafil and analogous PDE-5 inhibitors 
 
In 2002, shortly after the introduction of Viagra®, Cialis® and Levitra® on the Dutch 
market, the Netherlands Food and Consumer Product Safety Authority (NVWA) was 
alerted to the presence on the Dutch market of herbal food supplements claiming to 
enhance sexual performance, which contained undeclared sildenafil and also tadalafil. 
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At a later stage, also structural analogues of these three registered PDE-5 inhibitors 
were identified in herbal supplements on the Dutch market (Blok-Tip et al. 2004; Ven-
huis et al. 2008a; 2008b; 2011; Venhuis and de Kaste 2012). The use of non-registered 
ED products is growing worldwide. In literature at least 46 different analogues of 
sildenafil, vardenafil and tadalafil were identified until 2011. Most of these analogous 
PDE-5 inhibitors were found in food supplements, in counterfeits of registered medi-
cines or in unapproved medicines (RIVM 2010; Venhuis and de Kaste 2012). These ana-
logues are often the by-products of the typical drug development process. An analogue 
can be defined as a drug substance that is structurally and functionally comparable to a 
registered drug substance (RIVM 2010; Venhuis and de Kaste 2012).  
 As discussed above, health risks linked to the use of PDE-5 inhibitors may also arise 
from other side effects. For instance, aminotadalafil contains a reactive hydrazine struc-
tural element, which is suspected to have genotoxic potential (Orme et al. 2001; RIVM 
2007; Häberli et al. 2010; Elder et al. 2011; Venhuis and de Kaste 2012). Moreover, 
acetildenafil is a non-selective PDE-5 and PDE-6 inhibitor. Inhibition of the latter is as-
sociated with temporary visual disturbances (RIVM 2007; Venhuis et al. 2008a).  
 Although herbal food supplements are covered by food law, medicinal products 
legislation takes precedence when the product can be classified as a medicinal product. 
When this is the case, only medicinal products legislation applies and any legal measure 
has to be taken on the basis of this legislation. From case law of the European Court of 
Justice it can be concluded that a product which is able to appreciably modify physio-
logical functions by exerting a pharmacological action, taking into account its composi-
tion, including its content in active substances, and its intended use, could be classified 
as a medicinal product (European Court of Justice 2009). The aim of this study was to 
determine whether the observed API levels in various herbal food supplements on the 
Dutch market, such as sildenafil and analogous PDE-5 inhibitors, may result in signifi-
cant pharmacological effects. Information on in vitro inhibitory effects on PDE-5, pre-
scribed dose levels, and structural similarity in case of lack of information on activity, 
was used to assess the pharmacological effects. In addition, the existing regulatory 
framework was discussed. 
Material and methods 
Sampling 
For the present study data from 71 herbal supplements and two soft drinks for en-
hancement of sexual potency, sampled by NVWA-inspectors from 2003 up to and in-
cluding 2012, were evaluated. Sampling locations were identified by an Internet search 
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or selected from the NVWA inspection database. The sampling strategy was risk based. 
In the course of the survey inspectors became more experienced in finding these par-
ticular herbal supplements on the Dutch market. Key indicators for sampling were la-
beling and pricing. Products with two or more of the following characteristics were 
sampled with priority: i) a limited number of doses per container in combination with a 
relatively high price, statements on the labeling regarding ii) recommendations to use 
the product 1 or 2 hours prior to the intended effect (against ED), iii) contra-indications 
and adverse effects, and iv) the use of herbal ingredients from the Far East. The sup-
plements consisted mainly of capsules, tablets, and liquids. All samples of herbal sup-
plements were in pre-packaged form, and contained instructions for use. Brand names 
were anonymised by replacement with Roman numerals followed by the year of analy-
sis. 
Chromatographic screening for PDE-5 inhibitors 
A HPLC-DAD-MS/MS method was developed to screen for the presence of PDE-5 inhibi-
tors in herbal supplements (Venhuis et al. 2008a; 2008b; 2010; 2011). Briefly, half a dose 
unit was sonicated with methanol and then diluted 100 times using MeOH / 0,1% for-
mic acid (buffered at pH = 4 with concentrated ammonia). After filtration the solution 
was analyzed by LC-MS/MS. Between each sample a blank was injected to asses carry-
over. Compounds of interest were found by searching for marker fragments in MS/MS 
(Singh et al. 2009). Quantification was performed based on the Ultraviolet response 
using three or five point calibration curves. The Limit of Detection (LOD) of the com-
pound for which the method was least sensitive (tadalafil) was < 0.1 mg per dose unit.  
Assessment of the pharmacological effects of the APIs identified in the herbal 
supplements 
In order to investigate whether medicinal products legislation applied to the sampled 
herbal supplements, the NVWA it was assessed in the present study whether their use 
would produce a significant pharmacological effect caused by the adulterant. There-
fore, the pharmacological potencies and doses of the APIs identified were assessed. The 
pharmacological potency of the APIs found in the samples was estimated using differ-
ent approaches. First by comparing the concentration of the API to data on the in vitro 
pharmacological activity of sildenafil and analogous PDE-5 inhibitors found in literature. 
Analogue concentrations that produce 50% inhibition of PDE-5 activity (IC50) were com-
pared by order of magnitude (pIC50) (RIVM 2007; Venhuis et al. 2008a; 2008b). Further-
more, by comparing the dose of the API to the dose information for registered drugs 
with PDE-5 inhibitor activity available on the Dutch market, and other drugs with PDE-5 
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inhibitor activity identified from literature. Finally by assessing data on structural simi-
larities between APIs from literature, including patent literature. For the estimation of 
the pharmacological effects of the analyzed APIs identified in the herbal supplements, 
we compared the combined data on the pharmacological potency to the dose level of 
the analyzed APIs resulting from intake of the herbal supplement.  
Results and discussion 
In total 71 herbal supplements and two soft drinks were analyzed for the presence of 
sildenafil and analogous PDE-5 inhibitors. Table 1 shows the APIs identified in the sup-
plement and the dose levels, which were calculated from the analytically determined 
level. Table 2 shows the in vitro data identified in literature on the pharmacological 
activity of sildenafil and analogous PDE-5 inhibitors expressed as pIC50, which is the 
negative logarithm of the IC50. Dose information for registered PDE-5 inhibitors availa-
ble on the Dutch market is shown in Table 3. In addition to sildenafil, eight different 
analogues of registered PDE-5 inhibitors were identified 27 times in total (Table 1). The 
structures of these APIs are also shown in Figure 1. The APIs were found in 23 herbal 
supplements with 12 different product names. In three herbal supplements (V, VI and 
XII) more than one API was detected. Sildenafil was found in only one herbal supple-
ment (I) in 2003. Aildenafil (n=7) and acetildenafil (n=6) were the most frequently de-
tected APIs in the 23 herbal supplements (Table 1). In addition, acetildenafil was found 
in two soft drinks, the labeling of which claimed that these drinks possessed libido en-
hancing effects (XIII and XIV). 
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Table 1. Dose levels of sildenafil and analogous PDE-5 inhibitors in herbal supplements sampled on the 
Dutch market. 
Active Pharmaceutical 
Ingredient (API) 
No. of herbal 
supplement with API 
Dose levels (mg per dose unit)a
sildenafil 1 62.6 (I/2003)a
hydroxyhomosildenafil 4 33 (II/2004)a, 87 (III/2007)a, 65 (IV/2008)a, traces (V/2008)a,b,c  
thiosildenafil 1 0.2 (VI/2012)a,d
aildenafil 7 46 (VII/2008)a, 49 (VIII/2008)a, traces (V/2008b,, IX/2008, X/2008, 
XI/2008)a,c , traces (XII/2010)a,c  
thioaildenafil 1 82 (XII/2010)a,e 
acetildenafil 8 4 (XIII/2004)a,f, 7 (XIV/2004)a,f, 60 (XV/2004)a, 62 (XVI/2004)a, 64 
(XVII/2004)a, 42 (XVIII/2005)a, 52 (XIX/2006)a, 36 (XX/2007)a  
noracetildenafil 3 significant signals (XXI/2008, XXII/2008)a,g, traces (VI/2012)a,c,d  
aminotadalafil 2 0.3 (V/2008)a,b, 53 (XXIII/2008)a  
piperidino-vardenafil 2 2 (XXIV/2007)a, 8 (XXV/2007)a
Notes: 
a The names of the herbal supplements were replaced by Roman numerals, followed by the year of analysis of 
the herbal supplement  
b Herbal supplement V/2008 contains traces of hydroxyhomosildenafil, traces of aildenafil and 0.3 mg per 
dose unit of aminotadalafil  
c Trace levels were not quantified, but were below 0,1 mg  
d Herbal supplement VI/2012 contains 0.2 mg per dose unit of thiosildenafil and traces of noracetildenafil 
e Herbal supplement XII/2010 contains traces of aildenafil and 82 mg per dose unit of thioaildenafil  
f Soft drinks 
g Significant signals were found, but the levels were not assessed at the time of analysis 
 
Assessment of the pharmacological effects of the APIs identified in the herbal 
supplements  
Table 2 shows that the in vitro pharmacological activities of most PDE-5 inhibitors, ex-
pressed as pIC50, are in the same order of magnitude. Only vardenafil is more potent by 
one order of magnitude. Therefore, the dose of the API is an important factor in deter-
mining whether the product would exert a significant pharmacological effect. Below it 
is discussed for each PDE-5 inhibitor identified in the current study, whether the herbal 
supplements which contained this API could result in a significant pharmacological 
effect. 
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Table 2. In vitro pharmacological activities of sildenafil and analogous PDE-5 inhibitors expressed as the 
concentration that produces 50% inhibition of PDE-5 catalytic potency (IC50) and the negative logarithm of the 
IC50 (pIC50). 
Active pharmaceutical ingredient IC50 (nM)  pIC50 (nM) Relative pIC50 potency to sildenafil (in vitro)  
sildenafil 7.1a 8.1  1.0 
hydroxyhomosildenafil  3.4a 8.5  1.1 
acetildenafil 7.6a 8.1  1.0 
tadalafil 5.0b 8.3  1.0 
vardenafil 0.7c 10.2  1.3 
Notes:  
a RIVM (2007) 
b Patent: Pfizer-Research-and-Development-Company (1992) 
c Dale et al. (2000)  
 
Sildenafil was found in one herbal supplement (I) at a level of 62.6 mg per dose unit. 
Table 3 shows that for sildenafil the commercially available dose of a registered drug 
for the treatment of pulmonary hypertension is 20 mg (Revatio®) and the lowest avail-
able dose of sildenafil with a registered drug for the treatment of ED is 25 mg (Viagra®), 
which is lower than the estimated dose level of supplement I. It was therefore conclud-
ed that use of this herbal supplement can produce a significant pharmacological effect. 
 Hydroxyhomosildenafil was found in three herbal supplements (II, III and IV) at 
levels of 33, 87 and 65 mg per dose unit, respectively. Like sildenafil, hydroxy-
homosildenafil is part of a patent (Pfizer 1994) in which these compounds are both 
claimed as ED drugs. Table 2 shows that hydroxyhomosildenafil, in vitro, is slightly more 
potent than sildenafil. A prodrug of hydroxyhomosildenafil, termed lodendafil car-
bonate, is commercially available in 80 mg tablets as an ED-medicine named ‘Helluva’ in 
Brazil (Flores Toque et al. 2008; Toque et al. 2008; Codevilla et al. 2011). All three doses 
found in the samples exceeded the lowest commercially available sildenafil doses of a 
registered drug (Table 3). It was concluded that the three herbal supplements investi-
gated were likely to produce significant pharmacological effects.  
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Table 3. Registered drugs with PDE-5 inhibitors on the Dutch market and their indication, active 
pharmaceutical ingredient (API), available doses, and instruction for use. 
Drug name Manufacturer Indication API Available doses (mg) Instruction for use 
Viagra®a Pfizer EDf sildenafil 25, 50, and 100 As needed 
Revatio®b Pfizer PHg sildenafil 20 Chronic treatment, 3x 20 mg daily 
Levitra®c Bayer EDf vardenafil 5, 10, and 20 As needed 
Cialis®d Lilly EDf tadalafil 5, 10, and 20 As needed 
Adcirca®e Lilly PHg tadalafil 20 Chronic treatment, 2 x 20 mg daily 
Notes: 
a EMA (2013a) 
b EMA (2013b) 
c EMA (2013c) 
d EMA (2013d)  
e EMA (2013e)  
f Erectile Dysfunction 
g Pulmonary Hypertension 
 
Thiosildenafil was found in one herbal supplement (VI) at a level of 0.2 mg per dose 
unit. This API is reported to be more potent in both PDE-5 and PDE-6 inhibition than 
sildenafil (Cho et al. 2003). As the estimated dose of this API with this herbal supple-
ment was much lower than the lowest commercially available sildenafil dose of a regis-
tered drug (Table 3), this supplement was not considered to induce significant pharma-
cological effects. 
 Aildenafil was found to be present in two herbal supplements (VII and VIII) at levels 
of 49 and 46 mg per dose unit, respectively. Patent and scientific literature showed that 
the pharmacological effects and potency of aildenafil were similar to sildenafil (Liu 
2005; He et al. 2006; Li et al. 2007; Wang et al. 2007). As the dose levels found for 
aildenafil with these herbal supplements exceeded the lowest commercially available 
sildenafil dose of a registered drug (Table 3), these supplements were considered to 
produce significant pharmacological effects. 
 Thioaildenafil was found in one herbal supplement (XII) at a level of 82 mg per dose 
unit. This PDE-5 inhibitor was included in a patent from Li et al. (2007) describing pyra-
zolopyrimidinethione derivatives, and this API is chemically synthesised from aildenafil. 
Animal studies showed that thioaildenafil was slightly more effective as an ED drug 
than sildenafil (Liu 2005). Because the dose levels found for thioaildenafil considerably 
exceeded the lowest commercially sildenafil dose of a registered drug (Table 3), this 
herbal supplement was considered to produce significant pharmacological effects.  
 Acetildenafil was found in six herbal supplements (XV to XX) at levels in a range of 
36 up to 64 mg per dose unit. Like sildenafil, acetildenafil is part of a patent (Pfizer 
1994) in which these compounds are both claimed to be ED drugs. Table 2 shows that 
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acetildenafil, in vitro, is almost equipotent to sildenafil. Because the estimated doses of 
this API with all six herbal supplements exceeded the lowest commercially available 
sildenafil dose of a registered drug (Table 3), these herbal supplements were consid-
ered to produce significant pharmacological effects. Two soft drinks (XIII and XIV) con-
tained 4 and 7 mg acetildenafil per can, respectively, which is below the lowest com-
mercially available sildenafil dose of a registered drug (Table 3). As a result from this 
pharmacological effects were not expected from the consumption of one can of these 
soft drinks. 
 Noracetildenafil was found in three herbal supplements (VI, XXI and XXII). Trace 
levels (< 0,1 mg) were identified in supplement VI. Significant signals of noracetildenafil 
were found in the chromatogram of the supplements XXI and XXII, but the levels were 
not assessed at the time. Noracetildenafil is described in a patent (Pfizer 1994), which 
also includes sildenafil and acetildenafil. Significant pharmacological effects resulting 
from use of these herbal supplements were only expected for samples XXI and XXII.  
 Aminotadalafil was found to be present in two herbal supplements (V and XXIII) at 
levels of 0.3 and 53 mg per dose unit, respectively. Aminotadalafil is an analogue of 
tadalafil. This API is described in a patent in which it is reported to have a similar poten-
cy as tadalafil (Orme et al. 2001). Because the dose level of aminotadalafil estimated for 
herbal supplement XXIII (53 mg per dose unit) exceeded the highest commercially 
available dose of tadalafil of a registered drug (20 mg, Table 3), this herbal supplement 
was considered to produce significant pharmacological effects. For the herbal supple-
ment (V) with a level of aminotadalafil of 0.3 mg per dose unit, no pharmacological 
effects were expected because the dose level found was far below the lowest commer-
cially available tadalafil dose of a registered drug (5 mg, Table 3).  
 Piperidino-vardenafil was found in two supplements (XXIV and XXV), at levels of 2 
and 8 mg per dose unit, respectively. In a patent on phenylsubstituted imidazotria-
zinones as phosphodiesterase inhibitors (Bayer 1999), piperidino-vardenafil is also de-
scribed. Figure 1 shows that vardenafil and piperidino-vardenafil have very closely re-
lated molecular structures. We assumed piperidino-vardenafil and vardenafil to have 
similar pharmacological potencies. Based on the finding that the piperidino-vardenafil 
doses estimated for these supplements were close to the lowest commercially available 
vardenafil dose of a registered drug (5 mg, Table 3), we concluded that significant 
pharmacological effects resulting from the use of these two herbal supplements cannot 
be excluded.  
 From the assessment of the pharmacological effects of the APIs identified in the 
herbal supplements it was concluded that use of 18 herbal supplements, in which APIs 
were identified, could result in significant pharmacological effects.  
 It is of importance to note that other registered sildenafil analogues exist; including 
for example mirodenafil and udenafil (Göker et al. 2012), but their presence was not 
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detected in the herbal food supplements analyzed in the present study. In line with 
what others reported (Li et al. 2009; Göker et al. 2012) we occasionally detected 
dapoxetine, known to prevent premature ejaculation (McMahon 2012), but since it 
does not belong to the group of sildenafil analogues this was considered outside the 
scope of the present study. 
 Because our sampling protocol was specifically targeted at finding herbal supple-
ments for libido enhancement that were more likely to be adulterated with PDE-5 than 
other herbal supplements for libido enhancement, these findings can not be extrapo-
lated to all herbal supplements on the market that are claimed to enhance libido.  
 The labeling of some herbal supplements sampled in our study containing thio-
sildenafil, aildenafil, noracetildenafil and aminotadalafil suggested that these products 
were intended for women. However, the use of PDE-5 inhibitors on female libido is not 
supported by literature. In six herbal supplements (V, VI, IX, C, XI, XII) trace levels of 
hydroxyhomosildenafil, aildenafil and noracetildenafil were found. As trace levels are 
expected to have no pharmacological effects, the presence of these trace levels of PDE-
inhibitors could indicate that the production process was not sufficiently controlled 
which might be an indication for non-GMP production (Good Manufacturing Practice), 
which is another reason for concern for these types of products.  
 Our finding that acetildenafil was present in two soft drinks in 2004, is noteworthy 
as well. Only one similar case was reported in Asia by Shin et al. (2004). These findings 
suggest that official control authorities should not rule out these food products when 
investigating products for adulteration with PDE-5 inhibitors. 
 A limitation of our study is that pIC50 values were not available for all analogues 
identified in the herbal supplements. Furthermore, comparing in vitro data may have 
limited predictive value as to the pharmacological effects in vivo (Corbin and Francis 
2002; RIVM 2010; Venhuis and de Kaste 2012). For example, piperidino-vardenafil is 
reported to be more liphophilic than vardenafil (Pissarnitski 2006; RIVM 2007). There-
fore, relative to vardenafil, piperidino-vardenafil may be absorbed better, thereby pro-
ducing a significant pharmacological effect at a lower dose than would be derived by 
pIC50 comparison.  
 We also used data on the commercially available dose of registered drugs (Table 3) 
for the assessment of the pharmacological effect relevance of the levels of the APIs 
found in herbal supplements. Consequently, the low and trace levels of APIs found in 
herbal supplements V, VI, IX, X, XI, XII, XIII, XIV are not expected to be pharmacological-
ly relevant. Their presence may be the result of a contamination. Manufacturers might 
not adequately clean their equipment between production runs. When produced under 
non-GMP (Good Manufacturing Practice) conditions, such low and trace levels may also 
be the result of inhomogeneous mixing of the API and the herbal matrix resulting in a 
PDE-5 INHIBITORS IN HERBAL FOOD SUPPLEMENTS 
 99
product composition that is variable. Non-conformity with GMP is another important 
concern for these types of products. 
 It is possible that use of herbal supplements containing APIs at lower dose levels 
than registered drugs containing this API would also result in pharmacological effects. 
However, reliable data from literature on this topic is lacking.  
 The current enforcement actions on adulterated herbal supplements take place 
when these products are already on the market. Therefore, consumers might already 
be at risk of the adverse effects of the supplements containing these APIs. It would be 
desirable that control authorities could prevent these products from entering the mar-
ket. Alternatives to enforcement on the basis of medicinal products legislation, which 
requires investigation of the pharmacological action of the herbal supplements, might 
offer advantages over this method. Some alternative methods are employed in other 
countries. For example, imposing a generic ban on PDE-5 inhibitors in foods including 
herbal food supplements might simplify enforcement. A recent example of a related 
measure is the introduction of a generic ban on synthetic psychotropics in Austria cov-
ering all known classes of related psychoactive structures (Mayrhofer et al. 2012). Alt-
hough such a measure would not prevent the entering on the market of adulterated 
herbal supplements, it could result in more efficient market control.  
 Another possible way forward to increase the safety of herbal supplements on the 
market may be the introduction of a more formal pre-marketing assessment for these 
products, which is currently in place in Singapore in order to regulate Chinese Proprie-
tary Medicines. This type of medicines contains ingredients derived from (a combina-
tion) of plants, animals or minerals (Yee et al. 2005). A pre-marketing assessment sys-
tem was advocated as well by the European Food Safety Authority (EFSA) (EFSA 2009).  
 To conclude, from the 71 herbal supplements sampled on the Dutch market, 23 
supplements contained sildenafil and analogous PDE-5 inhibitors, from which most of 
the APIs found in our study are not registered as approved drugs. Enforcement actions 
based on medicinal products legislation were undertaken to remove 18 supplements 
from the market which contained sildenafil and analogous PDE-5 inhibitors, the use of 
which would result in significant pharmacological effects. Enforcement actions to re-
move such herbal supplements from the market on the basis of medicinal products 
legislation, require official control authorities to conduct investigations which can put a 
stress on their resources. In order to protect users of these herbal supplements the 
adequate use of the existing regulation and control measures seems necessary and the 
use of alternative methods for enforcement of adulterated herbal supplements should 
be explored. 
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Abstract  
Herbal food supplements, claiming to reduce weight, may contain active pharmacologi-
cal ingredients (APIs) that can be used for the treatment of overweight and obesity. The 
aim of this study was to determine whether herbal food supplements for weight loss on 
the Dutch market contain APIs with weight loss properties. Herbal food supplements 
intended for weight loss (n=50), were sampled from August 2004 up to and including 
May 2013. A HPLC-DAD-MS/MS method was used to screen for the presence of the 
APIs in herbal supplements. In 24 samples the APIs sibutramine, desmethylsibutramine 
(DMS), didesmethylsibutramine (DDMS), rimonabant, sildenafil, and/or the laxative 
phenolphthalein were identified 41 times. The presence of these APIs was however not 
stated on the label. The potential pharmacological effects of the detected APIs were 
estimated using data from reported effective doses of approved drugs. Use of 20 of the 
24 herbal food supplements, may result in potential pharmacological effects. Further-
more, risk assessment of phenolphthalein, a suspected carcinogen and found to be 
present in ten supplements, based on the Margin of Exposure (MOE) approach resulted 
in MOE values of 96-30,000. MOE values lower than 10,000 (96-220) were calculated 
for the daily intake levels of four out of these ten supplements in which phenolphtha-
lein was found. However, taking into account that weight loss preparations may be 
used for only a few weeks or months rather than during lifetime, MOE values may be 
two to three orders of magnitude higher. The current study shows that the use of food 
supplements with sibutramine, DMS, DDMS, and/or phenolphthalein could result in 
pharmacological effects. 
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Introduction 
Nowadays, overweight and obesity are a growing public health issue. The World Health 
Organization (WHO) estimates that more than 1.4 billion adults are overweight and at 
least 500 million people are obese. Overweight can be defined by a body mass index 
(BMI) between 25–30 kg m-2, and obesity is defined by a BMI greater or equal to 30 kg 
m-2 (WHO 2013).    
 In the last decennia synthetic drugs for treatment of overweight and obesity were 
introduced on the market such as Reductil®, Meridia®, Reduxade®, and Zelium®, con-
taining sibutramine as the active pharmacological ingredient (API), Acomplia®, contain-
ing rimonabant,  Fentrate Retard® and Ponderal®, containing fenfluramine, Isomeride®, 
containing dexfenfluramine, and Xenical®, containing orlistat (Ioannides-Demos et al. 
2006; RIVM 2009; EMA 2010a; EC 2013).  
 Herbal food supplements that claim to induce weight loss are marketed worldwide 
and are readily available from Internet shops (Jordan and Haywood 2007; De Carvalho 
et al 2011; Ozdemir et al. 2012; Ancuceanu et al. 2013). These products generally claim 
to be ‘all natural’ but there are frequent reports of adulterations with drugs for the 
treatment of overweight, obesity and constipation such as sibutramine, fenfluramine,  
rimonabant, orlistat, and phenolphthalein (Yuen et al. 2007; Zou et al. 2007; Wang et 
al. 2008; Chen et al. 2009; RIVM 2009; Tang et al. 2010; Vaysse et al. 2010; De Carvalho 
et al. 2012; Dunn et al. 2012; Stypulkowska et al. 2011; Phattanawasin et al. 2012; An-
cuceanu et al. 2013).  
 The API sibutramine (Figure 1a), which was initially developed as an antidepres-
sant, is a combined serotonin (5-HT) and noradrenaline (NA) re-uptake inhibitor. In the 
body sibutramine is rapidly metabolized through demethylation into desmethylsibu-
tramine (DMS; Figure 1b) and didesmethylsibutramine (DDMS; figure 1c) (Nisoli and 
Carruba 2000; Kang et al. 2010a). DMS and DDMS are both pharmacologically active, 
inducing satiety and stimulation of thermogenesis (Glick et al. 2000; Nisoli and Carruba 
2000; Ding et al. 2003; Padwal and Majumdar 2007). In 2010 the European Medicines 
Agency (EMA) recommended the suspension of the market authorizations for sibu-
tramine in the European Union because of an increased risk of serious, non-fatal cardi-
ovascular events, such as stroke or heart attack (EMA 2010a). Reported side effects of 
sibutramine include cardiovascular effects such as tachycardia and (arterial) hyperten-
sion (Ioannides-Demos et al. 2006; Padwal and Majumdar 2007; Müller et al. 2009; 
Cohen and Ernst 2010). Furthermore, several psychiatric symptoms are reported such 
as psychosis and (hypo)mania, occurring at dose levels of sibutramine in an estimated 
range of 2.8-60 mg (Taflinski and Chojnacka 2000; Litvan and Alcoverro-Fortuny 2007; 
Lee et al. 2008; Müller et al. 2009; Chen et al. 2010; Chong 2010; van Hunsel and van 
Grootheest 2011; Waszkiewicz et al. 2012).  
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Figure 1. Chemical structures of a) sibutramine b) desmethylsibutramine c) didesmethylsibutramine d) 
rimonabant, and e) phenolphthalein. 
 
 
Also adverse effects of DMS and DDMS have been clearly documented. Three cases of 
psychotic symptoms were linked to the use of slimming products containing DMS (Yuen 
et al. 2007; Chen et al. 2010), and cardiovascular effects were reported in a man who 
had used a herbal weight loss supplement containing DDMS (Fil et al. 2011).  
 Another weight loss drug, Acomplia®, which contains the API rimonabant (Figure 
1d), was withdrawn from the European market at the end of 2008 because of severe 
side effects such as depression, and suicidal behaviour, and lack of efficacy (EMA 2007; 
EMA 2009; Venhuis et al. 2011; EC 2013). Rimonabant is a selective cannabinoid-1 re-
ceptor (CB1) blocker, which regulates food intake (Van Gaal et al. 2005; Padwal and 
Majumdar 2007). After the withdrawal of Acomplia® in 2008 counterfeit Acomplia® and 
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imitation products, containing rimonabant polymorphs, were reported to be available 
on the Internet (Venhuis et al. 2011).   
 Phenolphthalein (Figure 1e), which is a benzofuran derivate, was used in a number 
of authorized medicinal products for treatment of constipation (IARC 1999; NTP 2011). 
In 1996, the US National Toxicology Program (NTP) published data on the genotoxity of 
phenolphthalein and its carcinogenicity in laboratory animal studies (NTP 1996). In 
1997, the EMA concluded that the National Competent Authorities should take these 
NTP data into account in their considerations of any restriction of phenolphthalein 
containing medical products on the national markets (EMA 1997).  
 In the Netherlands, the presence of sibutramine and phenolphthalein in a vitamin 
supplement and in capsules was first reported by the National Customs Laboratory in 
2004 (RIVM 2009). Subsequently the Netherlands Food and Consumer Product Safety 
Authority (NVWA) monitored the presence of APIs in various herbal food supplements 
for weight loss on the Dutch market. The current study describes the results of this 
survey, and also evaluates the possible pharmacological relevance of dose levels de-
tected based on data from reported effective doses of approved drugs. Furthermore, in 
the present study the risk assessment of the suspected carcinogenic effects of phenol-
phthalein was performed using the Margin of Exposure (MOE) approach (EFSA 2005). 
To this end, the MOE was determined by calculating the benchmark dose lower confi-
dence limit for 10% extra cancer risk (BMDL10) based on tumor data from animal studies 
and comparing this value to the intakes that would result from daily use of the herbal 
supplements at the recommended dosing.  
Material and methods 
Sampling 
For the present study 50 herbal supplements for weight loss were sampled on the 
Dutch market by NVWA inspectors from August 2004 up to and including May 2013. 
Sampling locations were identified by an Internet search or selected from the NVWA 
inspection database. The sampling strategy was partly risk based. Inspectors collected 
products based on experience and on the basis of reports and alerts of national and 
international health authorities concerning adulterated food supplements on the mar-
ket and reports of side effects linked to specific products. These national and interna-
tional reports and alerts included an official warning in the Netherlands of side effects 
of a food supplement containing green coffee (IGZ 2010) and consumer warnings from 
health authorities such as from Australia (Australian government 2007), Canada (Health 
Canada 2006), UK (MHRA 2010), and the US (FDA 2013). These reports and alerts 
CHAPTER 5 
 110 
pointed to herbal supplements that might contain APIs and these were indicated for 
sampling in our sampling strategy. Furthermore, the sampling strategy was also based 
on reports of side effects which were directly reported by consumers to the NVWA and 
on reports of side effects which were received from the Netherlands Pharmacovigilance 
Centre (Lareb). Moreover, previous analyses by the Dutch Customs Laboratory of food 
supplements imported into the Netherlands and findings of the APIs in these products 
were also taken as a basis for the sampling strategy. Additionally, one of the indicators 
for identifying suspected herbal supplements were user reports on Dutch Internet fo-
rums in which users reported side effects resulting from the use of herbal slimming 
products.  
 The sampled supplements consisted mainly of capsules, tablets, and sachets with 
powder. All samples of herbal supplements were in pre-packaged form, and contained 
instructions for use. Brand names were anonymized by replacement with Roman num-
bers. 
Chromatographic screening for APIs in the herbal supplements   
An HPLC-DAD-MS/MS method was developed to screen for the presence of APIs in 
herbal supplements (Venhuis et al. 2011). Briefly, half a dose unit was sonicated with 
methanol and then diluted 100 times using MeOH / 0,1% formic acid (buffered at pH = 
4 with 35% concentrated ammonia). After filtration over a 0.45 µm filter (Whatman 
GmbH, Dassel, DE) the solution was analyzed for common weight-loss drugs by LC-DAD-
MS/MS. Between each sample a blank was injected to prevent carry-over. Compounds 
of interest were found by searching for MH+ ions (full scan) and marker fragments 
(MS/MS) (Venhuis et al. 2011). Quantification was performed based on the UV re-
sponse using three or five point calibration curves. Because the sample matrices were 
complex and highly variable, each negative screening result was challenged by spiking 
the sample with a pharmacologically irrelevant level of sibutramine. In most instances 
spiked sibutramine could be identified at a level of 0.1 mg dose-1. In a few cases the 
matrix required spiking at a level of up to 0.6 mg dose-1 before sibutramine could be 
identified.       
Assessment of the pharmacological effects of the APIs identified in the herbal 
supplements  
In order to investigate whether the use of an analyzed herbal supplement would be of 
pharmacological relevance, the pharmacological potencies and doses of the APIs identi-
fied in the herbal supplements were assessed. The pharmacological potency of the APIs 
found in the sample was estimated by comparing the daily intake of the API that would 
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result from its use according to the manufacturer’s prescriptions to the dose infor-
mation for registered drugs. Furthermore, the recommended daily dose of the herbal 
supplement was compared to the lowest commercially available daily dose of a drug 
containing the API. The recommended daily dose of the herbal supplement was identi-
fied from the label, or from an Internet search.  For the calculation of the resulting 
intake of the API we selected the upper range of the recommended daily dose of the 
herbal supplement. For the herbal supplements for which no recommended daily dose 
could be identified we assumed the recommended daily dose to be one dosing unit day-
1. The pharmacological potencies of DMS and DDMS were estimated by comparing data 
from (patent) literature on pharmacological profiles of sibutramine to DMS and DDMS. 
Risk assessment of phenolphthalein identified in the herbal supplements 
For the risk assessment of phenolphthalein detected in the herbal supplements, we 
applied the Margin of Exposure (MOE) approach (EFSA 2005). Benchmark dose (BMD) 
and BMDL10 values were obtained by fitting the carcinogenicity data obtained from 
literature to a number of different mathematical models using BMDS software, version 
EPA 2.4 (EPA 2013). The following models were used: Gamma, Logistic, LogLogistic, 
LogProbit, Multistage-cancer, Multistage, Probit, Quantal-Linear and the Weibull mod-
el. BMDS software was applied without model restrictions, using default setting of extra 
risk type, a 95% confidence level, and a Benchmark response (BMR) of 10%. The 
BMD(L)10 values derived from the different fitted models were only accepted if the fit of 
the selected model was not of poorer quality than that of the so-called full model rep-
resenting a perfect fit to the dose-response data. For this purpose, the p-value was 
taken into account with a value below 0.05 resulting in model rejection. For calculation 
of the MOE the lowest BMDL10 value was selected (EFSA 2005). The estimated daily 
intake (EDI) for phenolphthalein from the herbal supplements was calculated based on 
the concentration of phenolphthalein detected in the supplement and the recom-
mended daily dose indicated on the label, using a default body weight of 70 kg (EFSA 
2012). The MOE values were calculated by dividing the BMDL10 by the EDI (EFSA 2005).  
Results  
Presence of APIs in herbal supplements 
In total 50 herbal supplements for weight loss were analyzed for the presence of APIs. 
Table 1 shows the APIs identified, the recommended daily dose in dose units day-1 for 
the respective herbal supplements and the dose levels of the APIs that would result 
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from this level of use. The latter values were calculated from the analytically deter-
mined level of the API and the recommended daily use of the herbal supplement indi-
cated on the label or identified from an Internet search. For some herbal supplements 
no recommended daily dose could be identified, and for these herbal supplements the 
recommended daily dose was set to one dosing unit day-1. Sibutramine, DMS, DDMS, 
phenolphthalein, sildenafil or rimonabant were identified in 24 herbal supplements 
with 12 different brand names. In 11 herbal supplements more than one API was de-
tected. Sibutramine was found in 17 herbal supplements and was the most frequently 
detected API. In addition, phenolphthalein, DDMS, and DMS were found in ten, six, and 
four herbal supplements, respectively. Rimonabant was found in one herbal supple-
ment. Additionally, in two herbal supplements (XVIII and XIX) trace levels of the PDE-5 
inhibitor sildenafil were found, and in one herbal supplement (XVI) a dose level of 0.9 
mg dosing unit-1 of sildenafil was found (Table 1). The APIs fenfluramine and N-
nitrosofenfluramine were not found. 
 
Table 1. Dose levels of the Active Pharmaceutical Ingredients (APIs) sibutramine (sib), 
desmethylsibutramine (DMS), didesmethylsibutramine (DDMS), rimonabant (rim), sildenafil (sil) and 
phenolphthalein (phen) in herbal supplements sampled on the Dutch market. 
Herbal supplementaBrand 
nameb 
Year of 
sampling 
Analytically determined 
concentration (mg dosing 
unit-1)c 
Recommended daily 
dose (dosing unit day-1)
Estimated daily 
dose level (mg 
day-1)d 
I  A 2010 11 (sib) 1 11 (sib) 
II  A 2010 21(sib) 1 21 (sib) 
III A 2010 21 (sib) 1 21 (sib) 
IV A 2010 19 (sib) 1 19 (sib) 
V B 2011 18 (sib) 1-2 18-36 (sib) 
VI B 2011 3.7 (DDMS); 0.3 (phen) 1-2 3.7-7.4 (DDMS); 
0.3-0.6 (phen) 
VII B 2011 3.6 (DDMS); 0.2 (phen) 1-2 3.6-7.2 (DDMS); 
0.2-0.4 (phen) 
VIII B 2011 3.7 (DDMS); 0.2 (phen) 1-2 3.7-7.4 (DDMS); 
0.2-0.4 (phen) 
IX B 2011 8 (sib) 1-2 8-16 (sib) 
X C 2011 2 (sib) 2 4 (sib) 
XI C 2011 13 (sib) 2 26 (sib) 
XII D 2011 16.8 (sib) 1 16.8 (sib) 
XIII E 2011 6 (sib); 43 (phen) 1 6 (sib); 43 (phen) 
XIV F 2012 16 (DDMS) 0.5-1  8-16 (DDMS) 
XV F 2012 16 (DDMS) 0.5-1  8-16 (DDMS) 
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Herbal supplementaBrand 
nameb 
Year of 
sampling 
Analytically determined 
concentration (mg dosing 
unit-1)c 
Recommended daily 
dose (dosing unit day-1)
Estimated daily 
dose level (mg 
day-1)d 
XVI G 2012 traces (DDMS); 43 (phen); 
0.9 (sil) 
1e 43 (phen); 0.9 (sil) 
XVII H 2012 12 (sib); 27 (phen) 1  12 (sib); 27 (phen) 
XVIII I 2012 10 (sib); traces (DMS); 
traces (sil) 
1e 10 (sib) 
XIX J 2012 15 (sib); 31(phen); traces 
(sil) 
1-2 15-30 (sib); 31-62 
(phen) 
XX K 2012 20 (sib) 1e 20 (sib) 
XXI  A 2012 0.3 (rim) 1e 0.3 (rim) 
XXII A 2013 traces (sib); 0.1 (DMS); 
traces (phen) 
1e 0.1 (DMS) 
XXIII A 2013 traces (sib); 0.2 (DMS); 
traces (phen) 
1e 0.2 (DMS) 
XXIV L 2013 traces (sib); 0.1 (DMS); 
traces (phen) 
1e 0.1 (DMS) 
Notes: 
a The samples of the herbal supplements were numbered by Roman numbers 
b The brand names of the herbal supplements were replaced by alphabetic letters 
c  Sibutramine, DMS, and DDMS are reported as a free base 
d Analyzed dose level multiplied by recommended daily dose 
e No recommended daily dose could be identified; recommended daily dose set on 1 dosing unit day-1 
 
Assessment of the pharmacological effects of the APIs identified in the herbal 
supplements  
Below it is discussed for each API identified in the current study, whether the use of the 
herbal supplements which contained the APIs identified would be of pharmacological 
relevance.  
Sibutramine 
Sibutramine was found in 14 samples at levels that would result in estimated daily dose 
levels of 4 up to 36 mg sibutramine (as a free base) day-1. Additionally, in three herbal 
supplements traces of sibutramine were found (Table 1). For treatment of weight loss 
sibutramine-HCl is commercially available as a registered drug in doses of 10 and 15 
mg, and prescribed at one dosing unit day-1 (EMA 2002; EMA 2010b). For estimating the 
potential pharmacological effect of the herbal supplements we selected the lowest 
commercially available dose of 10 mg sibutramine-HCl, which corresponds to 8.3 mg of 
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the free base. The use of 12 herbal supplements (I-V, IX, XI, XII, XVII-XX) at the recom-
mended daily dosing would exceed the lowest commercially available daily recom-
mended sibutramine dose as the free base (8.3 mg) of this formerly registered drug, 
and these 12 herbal supplements were thus considered to induce pharmacological 
effects.  
DMS 
DMS was found to be present in three samples at levels that would result in estimated 
daily dose levels of 0.1 (XXII, XXIV) and 0.2 mg day-1 (XXIII) when used as recommended. 
Additionally, one herbal supplement contained traces of DMS (Table 1). From a litera-
ture search we concluded that DMS and DDMS have similar pharmacological effects as 
sibutramine in vivo (Jerussi et al. 2001; Kang et al. 2010b). Furthermore, based on the 
differences of sibutramine, DDMS and DMS on the uptake of norepinephrine, serotonin 
and dopamine, we estimated DMS and DDMS to be up to 50-fold more potent than 
sibutramine (Glick et al. 2000). Patent literature suggests an effective dose for DDMS as 
off 0.2 mg day-1 (Barberich 2005) in the treatment of sleeping disorders. Because of the 
similarities in the pharmacological profiles of DDMS and DMS we assume both APIs are 
pharmacological active at a dose ≥ 0.2 mg day-1. Because the highest estimated daily 
dose of DMS was 0.2 mg day-1 (XXIII) we considered that use of this supplement is likely 
to induce pharmacological effects.  
DDMS 
DDMS was found to be present in five samples (VI-VIII, XIV, and XV) at levels that, when 
used as recommended, would result in an estimated intake of 3.6-16 mg day-1 (Table 1). 
Additionally, one herbal supplement (XVIII) contained traces of DDMS (Table 1). Be-
cause the lowest estimated daily dose of this API with herbal supplement VII (3.6 mg 
day-1) is above the lowest dose of DDMS (0.2 mg day-1) of which pharmacological ef-
fects are expected, the use of these five supplements as recommended at estimated 
daily DDMS levels from 3.6 to 16 mg day-1 was considered to induce pharmacological 
effects.  
Rimonabant 
Rimonabant was found in one herbal supplement (XXI) at a level that would result in an 
estimated daily dose level of 0.3 mg day-1 when used as recommended. The drug 
Acomplia® is commercially available in doses of 20 mg rimonabant per dosing unit, 
taken once daily (EMA 2013). Because the estimated daily dose level of rimonabant in 
herbal supplement XXI appears to be far below the commercially available rimonabant 
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dose of a registered drug amounting to 20 mg rimonabant day-1, it can be concluded 
that use of this herbal supplement as recommended, is unlikely to result in pharmaco-
logical effects. 
Sildenafil 
Sildenafil, which is a phosphodiesterase type 5 inhibitor, was identified on the Dutch 
market in herbal food supplements used to enhance sexual potency (Reeuwijk et al. 
2013).  For sildenafil the commercially available dose of a registered drug for the treat-
ment of pulmonary hypertension is 20 mg (Revatio®) and the lowest available dose of 
sildenafil with a registered drug for the treatment of erectile dysfunction is 25 mg (Vi-
agra®) (Reeuwijk et al. 2013), which is higher than the analyzed dose levels of supple-
ments XVI (0.9 mg day-1), XVIII (traces), and XIX (traces) (Table 1). It was therefore con-
cluded that use of these three herbal supplements as recommended, is not expected to 
produce a pharmacological effects. 
Phenolphthalein 
Phenolphthalein was found in seven herbal supplements at levels that would result in 
estimated daily dose levels ranging from 0.2 up to 62 mg day-1 (Table 1). EMA (1997) 
reported recommended clinical oral doses of phenolphthalein to be 50 to 200 mg, and 
an anticipated human intake in normal users of 4 mg phenolphthalein kg bw-1 day-1, 
which is equivalent to 280 mg day-1 for a 70 kg adult. Furthermore, NTP (2011) reported 
oral dose levels of phenolphthalein available as over the counter drugs ranging from 30 
to 200 mg for adults. Doses for children, aged from two to eleven years, were reported 
to be 15 to 60 mg (NTP 2011). Additionally, IARC (1999) reported phenolphthalein to be 
available as tablets in a range from 6.5 to 200 mg. For the assessment of the pharmaco-
logical effect of phenolphthalein present in the herbal supplements, we assumed the 
lowest daily dose level of phenolphthalein to be 6.5 mg phenolphthalein day-1, which 
was reported by IARC (1999). Estimated daily dose levels of four herbal supplements 
(XIII, XVI, XVII, and XIX) exceeded this selected lowest reported available daily dose (6.5 
mg day-1), and it was therefore considered that use of these herbal supplements can 
produce a pharmacological effect.    
 
Altogether, from the assessment of the pharmacological effects of the APIs identified in 
the herbal supplements it was concluded that use of 20 out of 24 herbal supplements, 
in which the APIs sibutramine, DMS, DDMS, and/or phenolphthalein were identified, 
could result in pharmacological effects.  
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Risk assessment of phenolphthalein identified in the herbal supplements 
Aside from its pharmacological effects, phenolphthalein also possesses carcinogenic 
potency (NTP 1996; 2011; IARC 1999). For the risk assessment of phenolphthalein we 
used data from the study of Dunnick and Hailey (1996) and NTP (1996) on the incidence 
of histiocytic sarcomas in B6C3F1 male mice exposed in four dose groups to phenol-
phthalein for 104 weeks by feed (Table 2). Table 3 shows the results from the BMD 
analysis of the data from the study of Dunnick and Hailey (1996) and NTP (1996). 
BMDL10 values were calculated and these were in a range of 85-557 mg kg bw-1 day-1. 
For the calculation of the MOE values resulting from exposure to phenolphthalein in 
herbal supplements we used the lowest BMDL10 value which was 85 mg kg bw-1 day-1. 
The MOE values obtained using the estimated daily intakes (EDI) that would result from 
use of the phenolphthalein containing herbal supplements varied from 96 to 30,000. 
Use as recommended of four of the herbal supplements containing phenolphthalein 
(XIII, XVI, XVII, and XIX) would result in MOE values ranging from 96 to 220.  
 
Table 2. Data on the incidence of hystiocytic sarcoma in B6C3F1 male mice exposed to increasing dose of 
phenolphthalein for 104 weeks by feed (Dunnick and Hailey 1996; NTP 1996) used in the current study for the 
BMD analysis. 
Dose (mg kg bw-1 day-1) No. of animals Incidence hystiocytic sarcoma  
0 50 1 
300 50 3
600 50 11
1200 49 12 
 
It must be emphasized that in this approach MOEs are calculated assuming lifetime 
exposure while herbal food supplements for weight loss may only be used during rela-
tively short periods for several weeks or months. For this reason, calculation of the 
MOEs assuming lifetime exposure at the estimated daily intakes might overestimate 
the potential risk for human health. However, a general framework for taking intermit-
tent and/or short-term instead of lifetime exposures to compounds that are both geno-
toxic and carcinogenic into account in the safety assessment is currently not in place. 
Felter et al. (2011) recently proposed to use the principle of Haber’s Rule for assessing 
the risk from less-than lifetime exposures to carcinogens, provided that chemical-
specific carcinogenicity data are available and that data support a linear dose-response 
relationship (Felter et al. 2011). Haber’s Rule assumes that the acceptable cumulative 
lifetime exposure can be averaged over the duration of short-term exposure, suggest-
ing that higher daily intakes are acceptable when short-term exposure is considered 
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(Felter et al. 2011). Applying Haber’s Rule to assess the potential risk for short-term 
exposure during a period of several weeks or months on an estimated life expectancy 
of 75 years may result in MOE values that are two to three orders of magnitude higher 
than those obtained when assuming lifetime (75 years) daily use of the herbal supple-
ments.  
 
Table 3. Results from a BMD analysis of the data on the incidence of hystiocytic sarcoma in B6C3F1 male 
mice exposed to phenolphthalein (NTP 1996; Dunnick and Hailey 2006) using BMDS software version 2.4, a 
BMD of 10% extra risk and default settings. 
Model Restriction No. of 
parameters 
Log  
Likelihood 
p-value Accepteda BMD10  
(mg kg bw-1 day-1) 
BMDL10  
(mg kg bw-1 day-1) 
Null  1 -79.011 - - - - 
Full  4 -69.872 - - - - 
Gamma none 3 -70.989 0.14 Yes 403 85 
Logistic nab 2 -72.501 0.07 Yes 690 557 
LogLogistic none 3 -70.935 0.15 Yes 401 98 
LogProbit none 3 -70.838 0.17 Yes 408 117 
Multistage-
cancer 
nab 2 -70.993 0.33 Yes 415 292 
Multistage none 3 -70.902 0.15 Yes 357 185 
Probit nab 2 -72.227 0.10 Yes 648 519 
Quantal-Linear nab 2 -70.993 0.33 Yes 415 292 
Weibull none 3 -70.985 0.14 Yes 398 89 
Notes: 
a Fitted model not significantly different (worse) than the full model at p<0.05 
b not applicable 
Discussion 
In this study 50 herbal supplements for weight loss available on the Dutch market were 
investigated for the presence of APIs. In 24 samples the APIs sibutramine, DMS, DDMS, 
rimonabant, sildenafil, and/or the laxative phenolphthalein were identified 41 times, 
and in 11 herbal supplements more than one API was identified. Possible pharmacolog-
ical effects, and for phenolphthalein also toxicological effects, resulting from the pres-
ence of these APIs in the herbal supplements were evaluated. It was found that the use 
as recommended of 20 out of the 24 herbal supplements, in which sibutramine, DMS, 
DDMS, and phenolphthalein were identified, would result in estimated daily dose levels 
that could result in pharmacological effects. Furthermore, the use of four out of ten 
herbal supplements containing phenolphthalein would result in daily intake levels that 
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result in MOE values in a range of 96-220, being lower than 10,000. For short term-
exposure (a few weeks or months) MOE values may be two or three orders of magni-
tude higher.   
Estimation of pharmacological effective doses of the APIs found 
To investigate whether medicinal products legislation could be applied to the sampled 
herbal supplements, we assessed whether their use would produce a pharmacological 
effect. For this, we compared the dose level of APIs resulting from the recommended 
use of the herbal supplements to the lowest dose level of commercially available drugs 
containing sibutramine, rimonabant, sildenafil, and phenolphthalein, identified in litera-
ture. We concluded that when the lowest dose level of the commercially available 
drugs was exceeded pharmacological effects could be expected. However, it cannot be 
excluded that dose levels resulting from the use of herbal supplements at estimated 
daily dose levels that are below the lowest commercially available daily dose will also 
produce pharmacological effects. Thus estimates presented for the possible pharmaco-
logical effects from the herbal supplements containing these APIs may be underesti-
mates. 
 A limitation of our study in this respect is that for the APIs DMS and DDMS no 
commercially available doses exist or have existed. Furthermore, reliable data from 
literature on the pharmacologically active doses of DMS and DDMS are lacking. Relative 
to sibutramine, we estimated that DMS and DDMS could produce pharmacological 
effects at doses that are 50 fold lower (Glick et al. 2000). Based on this estimate we 
assumed the lowest pharmacologically effective dose of DMS and DDMS to be 50 fold 
lower than the lowest pharmacologically effective dose of sibutramine (8.3 mg day-1), 
thus equating to 0.2 mg day-1. It should be noted that 0.2 mg day-1 is an estimation of 
the pharmacological effective dose of DMS and DDMS, and this dose may be an under-
estimation or an overestimation.  
Herbal supplements containing a combination of sibutramine, DMS, or DDMS with 
phenolphthalein 
In our study the combination of sibutramine, DMS or DDMS with phenolphthalein was 
found in ten herbal supplements. The presence of the combination of sibutramine with 
phenolphthalein in a herbal supplement was reported earlier in the Netherlands (RIVM 
2009). Also in other countries such as in the US (Dunn et al. 2012), France (Vaysse et al. 
2010), China (Wang et al. 2008), and Hong Kong (Yuen al. 2007) combinations of sibu-
tramine, DMS or DDMS with phenolphthalein were reported. Laxatives, like phenol-
phthalein are considered not very effective as weight loss drugs (Martin et al. 1998). 
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However, a reported side effect of sibutramine is constipation (Nisoli and Carruba 
2000; Wilfley et al. 2008; Müller et al. 2009), and phenolphthalein might have been 
added because of its laxative properties.  
Levels of sibutramine found in herbal supplements with an identical brand name 
In our study we identified sibutramine levels in samples with a similar brand name 
which varied from trace levels to levels that would result in an estimated daily dose of 
21 mg sibutramine in the herbal supplements I-IV, XXII, and XXIII (Table 1). Further-
more, in a sample of a herbal supplement with the same brand name (XXI), sibutramine 
could not be identified. Moreover, we reported that in two brands of adulterated die-
tary supplements used for weight loss, the dose units in one package contained either 
no API, one API, or different APIs such as sibutramine, DMS and DDMS, and at different 
dosages (Venhuis et al. 2013). These results indicate variability in the contamination of 
herbal supplements of a specific brand name suggesting the APIs are not present at a 
systematic or fixed level. This suggests that the risks associated with use of these herbal 
supplements will be variable because of differences in the levels and type of APIs pre-
sent. In order to further quantify these differences, future work could focus on analysis 
of composite samples accompanied by analysis of several samples from individual dose 
units in one package and from different packages from a specific brand. 
Trace levels of APIs 
Trace levels of sibutramine, sildenafil, and phenolphthalein were found in some herbal 
supplements (XVIII, XIX, XXII, XXIII, XXIV), and trace levels of DMS were also found in 
one product (XVIII). These trace levels are not expected to be pharmacologically rele-
vant. Furthermore, the presence of trace levels of APIs is most likely a quality problem 
associated with manufacturing deficiencies such as inadequate cleaning of the equip-
ment between production runs, or inhomogeneous mixing of the API and the herbal 
matrix resulting in a variable product composition. It is of importance to note that trace 
levels of APIs, in combination with other APIs present at higher levels, might add to the 
pharmacological effect of the supplement. This possible additive pharmacological effect 
of combinations of different APIs remains to be investigated.  
Sampling protocol 
In our study we applied a targeted sampling protocol. Inspectors sampled products 
based on experience and on the basis of reports of national and international health 
authorities concerning adulterated food supplements on the market, and reports of 
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side effects linked to specific products. Prior to analysis we searched the Internet for 
more information on the sampled food supplements in order to assess the likelihood of 
APIs being present. In several cases we found in Internet forums on losing weight, re-
ports of consumers on side effects of the sampled products which were later analytical-
ly shown to contain APIs. These consumer reports might be used as a crude indicator 
for the presence of APIs.  
Risks phenolphthalein 
For the risk assessment of phenolphthalein, which is expected to be a possible human 
carcinogen (IARC 2000), we calculated BMDL10 values which were based on the inci-
dence of hystiocytic sarcomas in B6C3F1 male mice reported in the study of Dunnick 
and Hailey (1996) and NTP (1996) (Table 3). Although we are aware that this study was 
based on a limited amount of dosing groups, we decided to use the study for calcula-
tion of the BMDL10 because no other relevant studies on the carcinogenic properties of 
phenolphthalein were available. Whenever more precise toxicological data will become 
accessible, the calculated BMDL10 value and resulting MOE values can be refined.  
 
The MOE approach is recommended by the European Food Safety Authority (EFSA) and 
the Joint FAO/WHO Expert Committee on Food Additives (JECFA) for priority setting by 
risk managers (EFSA 2005; JECFA 2005). EFSA (2005) considers that a MOE of 10,000 or 
higher, which is based on the BMDL10 from an animal study, would be of low concern 
from a public health point of view and might be considered as a low priority for risk 
management actions. Use of four herbal supplements containing phenolphthalein (XIII, 
XVI, XVII, and XIX) at the recommended daily doses would result in MOE values lower 
than 10,000 (96-220). However, assessing the risk from less-than lifetime exposures 
and considering the use of the herbal supplements during a period of only a few weeks 
or months will result in MOE values which may be 2 to 3 orders of magnitude higher.  
Side effects of API levels found in sampled herbal supplements 
Results of the present study indicate that consumers of weight loss herbal supplements 
should be aware that these products can contain APIs. Because the current study was 
based on a targeted sampling protocol, the current results can not be extrapolated to 
the entire market of weight loss food supplements. However, when the product pro-
duces significant results, such as weight loss, users should also be attentive to side 
effects, which might be caused by APIs. For sibutramine present in herbal supplements 
side effects such as psychiatric symptoms are reported at dose levels in an estimated 
range of 2.8-60 mg (Taflinski and Chojnacka 2000; Litvan and Alcoverro-Funy 2007; Lee 
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et al. 2008; Müller et al. 2009; Chen et al. 2010; Chong 2010; van Hunsel and van 
Grootheest 2011; Waszkiewicz et al. 2012). In our study sibutramine was found in 14 
samples at levels that would result in estimated daily dose levels of 4 up to 36 mg sibu-
tramine day-1 when used according to recommendations. The lowest estimated daily 
dose level (4 mg day-1) is above the lowest dose of this API at which side effects are 
reported (2.8 mg), and based on this observation it is concluded that the use as rec-
ommended of these 14 supplements resulting in estimated daily sibutramine dose 
levels from 4 to 36 mg day-1 might induce side effects. Furthermore, the use of six 
herbal supplements containing DMS (XXIII) or DDMS (VI-VIII, XIV, and XV) as recom-
mended might induce side effects such as psychotic symptoms for DMS (Yuen et al. 
2007; Chen et al. 2010) and cardiovascular effects for DDMS (Fil et al. 2011).  
 
In conclusion, from the 50 herbal supplements sampled on the Dutch market, use of 20 
supplements as recommended would result in estimated daily dose levels of sibu-
tramine, DMS, DDMS, and/or phenolphthalein that could produce pharmacological 
effects. Furthermore, use of four out of ten herbal supplements as recommended 
would result in estimated daily phenolphthalein dose levels that would result in MOE 
values lower than 10,000. For short term-exposure (few weeks or months) MOE values 
may be two to three orders of magnitude higher. 
 To conclude, APIs should not be used as ingredients in food supplements. Such 
products should only be brought on the market as medicinal products because the legal 
framework for medicines is considerably better equipped to ensure the safe and effec-
tive use of these products. The current study shows that the use of food supplements 
with sibutramine, DMS, DDMS, and/or phenolphthalein could result in pharmacological 
effects.  
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The aim of the present PhD thesis was to investigate the presence and actual levels of 
contaminants of concern in selected food supplements on the Dutch market and to 
estimate the associated health risks. Clay products for oral use, herbal food 
supplements claiming to enhance sexual potency and herbal food supplements used for 
weight loss were the food supplements studied. These three categories of food 
supplements were selected for the studies in the present thesis based on reports in 
literature on contaminations in food and feed. 
 After an introduction to the topic of interest (Chapter 1), the thesis continues with 
reports on the presence of metals, the metalloid arsenic and dioxins in clay products for 
oral use (Chapters 2 and 3). Clay products, known by a variety of names such as 
mabele, calabash chalk, sikor and pimba are traditionally consumed by pregnant 
women in Africa, Asia and Suriname, but also immigrants. Furthermore, clay is also 
used by non-pregnant women for certain health purposes in Western societies. 
 Chapter 2 focusses on the presence of metals and the metalloid arsenic in clay 
products. Aim of this study was to determine lead, arsenic, mercury and cadmium in 
clay products for oral use available on the Dutch market. Traditional clays originating 
from Africa (n=10) and Suriname (n=26), and health clays (n=27) were sampled from 
2004 up to and including 2012. Total metal and metalloid contents were measured by 
ICP-MS and showed maximum levels of lead, arsenic, mercury and cadmium of 99.7, 
45.1, 2.2 and 0.75 mg kg-1 respectively. The potential exposure was estimated from the 
determined concentration, the estimated daily use level of the clays and the estimated 
bioaccessibility of the different metals and arsenic. The intake estimates were 
compared to existing health based guidance values. For lead, the use of 34 of the 36 
traditional clays and two of the 27 health clays would result in intake levels exceeding 
the toxicological limit by up to 20-fold. In the case of inorganic arsenic, the use of 15 of 
the 35 traditional clays and 11 of the 27 health clays would result in intake levels 
exceeding the toxicological limit for up to 19-fold. Although limited bioaccessibility 
from the clay may limit the exposure and exceedance of the health based guidance 
values, it was concluded that lead and arsenic intakes from some clay products could be 
of concern also because of their use by pregnant women and the potential 
developmental toxicity to the fetus. 
 In chapter 3 the contamination of clay products with dioxins was investigated. 
Certain types of clay are known to contain high concentrations of polychlorinated 
dibenzo-p-dioxins and dibenzofurans (PCDD/Fs) and therefore the aim of this study was 
to determine the PCDD/F contents of orally consumed clays purchased on the Dutch 
market, also comparing them to levels in clays from African markets. From the Dutch 
market thirteen clay products were examined, including seven clay products of African 
and six of Suriname origin. In addition from seven African countries, twenty clay 
products were collected. All 33 clay products were screened with a cell-based bioassay 
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and those showing a high response were analyzed by gas chromatography/high 
resolution mass spectrometry (GC/HRMS). High PCDD/F concentrations were measured 
in three clay products from the Dutch market, ranging from 66 to 103 pg TEQ g-1, 
whereas PCDD/F concentrations in the suspected clay products from African countries 
varied from 24 to 75 pg TEQ g-1. In the WHO mother milk studies it was discovered that 
pooled human milk samples from some African countries contain relatively high dioxin 
levels. Therefore, congener patterns in African clay were compared with those of 
pooled human milk samples collected by WHO in eight African countries, to investigate 
a possible similarity of congener patterns from human milk with congener patterns 
from clay used for consumption. From the similarity between the patterns in clays and 
the human milk samples from the Democratic Republic of The Congo and Côte d’Ivoire, 
it can be concluded that there is probably a relationship with the consumption of 
contaminated clay. Frequent use of clay products during pregnancy may result in 
increased exposure of the mother and subsequently the developing fetus and new-born 
child. Based on the results of especially the presence of metals found in the traditional 
clay products, which were described in chapter 2, the Stichting Voedingscentrum 
Nederland -Netherlands Nutrition Centre Foundation-, started a campaign to 
discourage the use of pimba during pregnancy (Voedingscentrum 2009). 
 Chapters 4 and 5 report on the presence of active pharmacological ingredients 
(APIs) in herbal food supplements. Chapter 4 focussed on herbal food supplements, 
claiming to enhance sexual potency, which may contain deliberately added APIs that 
can be used for the treatment of erectile dysfunction. The aim of this study was to 
determine whether herbal food supplements on the Dutch market contain APIs known 
to inhibit phosphodiesterase type 5 (PDE-5), such as sildenafil and other known analo-
gous PDE-5 inhibitors. Herbal food supplements intended to enhance sexual potency 
(n=71), and two soft drinks, were sampled from 2003 up to and including 2012. In 23 
herbal supplements, nine different PDE-5 inhibitors were identified, in a few cases 
(n=3) more than one. The presence of these APIs was however not stated on the label. 
The amounts of PDE-5 inhibitors per dose unit were determined. Subsequently, the 
possible occurrence of potential pharmacological effects upon intake of the supple-
ments with the detected PDE-5 inhibitors was estimated using data from scientific and 
patent literature regarding i) in vitro PDE-5 inhibitor activity of the detected APIs, ii) 
reported effective doses of registered drugs with PDE-5 inhibitor activity, and iii) simi-
larity to other structural analogues. It was concluded that 18 of the 23 herbal food 
supplements with PDE-5 inhibitors, when used as recommended, would have pharma-
cological effects due to the added APIs. Based on similar observations the U.S. Food 
and Drug Administration (FDA) provided consumer health information about what they 
called the ‘Hidden risks of erectile dysfunction “treatments” sold online’ 
(http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm048386.htm). These con-
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sumer health information includes the warning that men looking online for ‘dietary 
supplements’ to treat erectile dysfunction (ED) or enhance their sexual performance 
should beware that these products may contain prescription drugs or other undisclosed 
ingredients that can be harmful (FDA 2009). 
 In chapter 5 another group of herbal food supplements, claiming to reduce weight 
were investigated. These herbal food supplements may contain deliberately added 
active pharmacological ingredients (APIs) that can be used for the treatment of over-
weight and obesity. The aim of this study was to determine whether herbal food sup-
plements for weight loss on the Dutch market contain APIs with weight loss properties. 
Herbal food supplements intended for weight loss (n=50), were sampled from August 
2004 up to and including May 2013. A HPLC-DAD-MS/MS method was used to screen 
for the presence of the APIs in herbal supplements. In 24 samples the APIs sibutramine, 
desmethylsibutramine (DMS), didesmethylsibutramine (DDMS), rimonabant, sildenafil, 
and/or the laxative phenolphthalein were identified 41 times. The presence of these 
APIs was however not stated on the label. The potential pharmacological effects of the 
detected APIs were estimated using data from reported effective doses of approved 
drugs. Use of 20 of the 24 herbal food supplements, may result in potential pharmaco-
logical effects. Furthermore, risk assessment of phenolphthalein, a suspected carcino-
gen and found to be present in ten supplements, based on the Margin of Exposure 
(MOE) approach resulted in MOE values of 96-30,000. MOE values lower than 10,000 
(96-220) were calculated for the daily intake levels of four out of these ten supplements 
in which phenolphthalein was found. However, taking into account that weight loss 
preparations may be used for only a few weeks or months rather than during lifetime, 
MOE values may be two to three orders of magnitude higher. The current study shows 
that the use of food supplements with sibutramine, DMS, DDMS, and/or phenolphtha-
lein could result in both pharmacological but also other health effects. 
Future perspectives 
Given the results of the studies presented in this thesis, several topics for future actions 
and research priorities can be defined, and in the following sections several of these are 
discussed in more detail. 
Health risks of food supplements and legislation 
Already in 2004, EFSA pointed out that the use of botanicals, which include herbal sup-
plements, is increasing (EFSA 2009a). Concerns related to the safety of herbal supple-
ments containing botanicals or botanical preparations increase in significance as well. 
Since then, EFSA has issued documents on the safety of herbal food supplements such 
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as the ‘Guidance on safety assessment of botanicals and botanical preparations intend-
ed for use as ingredients in food supplements’ (EFSA 2009a) and the ‘Compendium of 
botanicals reported to contain naturally occurring substances of possible concern for 
human health when used in food and food supplements’ (EFSA 2012a). However, doc-
uments mainly focus on the naturally occurring endogenous botanical toxins. However, 
from the thesis of Martena (2010) and from the results presented in this thesis it is 
concluded that also the presence of exogenous contaminants in food supplements such 
as metals and the metalloid arsenic, PCDD/Fs, and APIs may raise concern. In European 
regulatory framework regarding contaminants in foods, maximum levels are also set for 
metals lead, mercury and cadmium in food supplements (EC 2006). 
 To enforce actions of food supplements containing APIs, a different approach 
applies than to the products containing heavy metals, metalloids or PCDD/Fs. For these 
botanical products containing APIs it has to be investigated whether the API found is 
present in a pharmacologically relevant dose. A botanical product can then be classified 
as a medicinal product as defined in the medicinal products legislation. It is important 
to note that these pharmacologically relevant doses may or may not represent the dose 
of the API that can result in adverse effects. For a drug to be approved, the therapeutic 
effects need to outweigh the adverse effects. For a food supplement with APIs such an 
assessment is not made. For the quantification of the possible adverse health effects of 
non-registered APIs found in the herbal supplements, data are often lacking. In addi-
tion, the applicability of the Novel Food legislation (EC 1997) could be considered for 
evaluation of herbal supplements containing APIs. Novel foods are foods that have not 
been used for human consumption to a significant degree in the EU before 15 May 
1997. Furthermore, novel foods can consist of or can be isolated from plants, but may 
not present a danger to the consumer or mislead the consumer. Therefore, prior to 
marketing a novel food, the company must apply to an EU member state competent 
authority for authorization, presenting the scientific information and a safety assess-
ment report.  
Selection of health based guidance values for risk assessment of metals and the 
metalloid arsenic found in clay products 
In chapter 2 the safety of the contaminated clay products was assessed using health 
based guidance values which were set by risk assessment agencies such as RIVM, EFSA 
and JECFA (Baars et al. 2001; EC SCF 2001; 2003; IPCS 2000; 2003; JECFA 1982; 1983; 
2007; 2011a; 2011b; EFSA 2008; 2009b; 2009c; 2010a; 2010b; 2012b; WHO 1996). These 
health based guidance values are in general based on data from toxicological studies in 
laboratory animals. In our study we applied the health based guidance values found in 
literature for the metals aluminum, cadmium, chromium, copper, iron, lead, mercury, 
zinc, and the metalloid arsenic. For our risk assessment in clay products we selected the 
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health based guidance values on the basis of chemical speciation of the metals and the 
metalloid in the clay matrix. Another criterion for selection was that the health based 
guidance value should be recently set. Furthermore, regarding the potential use during 
pregnancy, we selected, if present, the health based guidance value that was based on 
adverse effects on the fetus. However, upon finalization of our study for some ele-
ments such as aluminum (JECFA 2011a), arsenic (EFSA 2009b; JECFA 2011b), lead (EFSA 
2010b), and inorganic mercury (JECFA 2011b; EFSA 2012b), new health based guidance 
values were set. These new health based guidance values were tolerable intake levels 
for adverse effects with a threshold such as for aluminum (JECFA 2011a) and inorganic 
mercury (JECFA 2011b; EFSA 2012b) or benchmark dose (BMD) values for adverse ef-
fects such as for arsenic (EFSA 2009b; JECFA 2011b), and lead (EFSA 2010b). The use of 
the BMD approach is advocated by EFSA for deriving a reference point for risk assess-
ment. An advantage of the BMD approach is that all available dose-response data are 
used instead of only the NOAEL. Furthermore, the BMD approach takes the uncertain-
ties in the dose-response data into account (EFSA 2009d). Table 1 shows to what extent 
lowering or increasing these health based guidance values or the use of alternative 
health based guidance values such as BMD values would result in a modification of the 
number of clay products exceeding the health based guidance values, considering the 
metals and the metalloid would be equally bioaccessible as the salts used in the critical 
toxicological studies used to derive the health based guidance values (100% bioaccessi-
ble scenario). From this Table it can be concluded that, based on the newly identified 
health based guidance values for aluminium and mercury the number of exceedances is 
not affected to a large extent. 
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Matrix effects and risk assessment 
Another topic that needs further attention in future studies is the bioaccessibility of the 
metals and the metalloid from the clay matrix. Such data on this bioaccessibility from 
the clay products were not available but we assumed that metals and the metalloid 
present in clay products would not be fully available for intestinal absorption. We 
estimated per metal and the metalloid arsenic the bioaccessible fractions, and included 
these in the risk assessment. This estimate was based on data available in the literature 
from in vitro bioaccessibility studies in soil fractions (Abrahams 1997; Aufreiter et al. 
1997; Schoof and Nielsen 1997; Smith et al. 2000; 2009; Barnett and Turner 2001; 
Abrahams et al. 2006; Juhasz et al. 2007; Ljung et al. 2007; Palumbo-Roe and Klinck 
2007; Madrid et al. 2008; Lamb et al. 2009; Morman et al. 2009; Zagury et al. 2009; 
Meunier et al. 2010; Roussel et al. 2010; Appleton et al. 2012). Further refinement of 
the risk assessment requires more detailed quantification of the bioaccesibility from 
the clay products actually investigated. Since this correction on bioaccesibility may 
significantly affect the exposure estimates (correction may be up to a reduction by 
more than 99% of the bioaccessibility for aluminum, iron and mercury), exact 
knowledge on bioaccesibility from the adequate food matrix will reduce the uncertainty 
in the risk assessment. Therefore, it is important to investigate this bioaccessibility in 
relation to the salts used in the toxicological studies used to derive the health based 
guidance values. The issue of how to deal with matrix effects in risk assessment is an 
important topic for future research on the use of clays.  
 Furthermore, possible nutrient interactions with the contaminants found in the 
food supplements exist and might affect the degree of toxicity of contaminants present 
in food supplements as well. Grapefruit juice for example, is known as a selective 
CYP3A4 inhibitor, and can increase the bioavailability of sildenafil (Jetter et al. 2002; 
Mason 2010), but the medicinal herb St. John’s Wort induces the activity of CYP3A4 and 
is reported to decrease the bioavailability of sildenafil (Nowack 2008). Therefore, in 
order to refine the risk assessment, also nutrient interactions should be taken into 
consideration.  
 The results from the present study show that potential interactions of the food 
supplement matrix affect the risk assessment of contaminants present in food 
supplements. To adequately integrate this matrix or combination effect in the risk 
assessment is an important challenge for the future. EFSA has indicated that the matrix 
effects should be taken into account on a case-by-case basis (EFSA 2009a), and 
harmonisation on methods and procedures required to do so would be an important 
topic for future research. 
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Groups in the population of special concern 
In the present thesis the focus was on food supplements used by groups of the popula-
tion of special concern such as pregnant women and their unborn children (Chapters 2 
and 3), and consumers suffering from erectile dysfunction (Chapter 4), overweight and 
obesity (Chapter 5). These consumers may be more vulnerable than ‘healthy consum-
ers’ for the adverse effects resulting from the use of food supplements in which con-
taminants are found. In the following paragraphs these possible adverse effects result-
ing from consumption of the food supplements on each group of concern are discussed 
in some more detail. 
 The placenta is an important organ in the connection between mother and fetus. 
By this organ all necessary nutrients are delivered to the fetus, but the placenta also 
acts as a barrier for toxic substances including metals (Singh et al. 2010). However, a 
number of toxicants including metals are known to cross the placenta and can accumu-
late in the fetal tissues (Gundacker and Hengstschläger 2012). Critical periods or critical 
windows have been identified in the fetus development during which exposure to met-
als and the metalloid can be more harmful to the fetus because they can have adverse 
effects on the development of an organ or organ system such as the nervous system as 
is the case for lead (Baars et al. 2001). The nervous system mainly develops in the first 
trimester of pregnancy. In this early pregnancy it is reported that clay products are used 
by pregnant women to prevent morning sickness (De Korte 2006). Also PCDD/Fs have 
critical effects on the developing fetus (Van den Berg et al. 2000). Furthermore, lead 
and PCDD/Fs are known to accumulate in the skeleton (lead), liver and fat tissue 
(PCDD/Fs) (Gulson et al. 2003; Hoogenboom et al. 2010; Malish et al. 2010). During the 
lactation period these contaminants can be remobilized in the mother’s body and 
transferred to the baby via the milk (EFSA 2010b; Malish et al. 2010) and therefore may 
pose an additional health risk for the baby. 
 In our study we found PDE-5 inhibitors present in herbal supplements for the 
enhancement of sexual potency. Studies show that decrease of sexual potency such as 
erectile dysfunction is associated with an increasing age or unhealthy lifestyle such as 
lack of exercise or smoking. Erectile dysfunction is associated with e.g. hypertension, 
hypercholesterolaemia, metabolic syndrome, and obesity (Derby et al. 2000; Hatzi-
mouratidis et al. 2010; Gandaglia 2013). For the treatment of pulmonary hypertension, 
registered drugs such as Revatio® and Adcirca® are available on the market containing 
PDE-5 inhibitors as these are known to cause vasodilatation. Therefore, the unknown 
additional exposure to PDE-5 inhibitors through the use of herbal supplements for erec-
tile dysfunction might negatively interfere with this type of treatment with registered 
drugs containing PDE-5 inhibitors, and patients might be at risk using such herbal sup-
plements. Additionally, patients suffering from hypotension, who are not treated for 
this, might be at risk when using herbal supplements containing PDE-inhibitors.  
GENERAL DISCUSSION 
 137 
The use of sibutramine is associated with cardiovascular symptoms such as an in-
creased risk of serious, non-fatal cardiovascular events (stroke and heart attack), tachy-
cardia, and (arterial) hypertension (Ioannides-Demos et al. 2006; Padwal & Majumdar 
2007; Müller et al. 2009; Cohen & Ernst 2010; EMA 2010a). Furthermore, several psy-
chiatric symptoms have been reported resulting from the use of sibutramine, 
desmethylsibutramine (DMS) and didesmethylsibutramine (DDMS) such as psychosis 
and (hypo)mania (Taflinski and Chojnacka 2000; Litvan and Alcoverro-Fortuny 2007; 
Yuen et al. 2007; Lee et al. 2008; Müller et al. 2009; Chen et al. 2010; Chong 2010; van 
Hunsel and van Grootheest 2011; Waszkiewicz et al. 2012). These examples illustrate 
that risk assessment of food supplements should pay attention to groups at extra risk 
especially when specific health conditions may trigger supplement use. 
Risk-benefit balance 
The results obtained in the present thesis showed levels of contaminants which can 
have adverse effects on the users and in case of clay products also on the offspring. 
However, in literature some possible beneficial effects resulting from the use of clay 
products are reported as well, such as reduction of morning sickness, reduction of acid 
reflux, supplementation of extra minerals, prevention of miscarriage and promotion of 
delivery (Danford 1982; Abrahams and Parsons 1996; Aufreiter et al. 1997; Geissler et 
al. 1999; Henry and Matthews Kwong 2003; De Korte 2006; Kawai et al. 2009). These 
claimed beneficial health effects, some of which might be placebo effects on the moth-
er, might be beneficial for the health of the fetus as well. Furthermore, beneficial 
health effects, resulting from the high content of antioxidants such as flavonoids re-
ported to be present in spices, herbs,  supplements, and herb-containing medicaments 
may exist (Boots et al. 2008; Carlsen et al. 2010). In order to make a risk benefit analy-
sis, both the adverse and beneficial effects should be properly quantified. The quantifi-
cation of beneficial effects resulting from the use of clay products and herbal supple-
ments is hampered by a lack of scientific data. Furthermore, different type of effects 
such as toxicological, infectious, psychological, and placebo effects need to be weighed 
and mutually compared. Therefore, these effects should be qualified in such a way that 
between the effects a comparison can be made. This would enable a risk-benefit as-
sessment for food supplements weighing the possible health benefits against the risks 
(EFSA 2012b). This risk benefit balance for food supplements might be further explored 
in the (refinement) of risk assessment as well.  
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Contamination of herbal supplements with APIs and pharmacologial effectiveness of 
trace levels of APIs in herbal supplements 
In the studies described in this thesis, APIs were found at levels of pharmacological 
relevance in herbal supplement for the enhancement of sexual potency and herbal 
supplements for weight loss (Chapter 4 and 5). This clearly indicates the deliberate 
addition of these APIs. However, also trace and low levels of APIs were found in some 
of the herbal supplements. Additionally, in some supplements more than one API was 
identified. A question can be raised about the possible source of this contamination of 
food supplements with APIs. The presence of these low levels or multiple APIs might be 
related to the quality of the starting material including these impurities. Furthermore, 
insufficient control of the production process such as inadequate cleaning between 
production runs might also result in these trace levels and a variety of APIs and API 
levels present in a herbal supplement.  
 In some of the herbal supplements used to enhance sexual potency and for 
weight loss trace levels of APIs were found. Based on available data, these trace levels 
on itself are not expected to be pharmacologically relevant. However, aside of the qual-
ity problem associated with manufacturing deficiencies which is discussed above, it is of 
importance to note that trace levels of APIs, may be in combination with other APIs 
present at higher levels, might add to the pharmacological effect of the supplement. 
This possible additive pharmacological effect of combinations of different APIs remains 
to be investigated. Due to the lack of data on dose-response curves, it was not possible 
to assess to which extent such low levels or the combination of compounds might still 
have a pharmacological effect, at least in some people, and could therefore have been 
intentionally added.  
Drop outs from drug development 
In chapters 4 and 5 the presence of APIs added to herbal supplements are reported. 
The analogous PDE-5 inhibitors found in herbal supplements, described in chapter 4, 
are often by-products of the typical drug development process (RIVM 2010; Venhuis 
and de Kaste 2012). This is an issue that may require more attention from a food safety 
perspective than presently realised. Drugs developed by pharmaceutical companies are 
subject to a scientific pre-market evaluation by health authorities such as EMA (Europe) 
and FDA (US) and these drugs can only enter the market after their efficicay and safety 
have been shown. However, in the process of drug development, large numbers of 
analogues may be developed that may for various reasons not enter the final stages of 
drug development and safety evaluation for market entrance. This implies that these 
drop outs from the drug development process do not undergo the full scientific safety 
evaluation because these APIs will not be a candidate for entering the market. This may 
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be for a variety of reasons, one of them being safety issues observed in early phases of 
drug development. As a result scientific data on pharmacological and toxicological 
features of these by-products are often lacking or not available to the public. Therefore, 
the intentional addition of these by-products to herbal food supplements, may result in 
unforseen adverse side effects in consumers.  
Use of bioassays 
Given that compounds of concern detected in food products on the market may be 
unknown analogues of drugs or other active compounds, it is of interest to consider 
increased use of bioassays for future screening purposes and quality control. Bioassays 
are able to detect chemicals with a certain related mode of action and thus facilitate 
the detection of unknown compounds with a certain mode of action. In our study we 
used such a cell-based bioassay for the screening of dioxin-like activity in clay products 
(Chapter 3). Application of this bioassay for screening of feed ingredients led to the 
discovery of various brominated flame retardants but also brominated dioxins in cho-
line chloride, probably due to poor manufacturing conditions (Traag et al. 2009). Fur-
thermore, in order to assess the pharmacological potency of PDE-5 inhibitors data from 
bioassays on the inhibition of PDE-5 activity were used (Chapter 4). Such a bioassay 
may also be applied for screening purposes. Moreover, various bioassays have been 
developed for estrogenic and androgenic substances, and have been used for screening 
of urine from calves and for animal feed (Bovee et al. 2006). Application of the yeast 
androgen assay led to the discovery of 1-methyltestosterone in supplements, which 
was overlooked by the analytical method (Rijk et al. 2009), and using the yeast estrogen 
assay, high levels of diethylstilbestrol (DES) were detected in a herbal product used for 
prostate problems and causing gynaecomastia in the patient (Toorians et al. 2010). For 
the screening of PDE-5 inhibitors, the use of a bioassay should be considered and can 
be based on the fact that PDE-5 inhibitors inhibit a single enzyme system such as the 
nitric oxide–cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 
5 enzymes. For the screening of APIs in food supplements intended for weight loss, the 
use of a combination of bioassays should be considered as the APIs such as sibu-
tramine, found in this type of food supplements, might act via different biological 
mechanisms. The use of bioassays for the screening of APIs in food supplements might 
prove to be useful for the detection of unknown compounds, since the currently used 
methods such as HPLC-DAD-MS/MS require that the compound is defined and known, 
which may not always be the case for APIs present in food supplements. Thus, bioas-
says can be used as rapid first screening and are to be followed by chemical analysis of 
suspected samples by more expensive chemical methods to identify and quantify the 
compounds causing the effects in the bioassay. 
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Safety of food supplements on the Dutch market  
From this thesis the idea might arise that the Dutch market is dominated by unsafe 
food supplements. However, it is important to note that the sampling protocols, 
described in this thesis, were risk based and specifically targeted at finding food 
supplements that were more likely to be contaminated with metals, metalloids, dioxins 
and APIs. Therefore, these findings cannot be extrapolated to all food supplements 
present on the Dutch market. The type of retail channel is a factor influencing the 
chances on purchasing unsafe food supplements, with the retail via Internet and 
traditional shops being of particular concern. The Internet is a growing medium for the 
sales of food supplements with rapidly emerging and disappearing suppliers. 
Furthermore, the advertisements on Internet of these products often appear to lack 
information or to present disinformation, and consumers might not be able to assess 
the product information properly (Morris and Avorn 2003; Jordan and Haywood 2007; 
Vargas-Murga et al. 2011). This absence of information or information present in 
another language than the Dutch language might also apply to the products sold via 
traditional shops.  
Conclusions 
From our studies it can be concluded that, in addition to concerns over naturally occur-
ring endogenous toxins present in herbal supplements, the presence of exogenous 
contaminants in herbal supplements can pose a health concern. The results of the pre-
sent thesis also lead to the conclusion that in order to refine the risk assessment on the 
presence of contaminants such as metals, metalloids, dioxins and APIs in (herbal) food 
supplements more precise data are required on bioaccessibility of contaminants of 
concern from the food matrix. Also information on groups at increased risk may need 
to be increased. Additionally, the presence of APIs in herbal supplements, which may 
originate from drop outs in the drug development process, is of concern. In order to 
screen for unknown APIs the increased use of effect-based bioassays should be consid-
ered, as they have been shown to be successful in detecting unexpected and as yet 
unknown active ingredients. From the results obtained for the food supplements in-
cluded in our study it can be concluded that the risk of adverse health effects might 
increase when food supplements are purchased via Internet or via traditional shops, 
and consumers should be aware that this presents a serious risk.  
 The overall conclusion from the work described in this thesis is that for food sup-
plements ‘natural’ does not equal safe.    
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Summary 
Through the increasing use and availability of food supplements on the market, safety 
concerns relating to the safety of these food supplements are growing as well. The aim 
of the present PhD thesis was to investigate the presence and actual levels of contami-
nants of concern in selected food supplements on the Dutch market and to estimate 
the associated health risks.  
 First, in chapter 1, an overview is provided on the food supplements selected for 
the studies, which are clay products for oral use, herbal food supplements used to en-
hance sexual potency and herbal food supplements used for weight loss. Furthermore, 
an overview is given on the Dutch en European legal provisions for food supplements. 
 In the first study described in chapter 2 of this theses data are presented on the 
occurrence of metals such as lead, mercury and cadmium and the metalloid arsenic in 
clay products which are used via the oral route by pregnant and lactating women. For 
lead, the use of 34 of the 36 traditional clays and two of the 27 health clays would re-
sult in intake levels exceeding the selected health based guidance values, by up to 20-
fold. In the case of inorganic arsenic, the use of 15 of the 35 traditional clays and 11 of 
the 27 health clays would result in intake levels exceeding the health based guidance 
values by up to 19-fold. 
 The second study, described in chapter 3 of the thesis, reports data on the pres-
ence of dioxins in 33 clay products, which were collected on the Dutch market and in 
some African countries. Polychlorinated dibenzo-p-dioxins and polychlorinated diben-
zofurans (PCDD/F) were detected in clay products from the Dutch market, in concentra-
tions ranging from 66 to 103 pg TEQ g-1, whereas PCDD/F concentrations in the sus-
pected clay products from African countries varied from 24 to 75 pg TEQ g-1. Further-
more, in this study congener patterns in African clay products were compared with 
those of pooled human milk samples collected by WHO in eight African countries, to 
investigate a possible relation between PCDD/Fs in human milk with contaminated clay 
used for consumption. From the similarity between the patterns in clays and the human 
milk samples from the Democratic Republic of The Congo and Côte d’Ivoire, it can be 
concluded that there is probably a relationship with the consumption of contaminated 
clay.  
 The aim of the third study, described in chapter 4 of this thesis, was to determine 
whether herbal food supplements on the Dutch market contain active pharmacological 
ingredients (APIs) known to inhibit phosphodiesterase type 5 (PDE-5), such as sildenafil 
and other known analogous PDE-5 inhibitors. Therefore, herbal food supplements in-
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tended to enhance sexual potency (n=71), and two soft drinks, were analysed. In 23 
herbal supplements, nine different PDE-5 inhibitors were identified, in a few cases 
(n=3) more than one. The presence of these APIs was however not stated on the label. 
Subsequently, it was estimated whether intake of the supplements with the detected 
PDE-5 inhibitors could result in pharmacological effects. It was concluded that 18 of the 
23 herbal food supplements with PDE-5 inhibitors, when used as recommended, would 
have pharmacological effects due to the added APIs. 
 In the fourth study, described chapter 5 of in this thesis, another group of herbal 
food supplements, claiming to reduce weight, was investigated for the presence of APIs 
that can be used for the treatment of overweight and obesity. To this end, 30 herbal 
food supplements for weight loss on the Dutch market were collected and analysed for 
the presence of APIs with weight loss properties. In 24 samples the APIs sibutramine, 
desmethylsibutramine (DMS), didesmethylsibutramine (DDMS), rimonabant, sildenafil, 
and/or the laxative phenolphthalein were identified 41 times. The potential pharmaco-
logical effects of the detected APIs were estimated, and use of 20 of the 24 herbal food 
supplements, may result in potential pharmacological effects. Furthermore, a risk as-
sessment of phenolphthalein regarding its carcinogenic effects, resulted in Margin of 
Exposure (MOE) values of 96-30,000. MOE values lower than the minimum required 
10,000 (96-220) were calculated for the daily intake levels of four out of the ten sup-
plements in which phenolphthalein was found. However, taking into account that 
weight loss preparations may be used for only a few weeks or months rather than dur-
ing lifetime, MOE values may be two to three orders of magnitude higher. This study 
shows that the use of food supplements with sibutramine, DMS, DDMS, and/or phe-
nolphthalein could result in both pharmacological but also other health effects. 
 From the studies described in this thesis it can be concluded (chapter 6) that, in 
addition to concerns over naturally occurring endogenous toxins present in herbal sup-
plements, the presence of exogenous contaminants in herbal supplements can pose a 
health concern. Furthermore, the results of the present thesis also lead to the conclu-
sion that in order to refine the risk assessment on the presence of contaminants such 
as metals, metalloids, dioxins and APIs in (herbal) food supplements more precise data 
are required on bioaccessibility of contaminants of concern from the food matrix. Also 
information on groups at increased risk may need to be increased. Additionally, the 
presence of APIs in herbal supplements, which may originate from drop outs in the 
drug development process, is of concern. In order to screen for unknown APIs the use 
of effect-based bioassays should be considered more often, as they have been shown 
to be successful in detecting unexpected and as yet unknown active ingredients. From 
the results obtained for the food supplements included in our studies it can be con-
cluded that consumers should be aware that food supplements may not be without 
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risks. The overall conclusion from the work described in this thesis is that for food sup-
plements ‘natural’ does not equal ‘safe’.    
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Samenvatting (Summary in Dutch) 
Het toenemende gebruik en de ruime beschikbaarheid van voedingssupplementen op 
de markt geven reden tot zorg met betrekking tot de veiligheid van deze voedingssup-
plementen. Het doel van dit proefschrift is om de aanwezigheid en de gehalten van een 
aantal contaminanten in voedingssupplementen op de Nederlandse markt, die reden 
tot zorg voor de gezondheid geven, te onderzoeken en de daarmee samenhangende 
gezondheidsrisico’s te beoordelen. 
 Allereerst wordt in hoofdstuk 1 een overzicht gegeven van de voedingssupplemen-
ten die zijn gekozen voor de studies. Dit zijn kleiproducten voor oraal gebruik, kruiden-
supplementen die gebruikt worden om de seksuele potentie te verhogen en kruiden-
supplementen die worden toegepast voor gewichtsverlies. Ook wordt in hoofdstuk 1 
een overzicht gegeven van de huidige Nederlandse en Europese wetgeving voor voe-
dingssupplementen.  
 In de eerste studie, die wordt beschreven in hoofdstuk 2 van dit proefschrift, wor-
den gegevens gepresenteerd over het voorkomen van metalen zoals lood, kwik en 
cadmium en het metalloïde arseen in kleiproducten die worden geconsumeerd door 
zwangere en lacterende vrouwen. Voor lood zouden innameniveaus van 34 van de 36 
traditionele kleiproducten en twee van de 27 gezondheidskleiproducten resulteren in 
innameniveaus die de geselecteerde gezondheidskundige grenswaarden tot wel 20 
keer overschrijden. In het geval van anorganisch arseen zou het gebruik van 15 van de 
35 traditionele kleiproducten en 11 van de 27 gezondsheidskleiproducten resulteren in 
innameniveaus die de gezondheidskundige grenswaarden tot wel 19 keer kunnen over-
schrijden.  
 In de tweede studie, beschreven in hoofdstuk 3, worden data gerapporteerd over 
de aanwezigheid van dioxinen in 33 kleiproducten die werden verzameld op de Neder-
landse markt en in enkele Afrikaanse landen. Polychloordibenzo-p-dioxines en poly-
chloordibenzofuranen (PCDD/F) werden gevonden in kleiproducten op de Nederlandse 
markt in concentraties, variërend van 66 tot 103 pg TEQ g-1, terwijl PCDD/F-
concentraties in de verdachte kleiproducten afkomstig van Afrikaanse landen varieer-
den van 24 tot 75 pg TEQ g-1. Om een mogelijk verband tussen dioxines in moedermelk 
en het gebruik van besmette kleiproducten te onderzoeken, werden in deze studie de 
congenerpatronen van de kleiproducten vergeleken met die van gepoolde moeder-
melkmonsters die werden verzameld door de WHO in acht Afrikaanse landen. Uit de 
overeenkomst tussen de patronen in klei- en moedermelkmonsters afkomstig van de 
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Democratische Republiek Kongo en Ivoorkust, zou kunnen worden geconcludeerd dat 
er een mogelijke relatie is met de consumptie van gecontamineerde klei.  
 Het doel van de derde studie, beschreven in hoofdstuk 4, was om te bepalen of 
kruidensupplementen op de Nederlandse markt actieve farmacologische ingrediënten 
(API’s) bevatten waarvan bekend is dat deze fosfodiesterase type 5 (PDE-5) remmen 
zoals sildenafil en andere bekende analoge PDE-5-remmers. Daarom werden kruiden-
supplementen (n=71) en twee frisdranken, bedoeld om de seksuele potentie te verho-
gen, geanalyseerd. In 23 kruidensupplementen werden negen verschillende PDE-5-
remmers geïdentificeerd, in enkele gevallen (n=3) meer dan één. De aanwezigheid van 
deze API’s was echter niet vermeld op het etiket. Vervolgens werden de mogelijke far-
macologische effecten bij gebruik van deze supplementen met de aanwezige PDE-5 
remmers geschat. Hieruit kon worden geconcludeerd dat 18 van de 23 kruidensupple-
menten met PDE-5 remmers, indien gebruikt als aanbevolen, zouden kunnen resulteren 
in farmacologische effecten als gevolg van de toegevoegde API’s.  
 In de vierde studie, beschreven in hoofdstuk 5 van dit proefschrift, werd een ande-
re groep van kruidensupplementen, bestemd voor gewichtsverlies, onderzocht op de 
aanwezigheid van API’s die gebruikt kunnen worden voor behandeling van overgewicht 
en obesitas. Hiervoor werden 30 kruidensupplementen voor gewichtsverlies verzameld 
op de Nederlandse markt en geanalyseerd op de aanwezigheid van API’s die gewichts-
verlies kunnen veroorzaken. In 24 monsters werden de API’s sibutramine, desmethylsi-
butramine (DMS), didesmethylsibutramine (DDMS), rimonabant, sildenafil, en/of de 
laxantia fenolfthaleïne 41 keer geïdentificeerd. Vervolgens werden de potentiële far-
macologische effecten van de gedetecteerde gehaltes aan API’s geschat en hieruit 
bleek dat het gebruik van 20 van de 24 kruidensupplementen zou kunnen resulteren in 
potentiële farmacologische effecten. Een risicobeoordeling van fenolfthaleïne, dat 
naast een laxerende werking ook carcinogene eigenschappen bezit, resulteerde in Mar-
gin of Exposure (MOE)-waarden van 96-30.000. MOE-waarden kleiner dan de gewenste 
10.000 (96-220) werden berekend voor de dagelijkse innameniveaus van vier van de 
tien supplementen waarin fenolfthaleïne was gevonden. Echter, wanneer in aanmer-
king wordt genomen dat preparaten voor gewichtsverlies mogelijk gebruikt worden 
voor enkele weken of maanden in plaats van gedurende het gehele leven, dan zouden 
MOE-waarden twee of drie ordes van grootte hoger kunnen zijn. Deze studie laat zien 
dat het gebruik van supplementen met sibutramine, DMS, DDMS, en/of fenolfthaleïne 
kan resulteren in zowel farmacologische als ook andere gezondheidseffecten.  
 Op basis van de studies die in dit proefschrift zijn beschreven, kan worden gecon-
cludeerd (hoofdstuk 6) dat, in aanvulling op de reden tot zorg met betrekking tot na-
tuurlijk voorkomende endogene toxinen aanwezig in kruidensupplementen, ook de 
aanwezigheid van exogene contaminanten een reden tot zorg kunnen geven. Verder 
kan uit de resultaten van dit proefschrift ook worden geconcludeerd dat, om de risico-
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beoordeling met betrekking tot de aanwezigheid van contaminanten zoals metalen, 
metalloïden, dioxines en API’s in (kruiden)supplementen te verfijnen, meer exacte 
gegevens nodig zijn over de biobeschikbaarheid van deze contaminanten vanuit de 
voedingsmatrix. Ook zou meer informatie over gebruikersgroepen met een verhoogd 
risico beschikbaar moeten komen. Verder is de aanwezigheid van API’s in kruidensup-
plementen, die mogelijk afkomstig zijn van drop outs van het ontwikkelingsproces van 
medicijnen, een zorg, aangezien deze vaak niet of nauwelijks zijn onderzocht op scha-
delijke effecten. Om te screenen op onbekende API’s zou het toenemend gebruik van 
op effect gebaseerde bioassays moeten worden overwogen. Dit bleek in andere studies 
succesvol bij het detecteren van niet verwachte en onbekende actieve ingrediënten. Uit 
de resultaten die zijn verkregen over de voedingssupplementen uit onze studies, kan 
worden geconcludeerd dat consumenten zich bewust moeten zijn dat het gebruik van 
voedingssupplementen niet zonder risico’s is. De algemene conclusie van het werk 
beschreven in dit proefschrift is dat voor voedingssupplementen ‘natuurlijk’ niet auto-
matisch ‘veilig’ betekent.  
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Dankwoord 
Op deze plaats wil ik alle personen danken die bij mijn promotietraject betrokken zijn 
geweest voor hun hulp, inzet, betrokkenheid en enthousiasme. Een aantal personen wil 
ik speciaal noemen. 
 Als eerste wil ik mijn promotor Ivonne Rietjens danken. Zij heeft mij door haar 
praktische instelling en positieve visie, en vooral door de niet aflatende constructieve 
en snelle terugkoppeling op de respectieve artikelen die ik haar voorlegde, op een effi-
ciënte en effectieve wijze in dit promotietraject begeleid.  
 Copromotor Martijn Martena was eerder bij de NVWA gepromoveerd en daardoor 
een ervaringsdeskundige. Ik stelde het zeer op prijs dat ik met hem over veel onder-
werpen, die ik tijdens de te volgen weg naar mijn promotie tegenkwam, van gedachten 
kon wisselen. Met veel geduld heeft Martijn mij begeleid bij het schrijven van het eer-
ste artikel. Ook nadat Martijn bij het Ministerie van Volksgezondheid Welzijn en Sport 
ging werken, bleef hij intensief betrokken bij werkzaamheden aan dit proefschrift.  
 Ook ben ik mijn copromotor Ron Hoogenboom zeer erkentelijk voor de aangename 
samenwerking, het meedenken en zijn constructieve terugkoppeling op de diverse 
artikelen. Door zijn contacten met de World Health Organization en met Antonia Ta-
lidda, voormalig stagiaire bij het RIKILT, konden onderzoeksresultaten van de verschil-
lende bronnen worden gecombineerd. Dit resulteerde in het artikel over dioxinen in 
kleiproducten. Ook dank ik Wim Traag van het RIKILT voor zijn bijdrage aan dit artikel. 
 Bastiaan Venhuis en Dries de Kaste van het RIVM dank ik graag voor hun bijdragen. 
Hun kennis over de farmacochemie en farmacie betekent een toegevoegde waarde 
voor de twee laatste artikelen over actieve farmacologische ingrediënten in kruiden-
supplementen. Vooral Bastiaan wil ik bedanken voor zijn niet aflatende bereidheid om 
zich door mij ook op ’s avonds en in het weekend te laten bestoken met allerlei vragen. 
 Aan Ans Soffers van Toxicologie (WUR) wil ik mijn dank betuigen voor het maken 
van de chemische structuurformules die in de verschillende hoofdstukken zijn opgeno-
men. 
 Deze promotie had niet tot stand kunnen komen zonder de steun van velen binnen 
de NVWA. Hiervan komt dank toe aan een aantal met name te vermelden mensen. Als 
eerste Henk de Groot die, toen ik hem mijn plannen om te gaan promoveren voorlegde, 
mij vroeg één reden te geven om het niet te doen. Ghislaine Mittendorff, Karin Visser 
en Koen Wienk hebben zich sterk gemaakt om dit promotietraject te kunnen aanvan-
gen en te vervolgen in de hectische reorganisatieperiode van de NVWA en daar ben ik 
hen zeer erkentelijk voor. Walther Klerx dank ik voor zijn aanzienlijk aandeel in verwer-
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king van de gegevens en de methodiekbeschrijving over het voorkomen van metalen en 
metalloïden in kleiproducten. Hij wist hiervoor, ondanks zijn drukke (internationale) 
bezigheden, altijd wel tijd te maken. Ik heb de hulp van Eddy van de Male, Elly Tissen, 
Peter Verheijen, Bas Edelenbos en Monique Boersma-Greve zeer gewaardeerd met 
betrekking tot het analyseren van de monsters, het maken van resultaatoverzichten en 
het adequaat beantwoorden van vragen.  
 Zonder het verzamelen van de voedingssupplementen voor analyse was dit proef-
schrift niet mogelijk geweest. De juiste monsters hiertoe verkreeg ik door de inzet en 
expertise van de collega’s van het team Bijzondere eet- en drinkwaren (BED). Hennie 
van Lokven heeft mij de gelegenheid geboden monsters van voedingssupplementen te 
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